Professor Michael Friedlander

Back to

Phone

9382 2606

Publications

Book Chapters | 2022

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 23, http://dx.doi.org/10.1002/9781119000822.hfcm105.pub2

Book Chapters | 2022

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 18, http://dx.doi.org/10.1002/9781119000822.hfcm106.pub2

Book Chapters | 2020

Amant F; Hensley M; Pautier P; Friedlander M; Sagae S; Fujiwara K; Berton Rigaud D; Lorusso D; Ray-Coquard I, 2020, 'Management of Rare Uterine Malignant Tumors', in Management of Endometrial Cancer, Springer International Publishing, pp. 277 - 312, http://dx.doi.org/10.1007/978-3-319-64513-1_19

Book Chapters | 2020

Christie EL; Freimund AE; Fereday S; Alsop K; Hoang T; Pishas K; Au-Yeung G; Friedlander M; Bowtell DD, 2020, 'The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer', in Overcoming Ovarian Cancer Chemoresistance, pp. 43 - 53, http://dx.doi.org/10.1016/B978-0-12-819840-7.00013-3

Book Chapters | 2017

Berek JS; Friedlander ML; Bast RC, 2017, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 27, http://dx.doi.org/10.1002/9781119000822.hfcm105

Book Chapters | 2017

Berek JS; Friedlander ML; Bast RC, 2017, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 17, http://dx.doi.org/10.1002/9781119000822.hfcm106

Book Chapters | 2014

Berek JS; Friedlander ML; Hacker NF, 2014, 'Epithelial ovarian, fallopian tube, and peritoneal cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 464 - 529

Book Chapters | 2014

Berek JS; Friedlander ML; Hacker NF, 2014, 'Germ cell and nonepithelial ovarian cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 530 - 559

Book Chapters | 2014

Friedlander M; Thigpen JT, 2014, 'Response as a measure of treatment efficacy in clinical trials: Should recist be abandoned?', in Controversies in the Management of Gynecological Cancers, pp. 91 - 100, http://dx.doi.org/10.1007/978-0-85729-910-9_9

Book Chapters | 2014

Friedlander ML; Markman M, 2014, 'Chemotherapy', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 58 - 84

Book Chapters | 2014

Hacker NF; Friedlander ML, 2014, 'Uterine cancer', in Berek and Hacker's Gynecologic Oncology: Sixth Edition, pp. 390 - 442

Book Chapters | 2011

Berek JS; Longacre T; Friedlander M, 2011, 'Ovarian, Fallopian Tube and Peritoneal Cancer', in Berek JS (ed.), Berek and Novak's Gynecology, edn. 15th, Royal College of Obstetricians and Gynaecologists, UK, pp. 1350 - 1427

Book Chapters | 2011

Gainford M; Friedlander M, 2011, 'Squamous Cell Carcinomas Arising From Dermoids', in Reed N; Green JA; Gershenson DM; Siddiqui N; Connor R (ed.), Rare and Uncommon Gynecological Cancers, Springer, USA, pp. 131 - 134

Book Chapters | 2010

Hacker NF; Friedlander ML, 2010, 'Breast Disease: A Gynecologic Perspective', in Hacker &amp Moore's Essentials of Obstetrics and Gynecology, Elsevier, pp. 326 - 331, http://dx.doi.org/10.1016/b978-1-4160-5940-0.00029-1

Book Chapters | 1997

Friedlander ML; Gershenson D; Hacker NF; Arjun G; Smitj ; Barber HM, 1997, 'Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers.', in Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers., edn. Original, Mercel Dekker, New York, pp. 263 - 270
Journal articles | 2025

Francis KE; Simon S; Gebski V; Joly F; Ledermann JA; Penson RT; Oza AM; Korach J; Lainez N; Cecere SC; Tasca G; Gropp-Meier M; Fujiwara K; Lowe ES; Friedlander M; Pujade-Lauraine E; Lee CK, 2025, 'Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer', Gynecologic Oncology, 192, pp. 50 - 55, http://dx.doi.org/10.1016/j.ygyno.2024.11.004

Journal articles | 2025

Friedlander ML; Anderson L; Lee YC, 2025, 'Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101668

Journal articles | 2025

Lee YC; Whitely A; Burling M; Anderson L; Cohen PA; Naidoo M; Richardson G; Perera S; Scott CL; Friedlander M; Brand A; McNally O; Hyde S; Bunting M; Jobling T; Zalcberg J; Rome R, 2025, 'Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2024.100052

Journal articles | 2025

Na R; Jordan SJ; DeFazio A; Williams M; Livingstone K; Obermair A; Friedlander M; Grant P; Webb PM, 2025, 'Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival—A prospective cohort study in Australia', International Journal of Cancer, 156, pp. 280 - 292, http://dx.doi.org/10.1002/ijc.35154

Journal articles | 2025

Nahm SH; Kiely BE; O'Connell RL; Lee YC; Davis A; Avall-Lundqvist E; Berek JS; Berton D; Donnellan P; Hilpert F; Joly F; Lanceley A; Ledermann JA; Okamoto A; Oza A; Pignata S; Sehouli J; King MT; Friedlander M; Stockler MR; Roncolato FT; GCIG Symptom Benefit Group , 2025, 'Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.', Int J Gynecol Cancer, 35, pp. 100030, http://dx.doi.org/10.1016/j.ijgc.2024.100030

Journal articles | 2025

Phillips KA; Kotsopoulos J; Domchek SM; Terry MB; Chamberlain JA; Bassett JK; Aeilts AM; Andrulis IL; Buys SS; Cui W; Daly MB; Eisen AF; Foulkes WD; Friedlander ML; Gronwald J; Hopper JL; John EM; Karlan BY; Kim RH; Kurian AW; Lubinski J; Metcalfe K; Nathanson KL; Singer CF; Southey MC; Symecko H; Tung N; Narod SA; Milne RL; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Bodek S; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Chenevix-Trench G; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; Defazio A; Delatycki M; Dickson R; Dixon J; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Friedlander M; Gaff C; Gattas M; George P; Greening S; Harris M; Hart S; Harraka P; Hayward N; Hopper J; Hoskins C; Hunt C; James P; Jenkins M; Kidd A; Kirk J; Koehler J; Kollias J; Lakhani S; Lawrence M; Lee J; Li S; Lindeman G; Lippey J; Lipton L; Lobb L; Loi S; Mann G, 2025, 'Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2', Journal of Clinical Oncology, 43, pp. 422 - 431, http://dx.doi.org/10.1200/JCO.24.00176

Journal articles | 2025

Pitiyarachchi O; Friedlander M, 2025, 'Age disparities in clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with high grade serous ovarian cancer: A wake up call to improving outcomes in older patients', Journal of Geriatric Oncology, 16, http://dx.doi.org/10.1016/j.jgo.2024.102152

Journal articles | 2024

Burdett NL; Willis MO; Pandey A; Twomey L; Alaei S; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; Malt M; Chiew YE; Stenlake A; Sullivan H; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; White J; Jayde V; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Ball C; Young C; Brooks J; Mileshkin L; Au-Yeung G; Phillips K; Rischin D; Delahunty R; Christie E; Garsed D; Fox S; Johnson D; Lade S; Loughrey M; O’Callaghan N; Murray W; Purdie D; Whiteman D; Proietto A; Braye S; Otton G; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Beale P; Beith J; Carter J; Dalrymple C; Houghton R; Russell P; Davy M; Oehler MK; Hall C; Dodd T; Blomfield P, 2024, 'Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-50137-y

Journal articles | 2024

Danska-Bidzinska A; Makker V; Salutari V; Ayhan A; Romero I; Levy T; McCormack M; Baurain J-F; Mach P; Cadoo KA; Mackay H; Friedlander ML; Santin AD; Slomovitz BM; Miller DS; McKenzie J; Yao L; Khemka V; Nogueira-Rodrigues A; Marth C, 2024, '737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study', Annals of Oncology, 35, pp. S561 - S561, http://dx.doi.org/10.1016/j.annonc.2024.08.799

Journal articles | 2024

Diéras V; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Loirat D; Ratajczak C; Adamu H; Girardi V; Arun BK, 2024, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial', European Journal of Cancer, 200, http://dx.doi.org/10.1016/j.ejca.2024.113580

Journal articles | 2024

Ganz PA; Bandos H; Španić T; Friedman S; Müller V; Kuemmel S; Delaloge S; Brain E; Toi M; Yamauchi H; De Dueñas EM; Armstrong A; Im SA; Song CG; Zheng H; Sarosiek T; Sharma P; Geng C; Fu P; Rhiem K; Frauchiger-Heuer H; Wimberger P; T'Kint De Roodenbeke D; Liao N; Goodwin A; Chakiba-Brugère C; Friedlander M; Lee KS; Giacchetti S; Takano T; Henao-Carrasco F; Virani S; Valdes-Albini F; Domchek SM; Bane C; McCarron EC; Mita M; Rossi G; Rastogi P; Fielding A; Gelber RD; Scheepers ED; Cameron D; Garber J; Geyer CE; Tutt ANJ, 2024, 'Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer', Journal of Clinical Oncology, 42, pp. 1288 - 1300, http://dx.doi.org/10.1200/JCO.23.01214

Journal articles | 2024

Haggstrom L; Lee YC; Scott C; Harter P; Woelber L; Ledermann J; Gourley C; McNeish IA; Amant F; Ray-Coquard I; Leary A; Oza AM; Tinker A; González Martin A; Cecere SC; Pignata S; Colombo N; Yoshida H; Marth C; Rosengarten O; Moore KN; Gómez-García EM; Tan D; Friedlander ML, 2024, 'How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes', International Journal of Gynecological Cancer, 34, pp. 1932 - 1939, http://dx.doi.org/10.1136/ijgc-2024-005976

Journal articles | 2024

Haggstrom LR; Lee YC; Scott CL; Ledermann JA; Gourley C; McNeish I; Amant F; Ray-Coquard IL; Leary A; Oza AM; Tinker A; González-Martín A; Cecere SC; Colombo N; Yoshida H; Marth C; Gomez Garcia EM; Tan DS; Moore KN; Friedlander ML, 2024, '764P How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes', Annals of Oncology, 35, pp. S578 - S579, http://dx.doi.org/10.1016/j.annonc.2024.08.825

Journal articles | 2024

Konstantinopoulos P; Kim J-W; Freyer G; Lee J-Y; Gaba L; Grisham R; Colombo N; Wu X; Sehouli J; Cruz F; Cibula D; Monk B; Nyvang G-B; Friedlander M; Lorusso D; Van Nieuwenhuysen E; Glasspool R; Marth C; Hinson P; Zuradelli M; Wang C; Su F; Miller M; Matulonis U; González-Martín A, 2024, 'Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial', Gynecologic Oncology, 190, pp. S12 - S12, http://dx.doi.org/10.1016/j.ygyno.2024.07.024

Journal articles | 2024

Kumari S; Moujaber T; Gloss B; Madsen I; Gao B; Provan P; Srirangan S; Bouantoun N; Kennedy C; Traficante N; Friedlander ML; Brand A; Gourley C; Garsed DW; Bowtell D; Harnett P; Balleine R; Defazio A, 2024, '8P Biomarkers to predict chemotherapy response in low-grade serous ovarian carcinoma', ESMO Open, 9, pp. 103508 - 103508, http://dx.doi.org/10.1016/j.esmoop.2024.103508

Journal articles | 2024

Lefkovits YR; Heriot N; Sporik A; Perera S; Friedlander M; Dixon C; Cohen PA; Lee YC; Hyde S; Richardson G; Webb P; Rome R; King M; Zalcberg J; Schofield P, 2024, 'Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges', BMC Health Services Research, 24, http://dx.doi.org/10.1186/s12913-024-11042-8

Journal articles | 2024

Li T; Timmins HC; Mahfouz FM; Mizrahi D; Horvath L; Harrison ML; Grimison PS; Friedlander M; Marx GM; Boyle FM; Wyld D; Henderson R; King T; Baron-Hay SE; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Identifying optimized assessment of nerve damage during chemotherapy.', Journal of Clinical Oncology, 42, pp. 12016 - 12016, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12016

Journal articles | 2024

Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy', JAMA Network Open, 7, pp. e2424139, http://dx.doi.org/10.1001/jamanetworkopen.2024.24139

Journal articles | 2024

McDonald JA; Liao Y; Knight JA; John EM; Kurian AW; Daly M; Buys SS; Huang Y; Frost CJ; Andrulis IL; Colonna SV; Friedlander ML; Hopper JL; Chung WK; Genkinger JM; Macinnis RJ; Terry MB, 2024, 'Pregnancy-Related Factors and Breast Cancer Risk for Women Across a Range of Familial Risk', JAMA Network Open, 7, pp. e2427441, http://dx.doi.org/10.1001/jamanetworkopen.2024.27441

Journal articles | 2024

Na R; Nagle CM; Bartsch S; Ibiebele TI; Williams M; Grant P; Friedlander ML; Webb PM, 2024, 'Use of Dietary Supplements Before, During and After Treatment for Ovarian Cancer: Results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study', Nutrition and Cancer, http://dx.doi.org/10.1080/01635581.2024.2408775

Journal articles | 2024

Naidoo M; Scott CL; McNally O; Rome R; Perera S; Lee YC; Whitely A; Burling M; Anderson L; Cohen P; Richardson GE; Friedlander M; Brand A; Hyde S; Bunting M; Jobling T; Zalcberg JR, 2024, 'Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).', Journal of Clinical Oncology, 42, pp. e17554 - e17554, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e17554

Journal articles | 2024

Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M, 2024, 'Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over', Gynecologic Oncology, 187, pp. 221 - 226, http://dx.doi.org/10.1016/j.ygyno.2024.05.021

Journal articles | 2024

Ramachandran D; Tyrer JP; Kommoss S; DeFazio A; Riggan MJ; Webb PM; Fasching PA; Lambrechts D; García MJ; Rodríguez-Antona C; Goodman MT; Modugno F; Moysich KB; Karlan BY; Lester J; Kjaer SK; Jensen A; Høgdall E; Goode EL; Cliby WA; Kumar A; Wang C; Cunningham JM; Winham SJ; Monteiro AN; Schildkraut JM; Cramer DW; Terry KL; Titus L; Bjorge L; Thomsen LCV; Pejovic T; Høgdall CK; McNeish IA; May T; Huntsman DG; Pfisterer J; Canzler U; Park-Simon TW; Schröder W; Belau A; Hanker L; Harter P; Sehouli J; Kimmig R; de Gregorio N; Schmalfeldt B; Baumann K; Hilpert F; Burges A; Winterhoff B; Schürmann P; Speith LM; Hillemanns P; Berchuck A; Johnatty SE; Ramus SJ; Chenevix-Trench G; Pharoah PDP; Dörk T; Heitz F; Bowtell D; Fereday S; Traficante N; Hung J; Friedlander M; Obermair A; Grant P; Beesley V; Blomfield P; Brand A; Davis A; Leung Y; Nicklin J; Quinn M; Livingstone K; O’Neill H; Williams M, 2024, 'Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease', npj Genomic Medicine, 9, http://dx.doi.org/10.1038/s41525-024-00395-y

Journal articles | 2024

Ray-Coquard I; Casali PG; Croce S; Fennessy FM; Fischerova D; Jones R; Sanfilippo R; Zapardiel I; Amant F; Blay JY; Martin-Broto J; Casado A; Chiang S; Dei Tos AP; Haas R; Hensley ML; Hohenberger P; Kim JW; Kim SI; Meydanli MM; Pautier P; Abdul Razak AR; Sehouli J; Van Houdt W; Planchamp F; Friedlander M, 2024, 'ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas', International Journal of Gynecological Cancer, 34, pp. 1499 - 1521, http://dx.doi.org/10.1136/ijgc-2024-005823

Journal articles | 2024

Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M, 2024, 'Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer', Gynecologic Oncology, 185, pp. 128 - 137, http://dx.doi.org/10.1016/j.ygyno.2024.02.025

Journal articles | 2024

Ross TL; Na R; Au-Yeung G; DeFazio A; Friedlander M; Sivakumaran T; Livingstone K; Nagle CM; O'Neill H; Williams M; Webb PM; Beesley VL, 2024, 'Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?', Gynecologic Oncology, 190, pp. 53 - 61, http://dx.doi.org/10.1016/j.ygyno.2024.07.684

Journal articles | 2024

Scott CL; Friedlander ML; Francis K; Kartikasari AER; Diamante K; Bound N; Davies C; O’Connell R; Lee YC; Lombard J; Baron-Hay SE; Antill Y; Shannon C; Selva-Nayagam S; Beale PJ; Shield-Artin K; Wakefield M; Vandenberg C; Plebanski M; Lee CK, 2024, '747P SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)', Annals of Oncology, 35, pp. S566 - S567, http://dx.doi.org/10.1016/j.annonc.2024.08.808

Journal articles | 2024

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.', Support Care Cancer, 32, pp. 292, http://dx.doi.org/10.1007/s00520-024-08460-z

Journal articles | 2024

Tjokrowidjaja A; Friedlander ML; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Lord SJ; Scott CL; Goble S; York W; Lee CK; Khoon Lee C; You B; Paoletti X; Glasspool R; Mirza M; Antill Y; Mileshkin L; Ethier JL; Bookman M; Gourley C, 2024, 'Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor', Journal of Clinical Oncology, 42, pp. 1301 - 1310, http://dx.doi.org/10.1200/JCO.23.01182

Journal articles | 2024

Tjokrowidjaja A; Kok PS; Antill YC; Scott CL; Mileshkin LR; Friedlander ML; Lee CK, 2024, 'Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas—a meta-analysis', JNCI Cancer Spectrum, 8, http://dx.doi.org/10.1093/jncics/pkae101

Journal articles | 2024

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE, 2024, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial', Translational Oncology, 43, http://dx.doi.org/10.1016/j.tranon.2024.101914

Journal articles | 2024

Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK, 2024, 'Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00296

Journal articles | 2024

Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG, 2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690

Journal articles | 2024

Zebic DS; Tjokrowidjaja A; Francis KE; Friedlander M; Gebski V; Lortholary A; Joly F; Hasenburg A; Mirza M; Denison U; Cecere SC; Ferrero A; Pujade-Lauraine E; Lee CK, 2024, 'Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer', British Journal of Cancer, 130, pp. 425 - 433, http://dx.doi.org/10.1038/s41416-023-02528-z

Journal articles | 2024

Zwimpfer TA; Ewald H; Bilir E; Jayawardana M; Appenzeller-Herzog C; Bizzarri N; Razumova Z; Kacperczyk-Bartnik J; Heinzelmann-Schwarz V; Friedlander M; Bowtell DDL; Garsed DW, 2024, 'Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma', Cochrane Database of Systematic Reviews, 2024, http://dx.doi.org/10.1002/14651858.CD015896

Journal articles | 2023

Burdett NL; Willis MO; Pandey A; Fereday S; Zeps N; Whiteman D; Purdie D; Haviv I; Buck M; McCartney A; Leung Y; Hammond I; Ganju V; Blum R; Ng LF; Bell R; Underhill C; Quinn M; Neesham D; Pyman J; Billson V; Waring P; Murray W; O’Callaghan N; Loughrey M; Lade S; Johnson D; Fox S; Rischin D; Phillips K; Au-Yeung G; Mileshkin L; Simpson I; Sumithran E; Susil B; Rogers P; McNealage J; Manolitsas T; Jobling T; Healy D; Robbie M; Laurie R; Hyde S; Grant P; Allen D; Rome R; Brown B; Parker A; McIntosh R; Challis D; Blomfield P; Pierdes J; Miller J; Henderson D; Pittman K; Healy T; Dodd T; Hall C; Oehler MK; Davy M; Nicklin J; Wyld D; Perrin L; Obermair A; Horwood K; Cummings M; Crandon A; Papadimos D; Ward B; Wain G; Sharma R; Harnett P; Jaworski R; Byth K; Brand A; Hill J; Grygiel J; Links M; Russell P; Houghton R; Dalrymple C; Carter J; Beith J; Beale P; Robertson G; Marsden D; Hacker N; Edwards L; Crouch R; Camaris C; Young B; Valmadre S; Pavlakis N; Nevell D; Gard G; Ferrier A; Baron-Hay S; Bell D; Friedlander M; Begbie S, 2023, 'Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-48153-x

Journal articles | 2023

Campbell R; King MT; Stockler MR; Lee YC; Roncolato FT; Friedlander ML, 2023, 'Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.', Patient Relat Outcome Meas, 14, pp. 111 - 126, http://dx.doi.org/10.2147/PROM.S297301

Journal articles | 2023

Cohen PA; Webb PM; King M; Obermair A; Gebski V; Butow P; Morton R; Lawson W; Yates P; Campbell R; Meniawy T; McMullen M; Dean A; Goh J; McNally O; Mileshkin L; Beale P; Beach R; Hill J; Dixon C; Hegarty S; Codde J; Ives A; Lee YC; Brand A; Mellon A; Bilic S; Black I; Jeffares S; Friedlander M, 2023, 'Getting the MOST out of follow-up: A randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2021-002999

Journal articles | 2023

DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; McNamara J; Lowe ES; Ah-See M-L; Moore KN, 2023, 'Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial', Obstetrical & Gynecological Survey, 78, pp. 25 - 27, http://dx.doi.org/10.1097/ogx.0000000000001120

Journal articles | 2023

DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martí A; Aghajanian C; Bradley W; Mathews C; Liu J; McNamara J; Lowe ES; Ah-See ML; Moore KN, 2023, 'Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial', Obstetrical and Gynecological Survey, 78, pp. 25 - 27, http://dx.doi.org/10.1097/OGX.0000000000001120

Journal articles | 2023

Evans DG; Phillips KA; Milne RL; Fruscio R; Cybulski C; Gronwald J; Lubinski J; Huzarski T; Hyder Z; Forde C; Metcalfe K; Senter L; Weitzel J; Tung N; Zakalik D; Ekholm M; Sun P; Narod SA; Wood M; McKinnon W; Karlan B; Singer C; Couch F; Ainsworth P; Eng C; Cullinane C; Neuhausen S; Moller P; Foulkes W; Kim R; Sweet K; Eisen A; Stanhope L; O’Connor S; Picken S; Nesci S; McLachlan SA; Friedlander M; Wandzel P; Waśko B; Urbański K; Uciński M; Szczylik C; Ryś J; Posmyk M; Mierzwa T; Morawiec Z; Gugała K; Oszurek O; Niepsuj S; Mituś JW; Mackiewicz A; Lange D; Lamperska K; Kozak-Klonowska B; Synowiec A; Kordek R; Karczewska A; Jeziorski A; Grzybowska E; Goźdź S; Gozdecka-Grodecka S; Drosik K; Chosia M; Błasińska-Morawiec M, 2023, 'Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment (British Journal of Cancer, (2021), 124, 9, (1524-1532), 10.1038/s41416-020-01164-1)', British Journal of Cancer, 128, pp. 703, http://dx.doi.org/10.1038/s41416-022-02130-9

Journal articles | 2023

Friedlander M; Lee YC; Tew WP, 2023, 'Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.', Am Soc Clin Oncol Educ Book, 43, pp. e390876, http://dx.doi.org/10.1200/EDBK_390876

Journal articles | 2023

Friedlander M; Mileshkin L; Lombard J; Frentzas S; Gao B; Wilson M; Meniawy T; Baron-Hay S; Briscoe K; McCarthy N; Fountzilas C; Cervantes A; Ge R; Wu J; Spira A, 2023, 'Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial', British Journal of Cancer, 129, pp. 797 - 810, http://dx.doi.org/10.1038/s41416-023-02349-0

Journal articles | 2023

Hayes S; Obermair A; Mileshkin L; Davis A; Gordon LG; Eakin E; Janda M; Beesley VL; Barnes EH; Spence RR; Sandler C; Jones T; Vagenas D; Webb P; Andrews J; Brand A; Lee YC; Friedlander M; Pumpa K; O'Neille H; Williams M; Stockler M, 2023, 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: Design and implementation of a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-067925

Journal articles | 2023

Johnston EA; Ibiebele TI; Friedlander ML; Grant PT; van der Pols JC; Webb PM, 2023, 'Association of Protein Intake with Recurrence and Survival Following Primary Treatment of Ovarian Cancer', American Journal of Clinical Nutrition, 118, pp. 50 - 58, http://dx.doi.org/10.1016/j.ajcnut.2023.05.002

Journal articles | 2023

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526

Journal articles | 2023

Kumari S; Moujaber T; Madsen I; Gao B; Provan P; Srirangan S; Bouantoun N; Kennedy C; Sharma R; Fereday S; Traficante N; Friedlander ML; Brand A; Gourley C; Garsed DW; Bowtell D; Balleine R; Harnett P; DeFazio A, 2023, '16P Response to taxanes in low-grade serous ovarian cancer patients and cell lines', ESMO Open, 8, pp. 101037 - 101037, http://dx.doi.org/10.1016/j.esmoop.2023.101037

Journal articles | 2023

Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB, 2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074

Journal articles | 2023

Majidi A; Na R; Jordan SJ; DeFazio A; Obermair A; Friedlander M; Grant P; Webb PM, 2023, 'Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study', Journal of the National Cancer Institute, 115, pp. 570 - 577, http://dx.doi.org/10.1093/jnci/djac239

Journal articles | 2023

May T; Bernardini M; Lheureux S; Aben KKH; Bandera EV; Beckmann MW; Benitez J; Berchuck A; Bjørge L; Carney ME; Cramer DW; Defazio A; Dörk T; Eccles DM; Friedlander M; García MJ; Goode EL; Hein A; Jensen A; Johnatty S; Kennedy CJ; Kiemeney LA; Kjær SK; Kupryjanczyk J; Matsuo K; McGuire V; Modugno F; Paddock LE; Pejovic T; Phelan CM; Riggan MJ; Rodriguez-Antona C; Rothstein JH; Sieh W; Song H; Terry KL; Altena AMV; Vanderstichele A; Vergote I; Thomsen LCV; Webb PM; Wentzensen N; Wilkens LR; Ziogas A; Jiang H; Tone A, 2023, 'Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis', CMAJ. Canadian Medical Association Journal, 66, pp. E310 - E320, http://dx.doi.org/10.1503/cjs.017020

Journal articles | 2023

Meagher NS; Hamilton P; Milne K; Thornton S; Harris B; Weir A; Alsop J; Bisinoto C; Brenton JD; Brooks-Wilson A; Chiu DS; Cushing-Haugen KL; Fereday S; Garsed DW; Gayther SA; Gentry-Maharaj A; Gilks B; Jimenez-Linan M; Kennedy CJ; Le ND; Piskorz AM; Riggan MJ; Shah M; Singh N; Talhouk A; Widschwendter M; Bowtell DDL; Candido dos Reis FJ; Cook LS; Fortner RT; García MJ; Harris HR; Huntsman DG; Karnezis AN; Köbel M; Menon U; Pharoah PDP; Doherty JA; Anglesio MS; Pike MC; Pearce CL; Friedlander ML; DeFazio A; Nelson BH; Ramus SJ, 2023, 'Profiling the immune landscape in mucinous ovarian carcinoma', Gynecologic Oncology, 168, pp. 23 - 31, http://dx.doi.org/10.1016/j.ygyno.2022.10.022

Journal articles | 2023

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834

Journal articles | 2023

Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; Sahlberg KK; Børresen-Dale AL; Gram IT; Olsen KS; Engebråten O; Naume B; Geisler J; OSBREAC ; Grenaker Alnæs GI; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; DeFazio A; Delatycki M; Dickson R; Dixon J; Edkins T; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Friedlander M; Gaff C, 2023, 'The impact of coding germline variants on contralateral breast cancer risk and survival', American Journal of Human Genetics, 110, pp. 475 - 486, http://dx.doi.org/10.1016/j.ajhg.2023.02.003

Journal articles | 2023

Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; Sahlberg KK; Børresen-Dale AL; Gram IT; Olsen KS; Engebråten O; Naume B; Geisler J; Grenaker Alnæs GI; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; Clarke C; Marsh D; Scott R; Baxter R; Yip D; Carpenter J; Davis A; Pathmanathan N; Simpson P; Graham JD; Sachchithananthan M; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Chenevix-Trench G; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; DeFazio A, 2023, 'Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival', Cancer Medicine, 12, pp. 16142 - 16162, http://dx.doi.org/10.1002/cam4.6272

Journal articles | 2023

Ngoi NYL; Sun H; Choi CH; Heong V; Ow SGW; Chay WY; Kim HS; Goss G; Goh JC; Lin M; Lim D; Kim J-W; Friedlander M; Tai BC; Kim K; Tan DSP, 2023, 'Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.', Journal of Clinical Oncology, 41, pp. e17564 - e17564, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17564

Journal articles | 2023

Pitiyarachchi O; Lee YC; Sim HW; Srirangan S; Mapagu C; Kirk J; Harnett PR; Balleine RL; Bowtell DDL; Samimi G; Brand AH; Marsh DJ; Beale P; Anderson L; Bouantoun N; Provan P; Ramus SJ; DeFazio A; Friedlander M, 2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638

Journal articles | 2023

Praiss AM; Miller A; Smith J; Lichtman SM; Bookman M; Aghajanian C; Sabbatini P; Backes F; Cohn DE; Argenta P; Friedlander M; Goodheart MJ; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray H; Secord AA; Van Le L; O'Cearbhaill RE, 2023, 'Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study', Gynecologic Oncology, 174, pp. 213 - 223, http://dx.doi.org/10.1016/j.ygyno.2023.05.013

Journal articles | 2023

Sia TY; Tew WP; Purdy C; Chi DS; Menzin AW; Lovecchio JL; Bookman MA; Cohn DE; Teoh DG; Friedlander M; Bender D; Mutch DG; Gershenson DM; Tewari KS; Wenham RM; Wahner Hendrickson AE; Lee RB; Gray HJ; Secord AA; Van Le L; Lichtman SM, 2023, 'The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study', Gynecologic Oncology, 173, pp. 130 - 137, http://dx.doi.org/10.1016/j.ygyno.2023.03.018

Journal articles | 2023

Smith D; Robledo KP; Yip S; Cummins MM; Kok PS; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Spurdle AB; Andrews J; Stockler MR; Mileshkin L; Antill Y, 2023, 'Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)', Cancers, 15, http://dx.doi.org/10.3390/cancers15010254

Journal articles | 2023

Solomon B; Gao B; Subbiah V; Millward M; Rosen L; Desai J; Sbar EI; Collins N; Thuy H; Song X; Shao W; Jaggi J; Edris B; Ramachandran P; Luo L; Friedlander M, 2023, 'Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.AM2023-CT033

Journal articles | 2023

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin LR; Ananda S; Shannon CM; Friedlander M; Warton K; Ford C, 2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.', Journal of Clinical Oncology, 41, pp. 5561 - 5561, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5561

Journal articles | 2023

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031

Journal articles | 2023

You B; Sehgal V; Hosmane B; Huang X; Ansell PJ; Dinh MH; Bell-Mcguinn K; Luo X; Fleming GF; Friedlander M; Bookman MA; Moore KN; Steffensen KD; Coleman RL; Swisher EM, 2023, 'CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis from the VELIA/GOG-3005 Study', Journal of Clinical Oncology, 41, pp. 107 - 116, http://dx.doi.org/10.1200/JCO.22.00430

Journal articles | 2022

Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL, 2022, 'Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial', Gynecologic Oncology, 164, pp. 278 - 287, http://dx.doi.org/10.1016/j.ygyno.2021.12.012

Journal articles | 2022

Beesley VL; Ross TL; King MT; Campbell R; Nagle CM; Obermair A; Grant P; DeFazio A; Webb PM; Friedlander ML, 2022, 'Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)', Gynecologic Oncology, 164, pp. 437 - 445, http://dx.doi.org/10.1016/j.ygyno.2021.12.006

Journal articles | 2022

Campbell R; Costa DSJ; Stockler MR; Lee YC; Ledermann JA; Berton D; Sehouli J; Roncolato FT; Connell RO; Okamoto A; Bryce J; Oza AM; Avall-Lundqvist E; Berek JS; Lanceley A; Joly F; Hilpert F; Feeney A; Kaminsky MC; Diamante K; Friedlander ML; King MT, 2022, 'Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer', Gynecologic Oncology, 166, pp. 254 - 262, http://dx.doi.org/10.1016/j.ygyno.2022.05.024

Journal articles | 2022

Cho D; Lord SJ; Simes J; Cooper W; Friedlander M; Bae S; Lee CK, 2022, 'Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221112822

Journal articles | 2022

Delahunty R; Nguyen L; Craig S; Creighton B; Ariyaratne D; Garsed DW; Christie E; Fereday S; Andrews L; Lewis A; Limb S; Pandey A; Hendley J; Traficante N; Carvajal N; Spurdle AB; Thompson B; Parsons MT; Beshay V; Volcheck M; Semple T; Lupat R; Doig K; Yu J; Chen XQ; Marsh A; Love C; Bilic S; Beilin M; Nichols CB; Greer C; Lee YC; Gerty S; Gill L; Newton E; Howard J; Williams R; Norris C; Stephens AN; Tutty E; Smyth C; O'connell S; Jobling T; Stewart CJR; Tan A; Fox SB; Pachter N; Li J; Ellul J; Mir Arnau G; Young MA; Gordon L; Forrest L; Harris M; Livingstone K; Hill J; Chenevix-Trench G; Cohen PA; Webb PM; Friedlander M; James P; Bowtell D; Alsop K, 2022, 'TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members', Journal of Clinical Oncology, 40, pp. 2036 - 2047, http://dx.doi.org/10.1200/JCO.21.02108

Journal articles | 2022

Devries AA; Dennis J; Tyrer JP; Peng PC; Coetzee SG; Reyes AL; Plummer JT; Davis BD; Chen SS; Dezem FS; Aben KKH; Anton-Culver H; Antonenkova NN; Beckmann MW; Beeghly-Fadiel A; Berchuck A; Bogdanova NV; Bogdanova-Markov N; Brenton JD; Butzow R; Campbell I; Chang-Claude J; Chenevix-Trench G; Cook LS; Defazio A; Doherty JA; Dork T; Eccles DM; Eliassen AH; Fasching PA; Fortner RT; Giles GG; Goode EL; Goodman MT; Gronwald J; Hakansson N; Hildebrandt MAT; Huff C; Huntsman DG; Jensen A; Kar S; Karlan BY; Khusnutdinova EK; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Labrie M; Lambrechts D; Le ND; Lubinski J; May T; Menon U; Milne RL; Modugno F; Monteiro AN; Moysich KB; Odunsi K; Olsson H; Pearce CL; Pejovic T; Ramus SJ; Riboli E; Riggan MJ; Romieu I; Sandler DP; Schildkraut JM; Setiawan VW; Sieh W; Song H; Sutphen R; Terry KL; Thompson PJ; Titus L; Tworoger SS; Van Nieuwenhuysen E; Edwards DV; Webb PM; Wentzensen N; Whittemore AS; Wolk A; Wu AH; Ziogas A; Freedman ML; Lawrenson K; Pharoah PDP; Easton DF; Gayther SA; Jones MR, 2022, 'Copy number variants are ovarian cancer risk alleles at known and novel risk loci', Journal of the National Cancer Institute, 114, pp. 1533 - 1544, http://dx.doi.org/10.1093/jnci/djac160

Journal articles | 2022

Francis KE; Kim SI; Friedlander M; Gebski V; Ray-Coquard I; Clamp A; Penson RT; Oza A; Perri T; Huzarski T; Martin-Lorente C; Cecere SC; Colombo N; Ataseven B; Fujiwara K; Sonke G; Vergote I; Pujade-Lauraine E; Kim JW; Lee CK, 2022, 'The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer', Annals of Oncology, 33, pp. 593 - 601, http://dx.doi.org/10.1016/j.annonc.2022.02.222

Journal articles | 2022

Garsed DW; Pandey A; Fereday S; Kennedy CJ; Takahashi K; Alsop K; Hamilton PT; Hendley J; Chiew YE; Traficante N; Provan P; Ariyaratne D; Au-Yeung G; Bateman NW; Bowes L; Brand A; Christie EL; Cunningham JM; Friedlander M; Grout B; Harnett P; Hung J; McCauley B; McNally O; Piskorz AM; Saner FAM; Vierkant RA; Wang C; Winham SJ; Pharoah PDP; Brenton JD; Conrads TP; Maxwell GL; Ramus SJ; Pearce CL; Pike MC; Nelson BH; Goode EL; DeFazio A; Bowtell DDL, 2022, 'The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer', Nature Genetics, 54, pp. 1853 - 1864, http://dx.doi.org/10.1038/s41588-022-01230-9

Journal articles | 2022

Gersekowski K; Delahunty R; Alsop K; Goode EL; Cunningham JM; Winham SJ; Pharoah P; Song H; Jordan S; Fereday S; DeFazio A; Friedlander M; Obermair A; Webb PM, 2022, 'Germline BRCA variants, lifestyle and ovarian cancer survival', Gynecologic Oncology, 165, pp. 437 - 445, http://dx.doi.org/10.1016/j.ygyno.2022.03.020

Journal articles | 2022

Han HS; Arun BK; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bach BA; Kundu MG; Khandelwal N; Feng D; Bhattacharya S; Maag D; Ratajczak CK; Diéras V, 2022, 'Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial', Annals of Oncology, 33, pp. 299 - 309, http://dx.doi.org/10.1016/j.annonc.2021.11.018

Journal articles | 2022

Hooshmand K; Goldstein D; Timmins HC; Li T; Harrison M; Friedlander ML; Lewis CR; Lees JG; Moalem-Taylor G; Guennewig B; Park SB; Kwok JB, 2022, 'Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study', Journal of Translational Medicine, 20, http://dx.doi.org/10.1186/s12967-022-03754-4

Journal articles | 2022

Konstantinopoulos PA; Gonzalez-Martin A; Cruz FM; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk BJ; Kim JW; Hinson P; Ajipa O; Pretre V; Han Y; Matulonis UA, 2022, 'EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)', Future Oncology, 18, pp. 3481 - 3492, http://dx.doi.org/10.2217/fon-2022-0666

Journal articles | 2022

Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M, 2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319

Journal articles | 2022

Lee C; Gebski V; Francis K; Grenier J; Welz J; Mosconi AM; Rubio-Perez MJ; Grimm C; Matsumoto T; Vergote I; Colombo N; Mirza MR; Follana P; de Gregorio N; Zamagni C; Garcia-Garcia Y; Meunier J; Pujade-Lauraine E; Friedlander M; Ray-Coquard I, 2022, 'A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer', GYNECOLOGIC ONCOLOGY, 166, pp. S160 - S160, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000892330200198&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2022

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky M-C; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075

Journal articles | 2022

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical and Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/OGX.0000000000001075

Journal articles | 2022

Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK, 2022, 'CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors', Journal of Experimental and Clinical Cancer Research, 41, http://dx.doi.org/10.1186/s13046-022-02570-4

Journal articles | 2022

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubinski J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F, 2022, 'Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes', Clinical Cancer Research, 28, pp. 5383 - 5395, http://dx.doi.org/10.1158/1078-0432.CCR-22-1206

Journal articles | 2022

Phillips KA; Friedlander ML, 2022, 'Risk of Peritoneal Cancer after Risk-Reducing Bilateral Salpingo-Oophorectomy for Women with Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?', Journal of Clinical Oncology, 40, pp. 1850 - 1852, http://dx.doi.org/10.1200/JCO.22.00325

Journal articles | 2022

Pitiyarachchi O; Friedlander M; Java JJ; Chan JK; Armstrong DK; Markman M; Herzog TJ; Monk BJ; Backes F; Secord AA; Bonebrake A; Rose PG; Tewari KS; Lentz SS; Geller MA; Copeland LJ; Mannel RS, 2022, 'What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer', Gynecologic Oncology, 166, pp. 410 - 416, http://dx.doi.org/10.1016/j.ygyno.2022.07.004

Journal articles | 2022

Pitiyarachchi O; Phillips KA; Friedlander M, 2022, 'Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation', Cancer Treatment and Research Communications, 30, http://dx.doi.org/10.1016/j.ctarc.2021.100504

Journal articles | 2022

Simon S; Francis KE; Dalrymple JE; Gebski V; Lord SJ; Friedlander M; Lee CK, 2022, 'Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis', European Journal of Cancer, 170, pp. 169 - 178, http://dx.doi.org/10.1016/j.ejca.2022.04.022

Journal articles | 2022

Sivakumaran T; Krasovitsky M; Freimund A; Lee YC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2022, 'Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients', International Journal of Gynecological Cancer, 32, pp. 906 - 912, http://dx.doi.org/10.1136/ijgc-2021-003009

Journal articles | 2022

Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL, 2022, 'Impact of Homologous Recombination Status and Responses with Veliparib Combined with First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study', Journal of Bone and Joint Surgery, 77, pp. 277 - 278, http://dx.doi.org/10.1097/01.ogx.0000827620.82650.68

Journal articles | 2022

Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL, 2022, 'Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study', Gynecologic Oncology, 164, pp. 245 - 253, http://dx.doi.org/10.1016/j.ygyno.2021.12.003

Journal articles | 2022

Timmins HC; Li T; Goldstein D; Trinh T; Mizrahi D; Harrison M; Horvath LG; Friedlander M; Kiernan MC; Park SB, 2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y

Journal articles | 2022

Woodford RG; Zhou DDX; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK, 2022, 'The validity of progression-free survival 2 as a surrogate trial end point for overall survival', Cancer, 128, pp. 1449 - 1457, http://dx.doi.org/10.1002/cncr.34085

Journal articles | 2022

2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', Medicine & Science in Sports & Exercise, 54, pp. 322 - 322, http://dx.doi.org/10.1249/01.mss.0000879060.88938.0b

Journal articles | 2022

2022, 'Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia', JOURNAL OF IMMUNOLOGY, 208, http://dx.doi.org/10.4049/jimmunol.208.Supp.179.04

Journal articles | 2022

2022, 'Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial', ANNALS OF ONCOLOGY, 33, pp. S779 - S779, http://dx.doi.org/10.1016/j.annonc.2022.07.645

Journal articles | 2021

Aghajanian C; Bookman MA; Fleming GF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Jackson CG; Sullivan D; Ratajczak CK; Coleman RL, 2021, 'Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial', Gynecologic Oncology, 162, pp. 375 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.05.031

Journal articles | 2021

Al Ramadhani RM; Nagle CM; Ibiebele TI; Grant P; Friedlander M; De Fazio A; Webb PM, 2021, 'Pre- And post-diagnosis diet quality and ovarian cancer survival', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 229 - 232, http://dx.doi.org/10.1158/1055-9965.EPI-20-1036

Journal articles | 2021

Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L, 2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for ImmunoTherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255

Journal articles | 2021

Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bell-McGuinn KM; Bach BA; Kundu MG; Ratajczak CK; Maag D; Diéras V, 2021, 'Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial', European Journal of Cancer, 154, pp. 35 - 45, http://dx.doi.org/10.1016/j.ejca.2021.05.037

Journal articles | 2021

Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V, 2021, 'Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial', Therapeutic Advances in Medical Oncology, 13, http://dx.doi.org/10.1177/17588359211059601

Journal articles | 2021

Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P, 2021, 'Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 1721 - 1731, http://dx.doi.org/10.1016/S1470-2045(21)00531-3

Journal articles | 2021

Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M, 2021, 'A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial', Gynecologic Oncology, 163, pp. 72 - 78, http://dx.doi.org/10.1016/j.ygyno.2021.07.024

Journal articles | 2021

Berek JS; Renz M; Kehoe S; Kumar L; Friedlander M, 2021, 'Cancer of the ovary, fallopian tube, and peritoneum: 2021 update', International Journal of Gynecology and Obstetrics, 155, pp. 61 - 85, http://dx.doi.org/10.1002/ijgo.13878

Journal articles | 2021

Cameron B; Webber K; Li H; Bennett BK; Boyle F; de Souza P; Wilcken N; Lynch J; Friedlander M; Goldstein D; Lloyd AR, 2021, 'Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study', Brain, Behavior, and Immunity - Health, 10, pp. 100189, http://dx.doi.org/10.1016/j.bbih.2020.100189

Journal articles | 2021

Campbell R; King MT; Ross TL; Cohen PA; Friedlander ML; Webb PM, 2021, 'Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment', Gynecologic Oncology, 163, pp. 398 - 407, http://dx.doi.org/10.1016/j.ygyno.2021.08.022

Journal articles | 2021

Chiang JCB; Goldstein D; Tavakoli A; Trinh T; Klisser J; Lewis CR; Friedlander M; Naduvilath TJ; Au K; Park SB; Krishnan AV; Markoulli M; Tavakkolinasab A, 2021, 'Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel', Scientific Reports, 11, pp. 22884, http://dx.doi.org/10.1038/s41598-021-02439-0

Journal articles | 2021

Colombo N; Moore K; Scambia G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Kim JW; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2021, 'Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial', Gynecologic Oncology, 163, pp. 41 - 49, http://dx.doi.org/10.1016/j.ygyno.2021.07.016

Journal articles | 2021

Conduit C; Milne RL; Friedlander ML; Phillips KA, 2021, 'Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence', Cancer Prevention Research, 14, pp. 983 - 994, http://dx.doi.org/10.1158/1940-6207.CAPR-21-0141

Journal articles | 2021

Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M, 2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, 163, pp. 524 - 530, http://dx.doi.org/10.1016/j.ygyno.2021.09.010

Journal articles | 2021

Evans DG; Phillips KA; Milne RL; Fruscio R; Cybulski C; Gronwald J; Lubinski J; Huzarski T; Hyder Z; Forde C; Metcalfe K; Senter L; Weitzel J; Tung N; Zakalik D; Ekholm M; Sun P; Narod SA; Blasinska-Morawiec M; Chosia M; Drosik K; Gozdecka-Grodecka S; Gozdz S; Grzybowska E; Jeziorski A; Karczewska A; Kordek R; Synowiec A; Kozak-Klonowska B; Lamperska K; Lange D; Mackiewicz A; Mitus JW; Niepsuj S; Oszurek O; Gugala K; Morawiec Z; Mierzwa T; Posmyk M; Rys J; Szczylik C; Ucinski M; Urbanski K; Wasko B; Wandzel P; Friedlander M; McLachlan SA; Nesci S; Picken S; O’Connor S; Stanhope L; Eisen A; Sweet K; Kim R; Foulkes W; Moller P; Neuhausen S; Cullinane C; Eng C; Ainsworth P; Couch F; Singer C; Karlan B; McKinnon W; Wood M, 2021, 'Survival from breast cancer in women with a BRCA2 mutation by treatment', British Journal of Cancer, 124, pp. 1524 - 1532, http://dx.doi.org/10.1038/s41416-020-01164-1

Journal articles | 2021

Francis KE; Gebski V; Lord SJ; Friedlander M; Pujade-Lauraine E; Lee CK, 2021, 'Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting', European Journal of Cancer, 148, pp. 251 - 259, http://dx.doi.org/10.1016/j.ejca.2021.02.006

Journal articles | 2021

Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P, 2021, 'Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial', The Lancet Oncology, 22, pp. 632 - 642, http://dx.doi.org/10.1016/S1470-2045(21)00098-X

Journal articles | 2021

Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; Chenevix-Trench G; Green A; Webb P; De Fazio A; Gertig D; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N, 2021, 'Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses', Modern Pathology, 34, pp. 194 - 206, http://dx.doi.org/10.1038/s41379-020-0618-9

Journal articles | 2021

Kehm RD; MacInnis RJ; John EM; Liao Y; Kurian AW; Genkinger JM; Knight JA; Colonna SV; Chung WK; Milne R; Zeinomar N; Dite GS; Southey MC; Giles GG; McLachlan SA; Whitaker KD; Friedlander ML; Weideman PC; Glendon G; Nesci S; Phillips KA; Andrulis IL; Buys SS; Daly MB; Hopper JL; Terry MB, 2021, 'Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkab090

Journal articles | 2021

Kok PS; Yoon WH; Lord S; Marschner I; Friedlander M; Lee CK, 2021, 'Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis', JCO Precision Oncology, 5, pp. 1151 - 1159, http://dx.doi.org/10.1200/PO.21.00108

Journal articles | 2021

Konstantinopoulos P; Gonzalez-Martin A; Cruz F; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk B; Kim J-W; Alsadius D; Pretre V; Han Y; Matulonis U, 2021, 'EPIK-O/ENGOT-OV61: A PHASE 3, RANDOMIZED STUDY OF ALPELISIB plus OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR -REFRACTORY, HIGH-GRADE SEROUS OVARIAN CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 31, pp. A139 - A140, http://dx.doi.org/10.1136/ijgc-2021-IGCS.350

Journal articles | 2021

Kurtz JE; Gebski V; Sukhin V; Carey M; Kong I; Glasspool RM; Berek JS; de Paiva Batista M; Hall M; Kim JW; Yeoshoua E; Fujiwara N; Nam BH; Polleis S; Lee JY; Strojna A; Farrelly L; Schwameis R; Fossati R; Darlington AS; Lai CH; Wright AA; Rosenblat O; Harter P; Roxburgh P; Chowdhury RR; Chang TC; Paoletti X; Friedlander M, 2021, 'Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee', Gynecologic Oncology, 161, pp. 502 - 507, http://dx.doi.org/10.1016/j.ygyno.2021.02.018

Journal articles | 2021

Ledermann JA; Embleton-Thirsk AC; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Oza A; Vaughan M; Friedlander M; González-Martín A; Deane E; Popoola B; Farrelly L; Swart AM; Kaplan RS; Parmar MKB, 2021, 'Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial', ESMO Open, 6, http://dx.doi.org/10.1016/j.esmoop.2020.100043

Journal articles | 2021

Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL, 2021, 'Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis', Cancer, 127, pp. 2432 - 2441, http://dx.doi.org/10.1002/cncr.33517

Journal articles | 2021

Lux MP; Ciani O; Dunlop WCN; Ferris A; Friedlander M, 2021, 'The impasse on overall survival in oncology reimbursement decision-making: How can we resolve this?', Cancer Management and Research, 13, pp. 8457 - 8471, http://dx.doi.org/10.2147/CMAR.S328058

Journal articles | 2021

MacDonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper JL; Friedlander ML; Emery J; Phillips KA, 2021, 'Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkaa110

Journal articles | 2021

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan SA; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips KA, 2021, 'Breast cancer chemoprevention: Use and views of australian women and their clinicians', Cancer Prevention Research, 14, pp. 131 - 144, http://dx.doi.org/10.1158/1940-6207.CAPR-20-0369

Journal articles | 2021

Park HA; Neumeyer S; Michailidou K; Bolla MK; Wang Q; Dennis J; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baten A; Beane Freeman LE; Becher H; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bogdanova NV; Bojesen SE; Brauch H; Brenner H; Brucker SY; Burwinkel B; Campa D; Canzian F; Castelao JE; Chanock SJ; Chenevix-Trench G; Clarke CL; Børresen-Dale AL; Grenaker Alnæs GI; Sahlberg KK; Ottestad L; Kåresen R; Schlichting E; Holmen MM; Sauer T; Haakensen V; Engebråten O; Naume B; Fosså A; Kiserud CE; Reinertsen KV; Helland Å; Riis M; Geisler J; Conroy DM; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; dos-Santos-Silva I; Dwek M; Eccles DM; Eliassen AH; Engel C; Eriksson M; Evans DG; Fasching PA; Flyger H; Fritschi L; García-Closas M; García-Sáenz JA; Gaudet MM; Giles GG; Glendon G; Goldberg MS; Goldgar DE; González-Neira A; Grip M; Guénel P; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Han S; Harkness EF; Hart SN; He W; Heemskerk-Gerritsen BAM; Hopper JL; Hunter DJ; Marsh D; Scott R; Baxter R; Yip D; Carpenter J; Davis A; Pathmanathan N; Simpson P; Graham D; Sachchithananthan M, 2021, 'Mendelian randomisation study of smoking exposure in relation to breast cancer risk', British Journal of Cancer, 125, pp. 1135 - 1145, http://dx.doi.org/10.1038/s41416-021-01432-8

Journal articles | 2021

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E; Byrski T; Pautier P; Harter P; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Poveda Velasco A; Rodrigues M; Lotz JP; Selle F; Ray-Coquard I; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Yunokawa M; Medioni J; Pécuchet N; Dubot C; De La Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Banerjee S; Cosin J; Hoffman J; Plante M; Covens A; Joly F; Hirte H; Amit A; Matsumoto K; Tjulandin S; Hoon Kim J; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez De Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I; Sikorska M; Słowińska A; Rogowski W; Bidziński M; Śpiewankiewicz B, 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 620 - 631, http://dx.doi.org/10.1016/S1470-2045(21)00073-5

Journal articles | 2021

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E, 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', Obstetrical and Gynecological Survey, 76, pp. 535 - 536, http://dx.doi.org/10.1097/OGX.0000000000000962

Journal articles | 2021

Puhalla SL; Diéras V; Arun BK; Kaufman B; Wildiers H; Han HS; Ayoub JP; Stearns V; Yuan Y; Helsten T; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak CK; Ramathal CY; Friedlander M, 2021, 'Relevance of platinum-free interval and BRCA reversion mutations for veliparib monotherapy after progression on carboplatin/paclitaxel for gBRCA advanced breast cancer (BROCADE3 Crossover)', Clinical Cancer Research, 27, pp. 4983 - 4993, http://dx.doi.org/10.1158/1078-0432.CCR-21-0748

Journal articles | 2021

Quinn MCJ; McCue K; Shi W; Johnatty SE; Beesley J; Civitarese A; O'Mara TA; Glubb DM; Tyrer JP; Armasu SM; Ong JS; Gharahkhani P; Lu Y; Gao B; Patch AM; Fasching PA; Beckmann MW; Lambrechts D; Vergote I; Velez Edwards DR; Beeghly-Fadiel A; Benitez J; Garcia MJ; Goodman MT; Dörk T; Dürst M; Modugno F; Moysich K; Du Bois A; Pfisterer J; Bauman K; Karlan BY; Lester J; Cunningham JM; Larson MC; McCauley BM; Kjaer SK; Jensen A; Hogdall CK; Hogdall E; Schildkraut JM; Riggan MJ; Berchuck A; Cramer DW; Terry KL; Bjorge L; Webb PM; Friedlander M; Pejovic T; Moffitt M; Glasspool R; May T; Ene GEV; Huntsman DG; Woo M; Carney ME; Hinsley S; Heitz F; Fereday S; Kennedy CJ; Edwards SL; Winham SJ; DeFazio A; Pharoah PDP; Goode EL; MacGregor S; Chenevix-Trench G, 2021, 'Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 1669 - 1680, http://dx.doi.org/10.1158/1055-9965.EPI-20-1817

Journal articles | 2021

Scott F; Smet ME; Hardy T; Sundercombe S; Friedlander M; Carey L; Kirk E; Li B; McLennan A, 2021, 'Concurrent maternal malignancy and fetal trisomy detected using genome-wide noninvasive prenatal screening', Prenatal Diagnosis, 41, pp. 1273 - 1276, http://dx.doi.org/10.1002/pd.6020

Journal articles | 2021

Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML, 2021, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer', Gynecologic Oncology, 161, pp. 374 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.02.002

Journal articles | 2021

Timmins HC; Li T; Trinh T; Kiernan MC; Harrison M; Boyle F; Friedlander M; Goldstein D; Park SB, 2021, 'Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response', Oncologist, 26, pp. 366 - 374, http://dx.doi.org/10.1002/onco.13697

Journal articles | 2021

Tjokrowidjaja A; Friedlander M; Lord SJ; Asher R; Rodrigues M; Ledermann JA; Matulonis UA; Oza AM; Bruchim I; Huzarski T; Gourley C; Harter P; Vergote I; Scott CL; Meier W; Shapira-Frommer R; Milenkova T; Pujade-Lauraine E; Gebski V; Lee CK, 2021, 'Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy', European Journal of Cancer, 154, pp. 190 - 200, http://dx.doi.org/10.1016/j.ejca.2021.06.024

Journal articles | 2021

Trinh T; Park SB; Murray J; Pickering H; Lin CSY; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV, 2021, 'Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial', Supportive Care in Cancer, 29, pp. 1103 - 1110, http://dx.doi.org/10.1007/s00520-020-05591-x

Journal articles | 2021

Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276, http://dx.doi.org/10.1038/s41416-021-01420-y

Journal articles | 2020

Aghajanian C; Bookman MA; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Sullivan DM; Fallstrom M; Dinh M; Ratajczak C; Coleman RL, 2020, 'PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).', Journal of Clinical Oncology, 38, pp. 6077 - 6077, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6077

Journal articles | 2020

Barnes DR; Rookus MA; McGuffog L; Leslie G; Mooij TM; Dennis J; Mavaddat N; Adlard J; Ahmed M; Aittomäki K; Andrieu N; Andrulis IL; Arnold N; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Benitez J; Berthet P; Białkowska K; Blanco AM; Blok MJ; Bonanni B; Boonen SE; Borg Å; Bozsik A; Bradbury AR; Brennan P; Brewer C; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Christensen LL; Chung WK; Claes KBM; Colas C; Collonge-Rame MA; Delnatte C; Faivre L; Giraud S; Lasset C; Mari V; Mebirouk N; Mouret-Fourme E; Schuster H; Stoppa-Lyonnet D; Antoniou A; Cook J; Davidson R; Easton D; Eeles R; Evans DG; Frost D; Hanson H; Izatt L; Ong KR; Side L; O’Shaughnessy-Kirwan A; Tischkowitz M; Walker L; Daly MB; de la Hoya M; de Putter R; Devilee P; Diez O; Ding YC; Domchek SM; Dorfling CM; Dumont M; Ejlertsen B; Engel C; Foretova L; Fostira F; Friedlander M; Friedman E; Ganz PA; Garber J; Gehrig A; Gerdes AM; Gesta P; Glendon G; Godwin AK; Goldgar DE, 2020, 'Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants', Genetics in Medicine, 22, pp. 1653 - 1666, http://dx.doi.org/10.1038/s41436-020-0862-x

Journal articles | 2020

Beesley VL; Webber K; Nagle CM; DeFazio A; Obermair A; Williams M; Friedlander M; Webb PM, 2020, 'When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer', Gynecologic Oncology, 159, pp. 179 - 186, http://dx.doi.org/10.1016/j.ygyno.2020.07.029

Journal articles | 2020

Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M, 2020, 'Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors', Journal for ImmunoTherapy of Cancer, 8, http://dx.doi.org/10.1136/jitc-2019-000453

Journal articles | 2020

Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B, 2020, 'Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors', Journal of Clinical Oncology, 38, pp. 2140 - 2150, http://dx.doi.org/10.1200/JCO.19.02654

Journal articles | 2020

DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN, 2020, 'Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial', Journal of Clinical Oncology, 38, pp. 3528 - 3537, http://dx.doi.org/10.1200/JCO.20.00799

Journal articles | 2020

Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK, 2020, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 21, pp. 1269 - 1282, http://dx.doi.org/10.1016/S1470-2045(20)30447-2

Journal articles | 2020

Gleeson M; Kentwell M; Meiser B; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill YC; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker KM, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', Gynecologic Oncology, 158, pp. 431 - 439, http://dx.doi.org/10.1016/j.ygyno.2020.05.001

Journal articles | 2020

Han HS; Arun B; Kaufman B; Wildiers H; Friedlander M; Ayoub J-PM; Puhalla SL; Bach BA; Dudley M; Kundu MG; Maag D; Ratajczak C; Dieras V, 2020, 'Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.', Journal of Clinical Oncology, 38, pp. 1091 - 1091, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1091

Journal articles | 2020

Hansen JM; Nagle CM; Ibiebele TI; Grant PT; Obermair A; Friedlander ML; DeFazio A; Webb PM, 2020, 'A healthy lifestyle and survival among women with ovarian cancer', International Journal of Cancer, 147, pp. 3361 - 3369, http://dx.doi.org/10.1002/ijc.33155

Journal articles | 2020

Heinzelmann-Schwarz V; Kind AB; Vetter M; Russell K; Omar S; Schoetzau A; Hoeck K; Fink D; Friedlander ML; Hacker NF, 2020, 'Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?', Journal of Cancer Research and Clinical Oncology, 146, pp. 695 - 704, http://dx.doi.org/10.1007/s00432-019-03091-y

Journal articles | 2020

Jones T; Spence R; Sandler C; Obermair A; Friedlander M; Mileshkin L; Davis A; Janda M; Eakin E; Barnes E; Beesley V; Gordon L; Brand A; Hayes S, 2020, 'Are The ACSM Exercise Guidelines Safe And Achievable For Women Receiving Chemotherapy For Ovarian Cancer?', Medicine & Science in Sports & Exercise, 52, pp. 483 - 484, http://dx.doi.org/10.1249/01.mss.0000679180.61253.83

Journal articles | 2020

Kasherman L; Siu DHW; Lee KWC; Lord S; Marschner I; Lewis CR; Friedlander M; Lee CK, 2020, 'Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis', Journal of Geriatric Oncology, 11, pp. 508 - 514, http://dx.doi.org/10.1016/j.jgo.2019.05.013

Journal articles | 2020

Kehm RD; Genkinger JM; MacInnis RJ; John EM; Phillips KA; Dite GS; Milne RL; Zeinomar N; Liao Y; Knight JA; Southey MC; Chung WK; Giles GG; McLachlan SA; Whitaker KD; Friedlander M; Weideman PC; Glendon G; Nesci S; Investigators K; Andrulis IL; Buys SS; Daly MB; Hopper JL; Terry MB, 2020, 'Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: A cohort study of women selected for familial and genetic risk', Cancer Research, 80, pp. 116 - 125, http://dx.doi.org/10.1158/0008-5472.CAN-19-1847

Journal articles | 2020

Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK, 2020, 'Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis', JAMA Network Open, 3, pp. E2011809, http://dx.doi.org/10.1001/jamanetworkopen.2020.11809

Journal articles | 2020

Li H; Terry MB; Antoniou AC; Phillips KA; Kast K; Mooij TM; Engel C; Nogues C; Stoppa-Lyonnet D; Lasset C; Berthet P; Mari V; Caron O; Barrowdale D; Frost D; Brewer C; Evans DG; Izatt L; Side L; Walker L; Tischkowitz M; Rogers MT; Porteous ME; Snape K; Meijers-Heijboer HEJ; Gille JJP; Blok MJ; Hoogerbrugge N; Daly MB; Andrulis IL; Buys SS; John EM; McLachlan SA; Friedlander M; Tan YY; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; Milne RL; Easton DF; Van Leeuwen FE; Rookus MA; Andrieu N; Goldgar DE, 2020, 'Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Results from the BRCA1 and BRCA2 cohort consortium', Cancer Epidemiology Biomarkers and Prevention, 29, pp. 368 - 378, http://dx.doi.org/10.1158/1055-9965.EPI-19-0546

Journal articles | 2020

Li T; Timmins HC; McCrary JM; Trinh T; Horvath LG; Friedlander ML; Kiernan MC; Goldstein D; Park SB, 2020, '5. Neurophysiological characteristics in the development and recovery of peripheral neuropathy in oxaliplatin and paxlitaxel treated patients', Clinical Neurophysiology, 131, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2019.11.038

Journal articles | 2020

Macdonald C; Mazza D; Hunter M; Keogh LA; Milne R; Hickey M; Saunders C; McLachlan SA; Friedlander M; Hopper J; Emery J; Jones S; Phillips KA, 2020, 'Chemoprevention for breast cancer: A survey of the views of Australian women and clinicians', European Journal of Cancer, 138, pp. S8, http://dx.doi.org/10.1016/S0959-8049(20)30547-5

Journal articles | 2020

Macinnis RJ; Liao Y; Knight JA; Milne RL; Whittemore AS; Chung WK; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; McLachlan SA; Weideman PC; Nesci S; Friedlander ML; Glendon G; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB, 2020, 'Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results', Journal of the National Cancer Institute, 112, pp. 418 - 422, http://dx.doi.org/10.1093/jnci/djz194

Journal articles | 2020

Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; Bowtell DD; Chenevix-Trench G; Green A; Webb P; deFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier,a A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D, 2020, 'Prognostic gene expression signature for high-grade serous ovarian cancer', Annals of Oncology, 31, pp. 1240 - 1250, http://dx.doi.org/10.1016/j.annonc.2020.05.019

Journal articles | 2020

Ngoi NYL; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DGZ; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DSP, 2020, 'A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)', International Journal of Gynecological Cancer, 30, pp. 1239 - 1242, http://dx.doi.org/10.1136/ijgc-2020-001604

Journal articles | 2020

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon T-W; Sonke GS; Lisyanskaya AS; Kim J-H; Filho EA; Vergote I; Rowe P; Pujade-Lauraine E, 2020, 'Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.', Journal of Clinical Oncology, 38, pp. 6002 - 6002, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6002

Journal articles | 2020

Puhalla SL; Dieras V; Arun B; Kaufman B; Wildiers H; Han HS; Ayoub J-PM; Stearns V; Yuan Y; Helsten TL; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak C; Ramathal C; Friedlander M, 2020, 'Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.', Journal of Clinical Oncology, 38, pp. 1097 - 1097, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1097

Journal articles | 2020

Roncolato FT; O'Connell RL; Joly F; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Fehm T; Ledermann J; Roemer-Becuwe C; Stockler MR; King MT; Friedlander ML, 2020, 'Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)', Gynecologic Oncology, 156, pp. 45 - 53, http://dx.doi.org/10.1016/j.ygyno.2019.10.001

Journal articles | 2020

Ross TL; DeFazio A; Friedlander M; Grant P; Nagle CM; Williams M; Webb PM; Beesley VL, 2020, 'Insomnia and its association with quality of life in women with ovarian cancer', Gynecologic Oncology, 158, pp. 760 - 768, http://dx.doi.org/10.1016/j.ygyno.2020.06.500

Journal articles | 2020

Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G, 2020, 'Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study', Gynecologic Oncology, 158, pp. 47 - 53, http://dx.doi.org/10.1016/j.ygyno.2020.04.706

Journal articles | 2020

Tjokrowidjaja A; Lee CK; Friedlander M; Gebski V; Gladieff L; Ledermann J; Penson R; Oza A; Korach J; Huzarski T; Manso L; Pisano C; Asher R; Lord SJ; Kim SI; Lee JY; Colombo N; Park-Simon TW; Fujiwara K; Sonke G; Vergote I; Kim JW; Pujade-Lauraine E, 2020, 'Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy', European Journal of Cancer, 139, pp. 59 - 67, http://dx.doi.org/10.1016/j.ejca.2020.08.021

Journal articles | 2020

Tjokrowidjaja A; Lee CK; Friedlander M; Gebski V; Gladieff L; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Manso L; Pisano C; Asher R; Colombo N; Park-Simon T-W; Fujiwara K; Sonke GS; Vergote I; Kim J-W; Pujade-Lauraine E, 2020, 'Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.', Journal of Clinical Oncology, 38, pp. 6014 - 6014, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6014

Journal articles | 2020

Trillsch F; Mahner S; Ataseven B; Asher R; Dubot C; Clamp AR; Penson RT; Oza AM; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; denys H; Lowe ES; Pujade-Lauraine E, 2020, 'Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.', Journal of Clinical Oncology, 38, pp. 6068 - 6068, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6068

Journal articles | 2019

Antill Y; Kok PS; Stockler MR; Robledo K; Yip S; Parry M; Smith D; Spurdle A; Barnes E; Friedlander ML; Baron-Hay S; Shannon C; Coward J; Beale PJ; Goss G; Meniawy T; Andrews J; Kelly M; Mileshkin L, 2019, 'Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)', Annals of Oncology, 30, pp. ix192 - ix192, http://dx.doi.org/10.1093/annonc/mdz446.011

Journal articles | 2019

Coleman RL; Fleming GF; Brady MF; Swisher E; Steffensen KD; Friedlander M; Okamoto A; Moore K; Ben-Baruch N; Werner TL; Oaknin A; Nam J-H; Leath CA; Nicum S; Cella D; Sullivan DM; Ansell PJ; Dinh M; Aghajanian C; Bookman MA, 2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', Annals of Oncology, 30, pp. v895 - v896, http://dx.doi.org/10.1093/annonc/mdz394.054

Journal articles | 2019

Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Efrat Ben-Baruch N; Werner TL; Cloven NG; Oaknin A; DiSilvestro PA; Morgan MA; Nam JH; Leath CA; Nicum S; Hagemann AR; Littell RD; Cella D; Baron-Hay S; Garcia-Donas J; Mizuno M; Bell-McGuinn K; Sullivan DM; Bach BA; Bhattacharya S; Ratajczak CK; Ansell PJ; Dinh MH; Aghajanian C; Bookman MA, 2019, 'Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer', New England Journal of Medicine, 381, pp. 2403 - 2415, http://dx.doi.org/10.1056/NEJMoa1909707

Journal articles | 2019

Diéras VC; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Dudley M; Ratajczak CK; Maag D; Arun BK, 2019, 'Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer', Annals of Oncology, 30, pp. v857 - v858, http://dx.doi.org/10.1093/annonc/mdz394.008

Journal articles | 2019

Figlioli G; Bogliolo M; Catucci I; Caleca L; Lasheras SV; Pujol R; Kiiski JI; Muranen TA; Barnes DR; Dennis J; Michailidou K; Bolla MK; Leslie G; Aalfs CM; Balleine R; Baxter R; Braye S; Carpenter J; Dahlstrom J; Forbes J; Lee CS; Marsh D; Morey A; Pathmanathan N; Scott R; Simpson P; Spigelman A; Wilcken N; Yip D; Zeps N; Adank MA; Adlard J; Agata S; Cadoo K; Agnarsson BA; Ahearn T; Aittomäki K; Ambrosone CB; Andrews L; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Arun BK; Asseryanis E; Auber B; Auvinen P; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Barwell J; Beane Freeman LE; Beauparlant CJ; Beckmann MW; Behrens S; Benitez J; Berger R; Bermisheva M; Blanco AM; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bonanni B; Borg A; Brady AF; Brauch H; Brenner H; Brüning T; Burwinkel B; Buys SS; Caldés T; Caliebe A; Caligo MA; Campa D; Campbell IG; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Claes KBM; Clarke CL; Collavoli A; Conner TA; Cox DG; Cybulski C; Czene K; Daly MB; de la Hoya M; Devilee P; Diez O; Ding YC; Dite GS; Ditsch N; Domchek SM; Dorfling CM; dos-Santos-Silva I; Durda K, 2019, 'The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0127-5

Journal articles | 2019

Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B, 2019, 'Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial', The Lancet Oncology, 20, pp. 1306 - 1315, http://dx.doi.org/10.1016/S1470-2045(19)30396-1

Journal articles | 2019

Friedlander ML; Hettle R; Parkhomenko E, 2019, 'Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy', Annals of Oncology, 30, pp. ix77 - ix78, http://dx.doi.org/10.1093/annonc/mdz426.001

Journal articles | 2019

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; DiSilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', Annals of Oncology, 30, pp. v405 - v406, http://dx.doi.org/10.1093/annonc/mdz250.004

Journal articles | 2019

Kee D; Parker C; Bae S; Tucker KM; Harrison M; Tohidi-Esfahani I; Black M; Delahunty R; Ananda S; Friedlander M; Cunliffe HE; Gibbs P; Desai J; Trotman J; Scott CL, 2019, 'CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research', JCO Clinical Cancer Informatics, 3, pp. 136 - 146, http://dx.doi.org/10.1200/CCI.19.00085

Journal articles | 2019

Kehm RD; Hopper JL; John EM; Phillips KA; MacInnis RJ; Dite GS; Milne RL; Liao Y; Zeinomar N; Knight JA; Southey MC; Vahdat L; Kornhauser N; Cigler T; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; Daly MB; Terry MB, 2019, 'Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study', Breast Cancer Research, 21, http://dx.doi.org/10.1186/s13058-019-1135-y

Journal articles | 2019

Kok PS; Beale P; O’Connell RL; Grant P; Bonaventura T; Scurry J; Antill Y; Goh J; Sjoquist K; Defazio A; Mapagu C; Amant F; Friedlander M, 2019, 'PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression', Journal of Gynecologic Oncology, 30, http://dx.doi.org/10.3802/jgo.2019.30.e86

Journal articles | 2019

Kok PS; Yoon W-H; Marschner I; Lord SJ; Friedlander M; Lee CK, 2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', Annals of Oncology, 30, pp. v520 - v520, http://dx.doi.org/10.1093/annonc/mdz253.103

Journal articles | 2019

Lee CK; Asher R; Friedlander M; Gebski V; Gonzalez-Martin A; Lortholary A; Lesoin A; Kurzeder C; Largillier R; Hilpert F; Hardy-Bessard AC; Kaminsky MC; Poveda A; Pujade-Lauraine E, 2019, 'Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy', European Journal of Cancer, 117, pp. 99 - 106, http://dx.doi.org/10.1016/j.ejca.2019.05.029

Journal articles | 2019

Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M, 2019, 'Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer', British Journal of Cancer, 120, pp. 279 - 285, http://dx.doi.org/10.1038/s41416-018-0349-6

Journal articles | 2019

Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK, 2019, 'The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis', Breast Cancer Research and Treatment, 174, pp. 271 - 278, http://dx.doi.org/10.1007/s10549-018-5054-x

Journal articles | 2019

Li A; Geyer FC; Blecua P; Lee JY; Selenica P; Brown DN; Pareja F; Lee SSK; Kumar R; Rivera B; Bi R; Piscuoglio S; Wen HY; Lozada JR; Gularte-Mérida R; Cavallone L; Aghmesheh M; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Blackburn A; Bogwitz M; Brown M; Burgess M; Burke J; Butow P; Caldon L; Campbell I; Christian A; Clarke C; Cohen P; Crook A; Cui J; Cummings M; Dawson SJ; De Fazio A; Delatycki M; Dobrovic A; Dudding T; Duijf P; Edkins E; Edwards S; Farshid G; Fellows A; Field M; Flanagan J; Fong P; Forbes J; Forrest L; Fox S; French J; Friedlander M; Ortega DG; Gattas M; Giles G; Gill G; Gleeson M; Greening S; Haan E; Harris M; Hayward N; Hickie I; Hopper J; Hunt C; James P; Jenkins M; Kefford R; Kentwell M; Kirk J; Kollias J; Lakhani S; Lindeman G; Lipton L; Lobb L; Lok S; Macrea F; Mann G; Marsh D; McLachlan SA; Meiser B; Milne R; Nightingale S; O’Connell S; Pachter N; Patterson B; Phillips K; Saleh M; Salisbury E; Saunders C; Saunus J; Scott C; Scott R; Sexton A; Shelling A; Simpson P; Spigelman A; Spurdle M; Stone J, 2019, 'Homologous recombination DNA repair defects in PALB2-associated breast cancers', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0115-9

Journal articles | 2019

Li A; Geyer FC; Blecua P; Lee JY; Selenica P; Brown DN; Pareja F; Lee SSK; Kumar R; Rivera B; Bi R; Piscuoglio S; Wen HY; Lozada JR; Gularte-Mérida R; Cavallone L; Aghmesheh M; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Blackburn A; Bogwitz M; Brown M; Burgess M; Burke J; Butow P; Caldon L; Campbell I; Christian A; Clarke C; Cohen P; Crook A; Cui J; Cummings M; Dawson SJ; De Fazio A; Delatycki M; Dobrovic A; Dudding T; Duijf P; Edkins E; Edwards S; Farshid G; Fellows A; Field M; Flanagan J; Fong P; Forbes J; Forrest L; Fox S; French J; Friedlander M; Ortega DG; Gattas M; Giles G; Gill G; Gleeson M; Greening S; Haan E; Harris M; Hayward N; Hickie I; Hopper J; Hunt C; James P; Jenkins M; Kefford R; Kentwell M; Kirk J; Kollias J; Lakhani S; Lindeman G; Lipton L; Lobb L; Lok S; Macrea F; Mann G; Marsh D; McLachlan SA; Meiser B; Milne R; Nightingale S; O’Connell S; Pachter N; Patterson B; Phillips K; Saleh M; Salisbury E; Saunders C; Saunus J; Scott C; Scott R; Sexton A; Shelling A; Simpson P; Spigelman A; Spurdle M; Stone J, 2019, 'Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (npj Breast Cancer, (2019), 5, 1, (23), 10.1038/s41523-019-0115-9)', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0140-8

Journal articles | 2019

Mavaddat N; Michailidou K; Dennis J; Lush M; Fachal L; Lee A; Tyrer JP; Chen TH; Wang Q; Bolla MK; Yang X; Adank MA; Ahearn T; Aittomäki K; Allen J; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Auer PL; Auvinen P; Barrdahl M; Beane Freeman LE; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bernstein L; Blomqvist C; Bogdanova NV; Bojesen SE; Bonanni B; Børresen-Dale AL; Brauch H; Bremer M; Brenner H; Brentnall A; Brock IW; Brooks-Wilson A; Brucker SY; Brüning T; Burwinkel B; Campa D; Carter BD; Castelao JE; Chanock SJ; Chlebowski R; Christiansen H; Clarke CL; Collée JM; Cordina-Duverger E; Cornelissen S; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; dos-Santos-Silva I; Dumont M; Durcan L; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Ellberg C; Engel C; Eriksson M; Evans DG; Fasching PA; Figueroa J; Fletcher O; Flyger H; Försti A; Fritschi L; Gabrielson M; Gago-Dominguez M; Gapstur SM; García-Sáenz JA; Gaudet MM; Georgoulias V; Giles GG; Gilyazova IR; Glendon G; Goldberg MS; Goldgar DE; González-Neira A; Grenaker Alnæs GI; Grip M; Gronwald J; Grundy A; Guénel P; Haeberle L; Hahnen E; Haiman CA; Håkansson N; Hamann U; Hankinson SE, 2019, 'Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes', American Journal of Human Genetics, 104, pp. 21 - 34, http://dx.doi.org/10.1016/j.ajhg.2018.11.002

Journal articles | 2019

McCabe M; Gauthier M-E; Chan C-L; Thompson T; De Sousa S; Puttick C; Grady J; Gayevskiy V; Tao J; Ying K; Cipponi A; Deng N; Swarbrick A; Thomas M; kConFab ; Lord R; Johns A; Kohonen-Corish M; O'Toole S; Clark J; Mueller S; Gupta R; McCormack A; Dinger M; Cowley M; Bastick P; Friedlander M; Colley A; Andrews L; Young M-A; Tucker K; Williams R, 2019, 'Development and validation of a targeted gene sequencing panel for application to disparate cancers', Scientific Reports, 9, pp. 17052, http://dx.doi.org/10.1038/s41598-019-52000-3

Journal articles | 2019

McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB, 2019, 'Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy', Journal of Pain and Symptom Management, 58, pp. 1023 - 1032, http://dx.doi.org/10.1016/j.jpainsymman.2019.07.021

Journal articles | 2019

McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB, 2019, 'Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments', JNCCN Journal of the National Comprehensive Cancer Network, 17, pp. 949 - 955, http://dx.doi.org/10.6004/jnccn.2019.7290

Journal articles | 2019

Mileshkin L; Edmondson R; O'Connell RL; Sjoquist KM; Andrews J; Jyothirmayi R; Beale P; Bonaventura T; Goh J; Hall M; Clamp A; Green J; Lord R; Amant F; Alexander L; Carty K; Paul J; Scurry J; Millan D; Nottley S; Friedlander M, 2019, 'Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903', Gynecologic Oncology, 154, pp. 29 - 37, http://dx.doi.org/10.1016/j.ygyno.2019.05.007

Journal articles | 2019

Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer', Obstetrical and Gynecological Survey, 74, pp. 86 - 87, http://dx.doi.org/10.1097/01.ogx.0000552695.03241.d6

Journal articles | 2019

Oaknin A; Moore K; Colombo N; Scambia G; Kim B-G; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', Annals of Oncology, 30, pp. v405 - v405, http://dx.doi.org/10.1093/annonc/mdz250.003

Journal articles | 2019

Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2019, 'Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))', Gynecologic Oncology, 152, pp. 220, http://dx.doi.org/10.1016/j.ygyno.2018.10.022

Journal articles | 2019

Rose PG; Java JJ; Salani R; Geller MA; Secord AA; Tewari KS; Bender DP; Mutch DG; Friedlander ML; Van Le L; Method MW; Hamilton CA; Lee RB; Wenham RM; Guntupalli SR; Markman M; Muggia FM; Armstrong DK; Bookman MA; Burger RA; Copeland LJ, 2019, 'Nomogram for Predicting Individual Survival after Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma', Obstetrics and Gynecology, 133, pp. 245 - 254, http://dx.doi.org/10.1097/AOG.0000000000003086

Journal articles | 2019

Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Arnau GM; Okamoto A; Friedlander M; Bowtell DDL, 2019, 'Survival following chemotherapy in ovarian clear cell carcinoma is not associated with pathological misclassification of tumor histotype', Clinical Cancer Research, 25, pp. 3962 - 3973, http://dx.doi.org/10.1158/1078-0432.CCR-18-3691

Journal articles | 2019

Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M, 2019, 'PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors', Gynecologic Oncology, 154, pp. 531 - 538, http://dx.doi.org/10.1016/j.ygyno.2019.06.011

Journal articles | 2019

Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ, 2019, '10-year performance of four models of breast cancer risk: a validation study', The Lancet Oncology, 20, pp. 504 - 517, http://dx.doi.org/10.1016/S1470-2045(18)30902-1

Journal articles | 2019

Vergote I; du Bois A; Floquet A; Rau J; Kim JW; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Colombo N; Mirza MR; Monk BJ; Tsibulak I; Calvert PM; Herzog TJ; Hanker LC; Meunier J; Lee JY; Bologna A; Carrasco-Alfonso MJ; Harter P, 2019, 'Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer', Gynecologic Oncology, 155, pp. 186 - 191, http://dx.doi.org/10.1016/j.ygyno.2019.08.024

Journal articles | 2019

Webber K; Carolus E; Mileshkin L; Sommeijer D; McAlpine J; Bladgen S; Coleman RL; Herzog TJ; Sehouli J; Nasser S; Inci G; Friedlander M, 2019, 'OVQUEST – Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors', Gynecologic Oncology, 155, pp. 126 - 134, http://dx.doi.org/10.1016/j.ygyno.2019.08.009

Journal articles | 2019

Zeinomar N; Knight JA; Genkinger JM; Phillips KA; Daly MB; Milne RL; Dite GS; Kehm RD; Liao Y; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; John EM; MacInnis RJ; Hopper JL; Terry MB, 2019, 'Alcohol consumption, cigarette smoking, and familial breast cancer risk: Findings from the Prospective Family Study Cohort (ProF-SC)', Breast Cancer Research, 21, http://dx.doi.org/10.1186/s13058-019-1213-1

Journal articles | 2019

Zeinomar N; Phillips KA; Daly MB; Milne RL; Dite GS; MacInnis RJ; Liao Y; Kehm RD; Knight JA; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; John EM; Hopper JL; Terry MB, 2019, 'Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort', International Journal of Cancer, 145, pp. 370 - 379, http://dx.doi.org/10.1002/ijc.32112

Journal articles | 2018

Beesley VL; Smith DD; Nagle CM; Friedlander M; Grant P; DeFazio A; Webb PM, 2018, 'Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer', Supportive Care in Cancer, 26, pp. 4133 - 4142, http://dx.doi.org/10.1007/s00520-018-4284-0

Journal articles | 2018

Berek JS; Kehoe ST; Kumar L; Friedlander M, 2018, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 143, pp. 59 - 78, http://dx.doi.org/10.1002/ijgo.12614

Journal articles | 2018

Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Toloczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubinski J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Glaz A; Chenevix-Trench G; Cazorla A; Brucker SY; Bowtell DD; Green A; Webb P; de Fazio A; Gertig D; Moore S; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R, 2018, 'MyD88 and TLR4 Expression in Epithelial Ovarian Cancer', Mayo Clinic Proceedings, 93, pp. 307 - 320, http://dx.doi.org/10.1016/j.mayocp.2017.10.023

Journal articles | 2018

Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', Annals of Oncology, 29, pp. x24 - x25, http://dx.doi.org/10.1093/annonc/mdy487.042

Journal articles | 2018

Friedlander M; Gebski V; Gibbs E; Davies L; Bloomfield R; Hilpert F; Wenzel LB; Eek D; Rodrigues M; Clamp A; Penson RT; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Espinoza D; Joly F; Pujade-Lauraine E, 2018, 'Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial', The Lancet Oncology, 19, pp. 1126 - 1134, http://dx.doi.org/10.1016/S1470-2045(18)30343-7

Journal articles | 2018

Friedlander M; Matulonis U; Gourley C; du Bois A; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Shirinkin V; Selle F; Fielding A; Lowe ES; McMurtry EL; Spencer S; Rowe P; Mann H; Parry D; Ledermann J, 2018, 'Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy', British Journal of Cancer, 119, pp. 1075 - 1085, http://dx.doi.org/10.1038/s41416-018-0271-y

Journal articles | 2018

Friedlander M; Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; Disilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. ix174 - ix175, http://dx.doi.org/10.1093/annonc/mdy483.002

Journal articles | 2018

Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A, 2018, 'Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy', Annals of Oncology, 29, pp. 737 - 743, http://dx.doi.org/10.1093/annonc/mdx796

Journal articles | 2018

Friedlander M; Shannon C; Goh J; Scott C; Mileshkin L, 2018, 'Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib', Asia-Pacific Journal of Clinical Oncology, 14, pp. 459 - 464, http://dx.doi.org/10.1111/ajco.13104

Journal articles | 2018

Friedlander M; van Rijn J, 2018, 'Ammonia and CO₂ enrichment of a Gracilaria cultivation pond through biofiltration of organic waste', AQUACULTURE, 482, pp. 45 - 48, http://dx.doi.org/10.1016/j.aquaculture.2017.08.041

Journal articles | 2018

Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Gares V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart C; Sharma R; Allan PE; Rambau PF; Traficante N; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Kobel M; Harnett P; Nelson BH; Bowtell DDL; DeFazio A, 2018, 'Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer', Clinical Cancer Research, 24, pp. 569 - 580, http://dx.doi.org/10.1158/1078-0432.CCR-17-1621

Journal articles | 2018

Grimison PS; Lawrence NJ; Stockler MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; McDermott R; Walker R; Winstanley M; Hanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC, 2018, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).', Journal of Clinical Oncology, 36, pp. TPS4596 - TPS4596, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.tps4596

Journal articles | 2018

Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S, 2018, 'Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study', Annals of Oncology, 29, pp. 154 - 161, http://dx.doi.org/10.1093/annonc/mdx505

Journal articles | 2018

Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M, 2018, 'Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients', Gynecologic Oncology, 148, pp. 79 - 85, http://dx.doi.org/10.1016/j.ygyno.2017.10.036

Journal articles | 2018

Hopper JL; Dite GS; MacInnis RJ; Liao Y; Zeinomar N; Knight JA; Southey MC; Milne RL; Chung WK; Giles GG; Genkinger JM; McLachlan SA; Friedlander ML; Antoniou AC; Weideman PC; Glendon G; Nesci S; Andrulis IL; Buys SS; Daly MB; John EM; Phillips KA; Terry MB, 2018, 'Age-specific breast cancer risk by body mass index and familial risk: Prospective family study cohort (ProF-SC)', Breast Cancer Research, 20, http://dx.doi.org/10.1186/s13058-018-1056-1

Journal articles | 2018

Joo JE; Dowty JG; Milne RL; Wong EM; Dugué PA; English D; Hopper JL; Goldgar DE; Giles GG; Southey MC; Sexton A; Christian A; Trainer A; Spigelman A; Fellows A; Shelling A; De Fazio A; Blackburn A; Crook A; Meiser B; Patterson B; Clarke C; Saunders C; Hunt C; Scott C; Amor D; Marsh D; Edkins E; Salisbury E; Haan E; Neidermayr E; Macrae F; Farshid G; Lindeman G; Chenevix-Trench G; Mann G; Gill G; Thorne H; Campbell I; Hickie I; Winship I; Goldblatt J; Flanagan J; Kollias J; Visvader J; Stone J; Taylor J; Burke J; Saunus J; Forbes J; Beesley J; Kirk J; French J; Tucker K; Wu K; Phillips K; Lipton L; Andrews L; Lobb E; Walker L; Kentwell M; Spurdle A; Cummings M; Gleeson M; Harris M; Jenkins M; Young MA; Delatycki M; Wallis M; Burgess M; Price M; Brown M; Bogwitz M; Field M; Friedlander M; Gattas M; Saleh M; Hayward N; Pachter N; Cohen P; Duijf P; James P; Simpson P; Fong P; Butow P; Williams R; Kefford R; Scott R; Balleine R; Dawson SJ; Lok S; O'Connell S; Greening S; Nightingale S; Edwards S; Fox S; McLachlan SA; Lakhani S; Thomas S; Antill Y, 2018, 'Heritable DNA methylation marks associated with susceptibility to breast cancer /631/67/69 /631/337/176/1988 /692/699/67/1347 /692/308/2056 /45 /45/61 article', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-03058-6

Journal articles | 2018

King MT; Stockler MR; O’Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML, 2018, 'Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer', Quality of Life Research, 27, pp. 59 - 74, http://dx.doi.org/10.1007/s11136-017-1729-8

Journal articles | 2018

Kirk J; Barlow-Stewart KK; Poplawski NK; Gleeson M; Tucker K; Friedlander M, 2018, 'Medicare-funded cancer genetic tests: A note of caution clinicians need appropriate education and support in keeping pace with the genomics revolution', Medical Journal of Australia, 209, pp. 193 - 196.e1, http://dx.doi.org/10.5694/mja17.01124

Journal articles | 2018

Kondrashova O; Topp M; Nesic K; Lieschke E; Ho GY; Harrell MI; Zapparoli GV; Hadley A; Holian R; Boehm E; Heong V; Sanij E; Pearson RB; Krais JJ; Johnson N; McNally O; Ananda S; Alsop K; Hutt KJ; Kaufmann SH; Lin KK; Harding TC; Traficante N; Chenevix-Trench G; Green A; Webb P; Gertig D; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J, 2018, 'Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-05564-z

Journal articles | 2018

Kovalenko S; Crooks R; Provan P; de Fazio A; Taylor P; Kennedy B; Friedlander M; Caramins M, 2018, 'Tumour profiling for treatment of patients with ovarian cancers', Pathology, 50, pp. S77 - S77, http://dx.doi.org/10.1016/j.pathol.2017.12.200

Journal articles | 2018

Loo CKC; Danieletto S; Friedlander M; Pearen MA; Ramm GA, 2018, 'Peritoneal hepatoid carcinoma with chemotherapy response and possible stem cell involvement', Human Pathology: Case Reports, 12, pp. 71 - 76, http://dx.doi.org/10.1016/j.ehpc.2018.02.008

Journal articles | 2018

Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML, 2018, 'Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials', Gynecologic Oncology, 150, pp. 527 - 533, http://dx.doi.org/10.1016/j.ygyno.2018.07.013

Journal articles | 2018

Mercieca-Bebber R; King MT; Calvert MJ; Stockler MR; Friedlander M, 2018, 'The importance of patient-reported outcomes in clinical trials and strategies for future optimization', PATIENT-RELATED OUTCOME MEASURES, 9, pp. 353 - 367, http://dx.doi.org/10.2147/PROM.S156279

Journal articles | 2018

Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer', New England Journal of Medicine, 379, pp. 2495 - 2505, http://dx.doi.org/10.1056/NEJMoa1810858

Journal articles | 2018

Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA, 2018, 'Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study', Gynecologic Oncology, 151, pp. 18 - 23, http://dx.doi.org/10.1016/j.ygyno.2018.07.021

Journal articles | 2018

Oskay-Özcelik G; Alavi S; Richter R; Keller M; Chekerov R; Cecere SC; Cormio G; Joly F; Kurtz JE; du Bois A; Maciejewski M; Jedryka M; Vergote I; Van Nieuwenhuysen E; Casado A; Mendiola C; Achimas-Cadariu P; Vlad C; Reimer D; Zeimet AG; Friedlander M; Sehouli J, 2018, 'Expression III: Patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries', Annals of Oncology, 29, pp. 910 - 916, http://dx.doi.org/10.1093/annonc/mdy037

Journal articles | 2018

Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK, 2018, 'Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis', JAMA Oncology, 4, pp. 522 - 528, http://dx.doi.org/10.1001/jamaoncol.2017.5236

Journal articles | 2018

Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M, 2018, 'Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)', Gynecologic Oncology, 148, pp. 36 - 41, http://dx.doi.org/10.1016/j.ygyno.2017.10.019

Journal articles | 2018

Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', Annals of Oncology, 29, pp. x28 - x28, http://dx.doi.org/10.1093/annonc/mdy487.007

Journal articles | 2018

Schrijver LH; Olsson H; Phillips KA; Terry MB; Goldgar DE; Kast K; Engel C; Mooij TM; Adlard J; Barrowdale D; Davidson R; Eeles R; Ellis S; Evans DG; Frost D; Izatt L; Porteous ME; Side LE; Walker L; Berthet P; Bonadona V; Leroux D; Mouret-Fourme E; Venat-Bouvet L; Buys SS; Southey MC; John EM; Chung WK; Daly MB; Bane A; van Asperen CJ; Garcia EBG; Mourits MJE; Roos-Blom MJ; Friedlander ML; McLachlan SA; Singer CF; Foretova L; Gerdes AM; Caldes T; Olah E; Jakubowska A; Noguès C; Andrieu N; Easton DF; van Leeuwen FE; Hopper JL; Milne RL; Antoniou AC; Rookus MA; Laborde L; Pontois P; Stoppa-Lyonnet D; Gauthier-Villars M; Buecher B; Caron O; Fricker JP; Lasset C; Faivre L; Luporsi E; Frénay M; Gladieff L; Gesta P; Sobol H; Eisinger F; Moretta J; Longy M; Dugast C; Colas C; Soubrier F; Coupier I; Pujol P; Lortholary A; Vennin P; Adenis C; Nguyen TD; Delnatte C; Rossi A; Tinat J; Tennevet I; Limacher JM; Maugard C; Bignon YJ; Demange L; Dreyfus H; Cohen-Haguenauer O; Gilbert B; Zattara-Cannoni H, 2018, 'Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study', JNCI Cancer Spectrum, 2, http://dx.doi.org/10.1093/jncics/pky023

Journal articles | 2018

Sjoquist KM; Lord SJ; Friedlander ML; John Simes R; Marschner IC; Lee CK, 2018, 'Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis', Therapeutic Advances in Medical Oncology, 10, http://dx.doi.org/10.1177/1758835918788500

Journal articles | 2018

Sousa M; Peate M; Lewis C; Jarvis S; Willis A; Hickey M; Friedlander M, 2018, 'Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy', European Journal of Cancer Care, 27, http://dx.doi.org/10.1111/ecc.12820

Journal articles | 2018

Terry MB; Liao Y; Kast K; Antoniou AC; McDonald JA; Mooij TM; Engel C; Nogues C; Buecher B; Mari V; Moretta-Serra J; Gladieff L; Luporsi E; Barrowdale D; Frost D; Henderson A; Brewer C; Evans DG; Eccles D; Cook J; Ong KR; Izatt L; Ahmed M; Morrison PJ; Dommering CJ; Oosterwijk JC; Ausems MGEM; Kriege M; Buys SS; Andrulis IL; John EM; Daly M; Friedlander M; McLachlan SA; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; van Leeuwen FE; Goldgar D; Milne RL; Easton DF; Rookus MA; Andrieu N, 2018, 'The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations', JNCI Cancer Spectrum, 2, http://dx.doi.org/10.1093/JNCICS/PKY078

Journal articles | 2018

Wilson MK; Friedlander ML; Joly F; Oza AM, 2018, 'A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve', Oncologist, 23, pp. 203 - 213, http://dx.doi.org/10.1634/theoncologist.2017-0297

Journal articles | 2018

Wilson MK; Mercieca-Bebber R; Friedlander M, 2018, 'A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer', Journal of Gynecologic Oncology, 29, http://dx.doi.org/10.3802/jgo.2018.29.e81

Journal articles | 2018

Zalcberg JR; Friedlander M, 2018, 'The value of participating in clinical trials: The whole is greater than the sum of its parts', Medical Journal of Australia, 209, http://dx.doi.org/10.5694/mja17.01266

Journal articles | 2017

Bonaventura A; O'Connell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML, 2017, 'Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer', International Journal of Gynecological Cancer, 27, pp. 900 - 906, http://dx.doi.org/10.1097/IGC.0000000000000978

Journal articles | 2017

Bookman MA; Okamoto A; Stuart G; Yanaihara N; Aoki D; Bacon M; Fujiwara K; González-Martín A; Harter P; Kim JW; Ledermann J; Pujade-Lauraine E; Quinn M; Ochiai K; Zeimet A; Marth C; du Bois A; Hilpert F; Pfisterer J; Reuss A; Friedlander M; Wilson MK; Kridelka F; Vergote I; Berek J; Dorigo O; Karam A; Bekkers RLM; Westermann A; Gatsonis C; Ng C; Herráez AC; Ottevanger N; Poveda A; Redondo A; Coleman R; Lu K; Gallardo-Rincón D; Gomez-Garcia E; Joly F; Leary A; Ray-Coquard I; Burger R; Moore KN; Fujiwara H; Hasegawa K; Gleeson N; Levy T; Rosengarten O; Katsumata N; Silverberg SG; Sugiyama T; Chang SJ; Kim BG; Nam BH; Colombo N; Ferrero A; Lorusso D; Scambia G; Edmondson R; McNeish I; Kohn E; Hirte H; McGee J; Provencher D; Sehouli J; Wimberger P; Maenpaa J; Mirza MR; Oza A; Welch S; Gaffney D; Small W; Glasspool R; Gourley C; Millan D; Zang R; Zhu J, 2017, 'Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference', Annals of Oncology, 28, pp. viii30 - viii35, http://dx.doi.org/10.1093/annonc/mdx449

Journal articles | 2017

Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA; Buck M; Dean A; Friedlander ML; Harnett P; Kichenadasse G; Denys H; Dirix L; Vergote I; Elit L; Ghatage P; Plante M; Provencher D; Welch S; Gladieff L; Joly F; Lortholary A; Lotz J; Medioni J; Tredan O; You B; El-Balat A; Hänle C; Krabisch P; Neunhöffer T; Pölcher M; Wimberger P; Amit A; Kovel S; Leviov M; Safra T; Shapira-Frommer R; Stemmer S; Bologna A; Pignata S; Sabbatini RF; Tamberi S; Zamagni C; O'Donnell A; Herraez AC; Guerra EM; Palacio I; Romero I; Sanchez A; Banerjee SN; Drew Y; Gabra HG; Jackson D; Parkinson C; Powell M; Birrer MJ; Buss MK; Chambers SK; Chen LM; Ma L; Morgan MA; Morris RT; Mutch DG; Slomovitz BM; Vanderkwaak T; Vulfovich M, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, 390, pp. 1949 - 1961, http://dx.doi.org/10.1016/S0140-6736(17)32440-6

Journal articles | 2017

Coleman RL; Oza AM; Lorusso D, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 390, pg 1949, 2017)', LANCET, 390, pp. 1948 - 1948, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413823200030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2017

Gligorov J; Ataseven B; Verrill M; de Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X; Koroveshi D; Bouzid K; Casalnuovo M; Cascallar D; Korbenfeld EP; Bastick P; Beith J; Colosimo M; Friedlander M; Ganju V; Green M; Patterson K; Redfern A; Richardson G; Ceric T; Gordana K; Beato CA; Ferrari M; Hegg R; Helena V; Ismael GF; Lessa AE; Mano M; Morelle A; Nogueira JA; Timcheva K; Tomova A; Tsakova M; Zlatareva-Petrova A; Asselah J; Assi H; Brezden-Masley C; Chia S; Freedman O; Harb M; Joy AA; Kulkarni S; Prady C; Gaete AAA; Matamala L; Torres R; Yanez E; Franco S; Urrego M; Gugić D; Vrbanec D; Melichar B; Prausová J; Vyzula R; Pilarte RG; León MI; Muñoz R; Ramos G; Azeem HA; Aziz AA; El Zawahry H; Osegueda FR; Alexandre J; Artignan X; Barletta H; Beguier E; Berdah JF; Marty CB; Bollet M; Bourgeois H; Bressac C; Burki F; Campone M; Coeffic D; Cojocarasu OZ; Dagada C; Dalenc F; Del Piano F; Desauw C; Desmoulins I; Dohollou N; Egreteau J; Ferrero JM; Foa C; Garidi R; Gasnault L; Guardiola E; Hamizi S; Jarcau R; Jacquin JP; Jaubert D; Jolimoy G; Mineur HL; Largillier R; Leduc B, 2017, 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients', European Journal of Cancer, 82, pp. 237 - 246, http://dx.doi.org/10.1016/j.ejca.2017.05.010

Journal articles | 2017

Gourley C; Friedlander M; Matulonis UA; Shirinkin V; Selle F; Scott CL; Safra T; Fielding A; Rowe P; Ledermann JA, 2017, 'Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', JOURNAL OF CLINICAL ONCOLOGY, 35, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5533

Journal articles | 2017

Hettle R; Sackeyfio A; Gill J; Siddiqui K; Nussey F; Friedlander M, 2017, 'Comparative Efficacy And Safety Of Olaparib 300 Mg Tablets Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients With Platinum-Sensitive Relapsed Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088

Journal articles | 2017

Isakoff SJ; Puhalla S; Domchek SM; Friedlander M; Kaufman B; Robson M; Telli ML; Diéras V; Han HS; Garber JE; Johnson EF; Maag D; Qin Q; Giranda VL; Shepherd SP, 2017, 'A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: Design and rationale', Future Oncology, 13, pp. 307 - 320, http://dx.doi.org/10.2217/fon-2016-0412

Journal articles | 2017

Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O’Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL, 2017, 'Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma', Cancer Discovery, 7, pp. 984 - 998, http://dx.doi.org/10.1158/2159-8290.CD-17-0419

Journal articles | 2017

Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H, 2017, 'Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', JAMA, 317, pp. 2402 - 2416, http://dx.doi.org/10.1001/jama.2017.7112

Journal articles | 2017

Lee CK; Scott CL; Lindeman GJ; Gibbs E; Badger HD; Paterson RJ; Macnab L; Kwan EM; Boyle FM; Friedlander M, 2017, 'Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA)', JOURNAL OF CLINICAL ONCOLOGY, 35, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.1104

Journal articles | 2017

Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA, 2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x

Journal articles | 2017

Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA, 2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004

Journal articles | 2017

Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L, 2017, 'Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical & Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/ogx.0000000000000451

Journal articles | 2017

Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L, 2017, 'Factors Associated with Deciding between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical and Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/OGX.0000000000000451

Journal articles | 2017

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v130 - v130, http://dx.doi.org/10.1093/annonc/mdx367.023

Journal articles | 2017

Mercieca-Bebber R; Friedlander M; Calvert M; Stockler M; Kyte D; Kok PS; King MT, 2017, 'A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: Implications for generalisability and clinical practice', Journal of Patient-Reported Outcomes, 1, http://dx.doi.org/10.1186/s41687-017-0008-3

Journal articles | 2017

Mercieca-Bebber R; Friedlander M; Kok PS; Calvert M; Kyte D; Stockler M; King MT, 2017, 'Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols (Quality of Life Research, (2016), 25, 10, (2457-2465), 10.1007/s11136-016-1339-x)', Quality of Life Research, 26, pp. 2249 - 2250, http://dx.doi.org/10.1007/s11136-017-1578-5

Journal articles | 2017

Park SB; Kwok JB; Asher R; Lee CK; Beale P; Selle F; Friedlander M, 2017, 'Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial', Annals of Oncology, 28, pp. 2733 - 2740, http://dx.doi.org/10.1093/annonc/mdx491

Journal articles | 2017

Penson R; Kaminsky-Forrett M-C; Ledermann J; Brown C; Plante M; Korach J; Huzarski T; Gomez de Liano Lista A; Pisano C; Friedlander M; Colombo N; Gropp-Meier M; Nakai H; Sonke GS; Kim J-W; Vergote I; Allen A; Pujade-Lauraine E, 2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', Annals of Oncology, 28, pp. v331 - v331, http://dx.doi.org/10.1093/annonc/mdx372.002

Journal articles | 2017

Pickett JL; Chou A; Andrici JA; Clarkson A; Sioson L; Sheen A; Reagh J; Najdawi F; Kim Y; Riley D; Maidens J; Nevell D; McIlroy K; Valmadre S; Gard G; Hogg R; Turchini J; Robertson G; Friedlander M; Gill AJ, 2017, 'Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required', American Journal of Surgical Pathology, 41, pp. 1433 - 1442, http://dx.doi.org/10.1097/PAS.0000000000000909

Journal articles | 2017

Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard IL; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P; Byrski T; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Poveda Velasco A; Rodrigues M; Lotz JP; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Tamura K; Yunokawa M; Lisyanskaya A; Medioni J; Pécuchet N; Dubot C; de la Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Cosin J; Hoffman J; Plante M; Covens A; Sonke G; Joly F; Floquet A; Hirte H; Amit A; Park-Simon TW; Matsumoto K; Tjulandin S; Kim JH; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez de Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Filho E; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I, 2017, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 18, pp. 1274 - 1284, http://dx.doi.org/10.1016/S1470-2045(17)30469-2

Journal articles | 2017

Rafii S; Gourley C; Kumar R; Geuna E; Ang JE; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Rhoda Molife L; Gore ME; Kaye SB; Yap TA, 2017, 'Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer', Oncotarget, 8, pp. 47154 - 47160, http://dx.doi.org/10.18632/oncotarget.17005

Journal articles | 2017

Ritchie G; Gasper H; Man J; Lord S; Friedlander M; Lee C; Marschner I, 2017, 'Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', Annals of Oncology, 28, pp. v411 - v411, http://dx.doi.org/10.1093/annonc/mdx376.023

Journal articles | 2017

Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA, 2017, 'The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: A systematic review', Human Reproduction, 32, pp. 1033 - 1045, http://dx.doi.org/10.1093/humrep/dex027

Journal articles | 2017

Roncolato FT; Gibbs E; Lee CK; Asher R; Davies LC; Gebski VJ; Friedlander M; Hilpert F; Wenzel L; Stockler MR; King M; Pujade-Lauraine E, 2017, 'Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: An AURELIA substudy', Annals of Oncology, 28, pp. 1849 - 1855, http://dx.doi.org/10.1093/annonc/mdx229

Journal articles | 2017

Roncolato FT; Joly F; O’Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M, 2017, 'Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—The GCIG symptombenefit study', Oncologist, 22, pp. 1117 - 1124, http://dx.doi.org/10.1634/theoncologist.2017-0047

Journal articles | 2017

Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD, 2017, 'What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study', Cancer, 123, pp. 985 - 993, http://dx.doi.org/10.1002/cncr.30414

Journal articles | 2017

Sackeyfio A; Gill J; Hettle R; Siddiqui K; Friedlander M; Ledermann JA, 2017, 'Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087

Journal articles | 2017

Samimi G; Caga-Anan CF; Dean M; Mechanic LE; Minasian LM; Sherman ME; Brody LC; Bernardini MQ; Lheureux S; Shaw PA; Kwon JS; Campbell IG; James PA; Takenaka M; Bowtell DD; Chenevix-Trench G; Friedlander M; Ramus SJ; Couch FJ; De Hullu JA; Harmsen MG; Domchek SM; Drapkin R; Mai PL; Feigelson HS; Gaudet MM; Hurley K; Robson ME; Lacbawan F; Slavin TP; Myers ER; Rezende LF; Swisher EM, 2017, 'Traceback: A proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach', Journal of Clinical Oncology, 35, pp. 2329 - 2337, http://dx.doi.org/10.1200/JCO.2016.70.3439

Journal articles | 2017

Sandler CX; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; segelov E; Boyle FM; Chin MT; webber K; Barry BK; Lloyd AR, 2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015

Journal articles | 2017

Scerri TS; Quaglieri A; Cai C; Zernant J; Matsunami N; Baird L; Scheppke L; Bonelli R; Yannuzzi LA; Friedlander M; MacTel Project Consortium ; Egan CA; Fruttiger M; Leppert M; Allikmets R; Bahlo M, 2017, 'Genome-wide analyses identify common variants associated with macular telangiectasia type 2.', Nat Genet, 49, pp. 559 - 567, http://dx.doi.org/10.1038/ng.3799

Journal articles | 2017

Sousa MS; Peate M; Jarvis S; Hickey M; Friedlander M, 2017, 'A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy', Therapeutic Advances in Medical Oncology, 9, pp. 269 - 285, http://dx.doi.org/10.1177/1758834016687260

Journal articles | 2017

Webber K; Friedlander M, 2017, 'Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer', Best Practice and Research: Clinical Obstetrics and Gynaecology, 41, pp. 126 - 138, http://dx.doi.org/10.1016/j.bpobgyn.2016.11.004

Journal articles | 2017

Wilson MK; Friedlander ML; Lheureux S; Small W; Poveda A; Pujade-Lauraine E; Karakasis K; Bacon M; Bowering V; Chawla T; Oza AM, 2017, 'Resisting RECISTV uniformity versus clinical validity', International Journal of Gynecological Cancer, 27, pp. 1619 - 1627, http://dx.doi.org/10.1097/IGC.0000000000001062

Journal articles | 2017

Wilson MK; Pujade-Lauraine E; Aoki D; Mirza MR; Lorusso D; Oza AM; du Bois A; Vergote I; Reuss A; Bacon M; Friedlander M; Gallardo-Rincon D; Joly F; Chang SJ; Ferrero AM; Edmondson RJ; Wimberger P; Maenpaa J; Gaffney D; Zang R; Okamoto A; Stuart G; Ochiai K, 2017, 'Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease', Annals of Oncology, 28, pp. 727 - 732, http://dx.doi.org/10.1093/annonc/mdw663

Journal articles | 2016

Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ, 2016, 'Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - A population-based study', Acta Oncologica, 55, pp. 226 - 233, http://dx.doi.org/10.3109/0284186X.2015.1054950

Journal articles | 2016

Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B, 2016, 'Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy', Gynecologic Oncology, 140, pp. 199 - 203, http://dx.doi.org/10.1016/j.ygyno.2015.12.020

Journal articles | 2016

Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J; Do V; Marschner I; Friedlander M; Gurney H; Simes J; Hague W; O’Connell R; Gorzeman M; Pike R; Miranda K; Waring P; Lau D; Fox S; Liu Y; Wood T; Cocks C; Simmons K; McCourt J; Jefford M; Hobinchet A; Mirco B; Sagong J; Dudukovic S; Aghmesheh M; Parker S; Segelov E; Ratnayake L; Ranieri N; Varma S; Page J; Heyer E; Abdi E; Chorlton C; Wilkinson L; Marshall I, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4

Journal articles | 2016

Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J, 2016, 'Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer', Asia-Pacific Journal of Clinical Oncology, 12, pp. 323 - 331, http://dx.doi.org/10.1111/ajco.12636

Journal articles | 2016

Friedlander M; Mercieca-Bebber RL; King MT, 2016, 'Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned', Annals of Oncology, 27, pp. i66 - i71, http://dx.doi.org/10.1093/annonc/mdw080

Journal articles | 2016

Friedlander ML; Russell K; Millis S; Gatalica Z; Bender R; Voss A, 2016, 'Molecular profiling of clear cell ovarian cancers: Identifying potential treatment targets for clinical trials', International Journal of Gynecological Cancer, 26, pp. 648 - 654, http://dx.doi.org/10.1097/IGC.0000000000000677

Journal articles | 2016

Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; Du Bois A, 2016, 'BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study', Gynecologic Oncology, 140, pp. 443 - 449, http://dx.doi.org/10.1016/j.ygyno.2015.12.027

Journal articles | 2016

Herzog TJ; Spetzler D; Xiao N; Burnett K; Maney T; Voss A; Reddy S; Burger R; Krivak T; Powell M; Friedlander M; McGuire W, 2016, 'Impact of molecular profiling on overall survival of patients with advanced ovarian cancer', Oncotarget, 7, pp. 19840 - 19849, http://dx.doi.org/10.18632/oncotarget.7835

Journal articles | 2016

Lawrence N; Martin A; Toner G; Stockler M; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Wong N; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Grimison P, 2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology, 27, pp. 2302 - 2303, http://dx.doi.org/10.1093/annonc/mdw313

Journal articles | 2016

Ledermann JA; Embleton AC; Raja F; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Eisenhauer E; Vaughan M; Friedlander M; González-Martín A; Stark D; Clark E; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB, 2016, 'Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial', The Lancet, 387, pp. 1066 - 1074, http://dx.doi.org/10.1016/S0140-6736(15)01167-8

Journal articles | 2016

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Bennett B; Parry D; Spencer S; Mann H; Matulonis U, 2016, 'Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer', British Journal of Cancer, 115, pp. 1313 - 1320, http://dx.doi.org/10.1038/bjc.2016.348

Journal articles | 2016

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U, 2016, 'Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial', The Lancet Oncology, 17, pp. 1579 - 1589, http://dx.doi.org/10.1016/S1470-2045(16)30376-X

Journal articles | 2016

Lehane C; Ho F; Thompson SR; Links D; Lewis C; Smee R; Parasyn A; Friedlander M; Williams J; Crowe P, 2016, 'Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma', Journal of Medical Imaging and Radiation Oncology, 60, pp. 539 - 544, http://dx.doi.org/10.1111/1754-9485.12442

Journal articles | 2016

Lundqvist A; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Sanz LM; Liang S; Murray S; Larsson O; Kiessling R; Mao Y; Sidhom J-W; Bessell CA; Havel J; Schneck J; Chan TA; Sachsenmeier E; Woods D; Berglund A; Ramakrishnan R; Sodre A; Weber J; Zappasodi R; Li Y; Qi J; Wong P; Sirard C; Postow M; Newman W; Koon H; Velcheti V; Callahan MK; Wolchok JD; Merghoub T; Lum LG; Choi M; Thakur A; Deol A; Dyson G; Shields A; Haymaker C; Uemura M; Murthy R; James M; Wang D; Brevard J; Monaghan C; Swann S; Geib J; Cornfeld M; Chunduru S; Agrawal S; Yee C; Wargo J; Patel SP; Amaria R; Tawbi H; Glitza I; Woodman S; Hwu W-J; Davies MA; Hwu P; Overwijk WW; Bernatchez C; Diab A; Massarelli E; Segal NH; Ribrag V; Melero I; Gangadhar TC; Urba W; Schadendorf D; Ferris RL; Houot R; Morschhauser F; Logan T; Luke JJ; Sharfman W; Barlesi F; Ott PA; Mansi L; Kummar S; Salles G; Carpio C; Meier R; Krishnan S; McDonald D; Maurer M; Gu X; Neely J; Suryawanshi S; Levy R; Khushalani N; Wu J; Zhang J; Basher F; Rubinstein M; Bucsek M; Qiao G; MacDonald C; Hylander B; Repasky E; Chatterjee S; Daenthanasanmak A; Chakraborty P; Toth K; Meek M; Garrett-Mayer E; Nishimura M; Paulos C; Beeson C; Yu X; Mehrotra S; Zhao F; Evans K; Xiao C; Holtzhausen A; Hanks BA; Scharping N; Menk AV; Moreci R; Whetstone R; Dadey R; Watkins S; Ferris R; Delgoffe GM; Peled J; Devlin S; Staffas A; Lumish M; Rodriguez KP; Ahr K; Perales M; Giralt S; Taur Y; Pamer E; van den Brink MRM; Jenq R; Annels N; Pandha H; Simpson G; Mostafid H; Harrington K; Melcher A; Grose M; Davies B; Au G; Karpathy R; Shafren D; Ricca J; Merghoub T; Wolchok JD; Zamarin D; Batista L; Marliot F; Vasaturo A; Carpentier S; Poggionovo C; Frayssinet V; Fieschi J; Van den Eynde M; Pagès F; Galon J; Hermitte F; Smith SG; Nguyen K; Ravindranathan S; Koppolu B; Zaharoff D; Schvartsman G; Bassett R; McQuade JL; Haydu LE; Davies MA; Tawbi H; Glitza I; Kline D; Chen X; Fosco D; Kline J; Overacre A; Chikina M; Brunazzi E; Shayan G; Horne W; Kolls J; Ferris RL; Delgoffe GM; Bruno TC; Workman C; Vignali D; Adusumilli PS; Ansa-Addo EA; Li Z; Gerry A; Sanderson JP; Howe K; Docta R; Gao Q; Bagg EAL; Tribble N; Maroto M; Betts G; Bath N; Melchiori L; Lowther DE; Ramachandran I; Kari G; Basu S; Binder-Scholl G; Chagin K; Pandite L; Holdich T; Amado R; Zhang H; Glod J; Bernstein D; Jakobsen B; Mackall C; Wong R; Silk JD; Adams K; Hamilton G; Bennett AD; Brett S; Jing J; Quattrini A; Saini M; Wiedermann G; Gerry A; Jakobsen B; Binder-Scholl G; Brewer J; Duong M; Lu A; Chang P; Mahendravada A; Shinners N; Slawin K; Spencer DM; Foster AE; Bayle JH; Bergamaschi C; Ng SSM; Nagy B; Jensen S; Hu X; Alicea C; Fox B; Felber B; Pavlakis G; Chacon J; Yamamoto T; Garrabrant T; Cortina L; Powell DJ; Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Dolton G; Szomolay B; Ott S; Lyngaa R; Hadrup SR; Sewell AK; Svane IM; Fan A; Kumai T; Celis E; Frank I; Stramer A; Blaskovich MA; Wardell S; Fardis M; Bender J; Lotze MT; Goff SL; Zacharakis N; Assadipour Y; Prickett TD; Gartner JJ; Somerville R; Black M; Xu H; Chinnasamy H; Kriley I; Lu L; Wunderlich J; Robbins PF; Rosenberg S; Feldman SA; Trebska-McGowan K; Kriley I; Malekzadeh P; Payabyab E; Sherry R; Rosenberg S; Goff SL; Gokuldass A; Blaskovich MA; Kopits C; Rabinovich B; Lotze MT; Green DS; Kamenyeva O; Zoon KC; Annunziata CM; Hammill J; Helsen C; Aarts C; Bramson J; Harada Y; Yonemitsu Y; Helsen C; Hammill J; Mwawasi K; Denisova G; Bramson J; Giri R; Jin B; Campbell T; Draper LM; Stevanovic S; Yu Z; Weissbrich B; Restifo NP; Trimble CL; Rosenberg S; Hinrichs CS; Tsang K; Fantini M; Hodge JW; Fujii R; Fernando I; Jochems C; Heery C; Gulley J; Soon-Shiong P; Schlom J; Jing W; Gershan J; Blitzer G; Weber J; McOlash L; Johnson BD; Kiany S; Gangxiong H; Kleinerman ES; Klichinsky M; Ruella M; Shestova O; Kenderian S; Kim M; Scholler J; June CH; Gill S; Moogk D; Zhong S; Yu Z; Liadi I; Rittase W; Fang V; Dougherty J; Perez-Garcia A; Osman I; Zhu C; Varadarajan N; Restifo NP; Frey A; Krogsgaard M; Landi D; Fousek K; Mukherjee M; Shree A; Joseph S; Bielamowicz K; Byrd T; Ahmed N; Hegde M; Lee S; Byrd D; Thompson J; Bhatia S; Tykodi S; Delismon J; Chu L; Abdul-Alim S; Ohanian A; DeVito AM; Riddell S; Margolin K; Magalhaes I; Mattsson J; Uhlin M; Nemoto S; Villarroel PP; Nakagawa R; Mule JJ; Mailloux AW; Mata M; Nguyen P; Gerken C; DeRenzo C; Spencer DM; Gottschalk S; Mathieu M; Pelletier S; Stagg J; Turcotte S; Minutolo N; Sharma P; Tsourkas A; Powell DJ; Mockel-Tenbrinck N; Mauer D; Drechsel K; Barth C; Freese K; Kolrep U; Schult S; Assenmacher M; Kaiser A; Mullinax J; Hall M; Le J; Kodumudi K; Royster E; Richards A; Gonzalez R; Sarnaik A; Pilon-Thomas S; Nielsen M; Krarup-Hansen A; Hovgaard D; Petersen MM; Loya AC; Junker N; Svane IM; Rivas C; Parihar R; Gottschalk S; Rooney CM; Qin H; Nguyen S; Su P; Burk C; Duncan B; Kim B-H; Kohler ME; Fry T; Rao AA; Teyssier N; Pfeil J; Sgourakis N; Salama S; Haussler D; Richman SA; Nunez-Cruz S; Gershenson Z; Mourelatos Z; Barrett D; Grupp S; Milone M; Rodriguez-Garcia A; Robinson MK; Adams GP; Powell DJ; Santos J; Havunen R; Siurala M; Cervera-Carrascón V; Parviainen S; Antilla M; Hemminki A; Sethuraman J; Santiago L; Chen JQ; Dai Z; Wardell S; Bender J; Lotze MT; Sha H; Su S; Ding N; Liu B; Stevanovic S; Pasetto A; Helman SR; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA; Hinrichs CS; Bhatia S; Burgess M; Zhang H; Lee T; Klingemann H; Soon-Shiong P; Nghiem P; Kirkwood JM; Rossi JM; Sherman M; Xue A; Shen Y-W; Navale L; Rosenberg SA; Kochenderfer JN; Bot A; Veerapathran A; Gokuldass A; Stramer A; Sethuraman J; Blaskovich MA; Wiener D; Frank I; Santiago L; Rabinovich B; Fardis M; Bender J; Lotze MT; Waller EK; Li J-M; Petersen C; Blazar BR; Li J; Giver CR; Wang Z; Grossenbacher SK; Sturgill I; Canter RJ; Murphy WJ; Zhang C; Burger MC; Jennewein L; Waldmann A; Mittelbronn M; Tonn T; Steinbach JP; Wels WS; Williams JB; Zha Y; Gajewski TF; Williams LC; Krenciute G; Kalra M; Louis C; Gottschalk S; Xin G; Schauder D; Jiang A; Joshi N; Cui W; Zeng X; Menk AV; Scharping N; Delgoffe GM; Zhao Z; Hamieh M; Eyquem J; Gunset G; Bander N; Sadelain M; Askmyr D; Abolhalaj M; Lundberg K; Greiff L; Lindstedt M; Angell HK; Kim K-M; Kim S-T; Kim S; Sharpe AD; Ogden J; Davenport A; Hodgson DR; Barrett C; Lee J; Kilgour E; Hanson J; Caspell R; Karulin A; Lehmann P; Ansari T; Schiller A; Sundararaman S; Lehmann P; Hanson J; Roen D; Karulin A; Lehmann P; Ayers M; Levitan D; Arreaza G; Liu F; Mogg R; Bang Y-J; O’Neil B; Cristescu R; Friedlander P; Wassman K; Kyi C; Oh W; Bhardwaj N; Bornschlegl S; Gustafson MP; Gastineau DA; Parney IF; Dietz AB; Carvajal-Hausdorf D; Mani N; Velcheti V; Schalper K; Rimm D; Chang S; Levy R; Kurland J; Krishnan S; Ahlers CM; Jure-Kunkel M; Cohen L; Maecker H; Kohrt H; Chen S; Crabill G; Pritchard T; McMiller T; Pardoll D; Pan F; Topalian S; Danaher P; Warren S; Dennis L; White AM; D’Amico L; Geller M; Disis ML; Beechem J; Odunsi K; Fling S; Derakhshandeh R; Webb TJ; Dubois S; Conlon K; Bryant B; Hsu J; Beltran N; Müller J; Waldmann T; Duhen R; Duhen T; Thompson L; Montler R; Weinberg A; Kates M; Early B; Yusko E; Schreiber TH; Bivalacqua TJ; Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng J; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert T; Ribas A; McClanahan TK; Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Nebozhyn M; Lunceford J; Joe A; Cheng J; Plimack E; Ott PA; McClanahan TK; Loboda A; Kaufman DR; Forrest-Hay A; Guyre CA; Narumiya K; Delcommenne M; Hirsch HA; Deshpande A; Reeves J; Shu J; Zi T; Michaelson J; Law D; Trehu E; Sathyanaryanan S; Hodkinson BP; Hutnick NA; Schaffer ME; Gormley M; Hulett T; Jensen S; Ballesteros-Merino C; Dubay C; Afentoulis M; Reddy A; David L; Fox B; Jayant K; Agrawal S; Agrawal R; Jeyakumar G; Kim S; Kim H; Silski C; Suisham S; Heath E; Vaishampayan U; Vandeven N; Viller NN; O’Connor A; Chen H; Bossen B; Sievers E; Uger R; Nghiem P; Johnson L; Kao H-F; Hsiao C-F; Lai S-C; Wang C-W; Ko J-Y; Lou P-J; Lee T-J; Liu T-W; Hong R-L; Kearney SJ; Black JC; Landis BJ; Koegler S; Hirsch B; Gianani R; Kim J; He M-X; Zhang B; Su N; Luo Y; Ma X-J; Park E; Kim DW; Copploa D; Kothari N; doo Chang Y; Kim R; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Knaus HA; Berglund S; Hackl H; Karp JE; Gojo I; Luznik L; Hong HS; Koch SD; Scheel B; Gnad-Vogt U; Kallen K-J; Wiegand V; Backert L; Kohlbacher O; Hoerr I; Fotin-Mleczek M; Billingsley JM; Koguchi Y; Conrad V; Miller W; Gonzalez I; Poplonski T; Meeuwsen T; Howells-Ferreira A; Rattray R; Campbell M; Bifulco C; Dubay C; Bahjat K; Curti B; Urba W; Vetsika E-K; Kallergi G; Aggouraki D; Lyristi Z; Katsarlinos P; Koinis F; Georgoulias V; Kotsakis A; Martin NT; Aeffner F; Kearney SJ; Black JC; Cerkovnik L; Pratte L; Kim R; Hirsch B; Krueger J; Gianani R; Martínez-Usatorre A; Jandus C; Donda A; Carretero-Iglesia L; Speiser DE; Zehn D; Rufer N; Romero P; Panda A; Mehnert J; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Sokol L; Stein M; Poplin E; Rodriguez-Rodriguez L; Silk A; Chan N; Frankel M; Kane M; Malhotra J; Aisner J; Kaufman HL; Ali S; Ross J; White E; Bhanot G; Ganesan S; Monette A; Bergeron D; Amor AB; Meunier L; Caron C; Morou A; Kaufmann D; Liberman M; Jurisica I; Mes-Masson A-M; Hamzaoui K; Lapointe R; Mongan A; Ku Y-C; Tom W; Sun Y; Pankov A; Looney T; Au-Young J; Hyland F; Conroy J; Morrison C; Glenn S; Burgher B; Ji H; Gardner M; Mongan A; Omilian AR; Conroy J; Bshara W; Angela O; Burgher B; Ji H; Glenn S; Morrison C; Mongan A; Obeid JM; Erdag G; Smolkin ME; Deacon DH; Patterson JW; Chen L; Bullock TN; Slingluff CL; Obeid JM; Erdag G; Deacon DH; Slingluff CL; Bullock TN; Loffredo JT; Vuyyuru R; Beyer S; Spires VM; Fox M; Ehrmann JM; Taylor KA; Korman AJ; Graziano RF; Page D; Sanchez K; Ballesteros-Merino C; Martel M; Bifulco C; Urba W; Fox B; Patel SP; De Macedo MP; Qin Y; Reuben A; Spencer C; Guindani M; Bassett R; Wargo J; Racolta A; Kelly B; Jones T; Polaske N; Theiss N; Robida M; Meridew J; Habensus I; Zhang L; Pestic-Dragovich L; Tang L; Sullivan RJ; Logan T; Khushalani N; Margolin K; Koon H; Olencki T; Hutson T; Curti B; Roder J; Blackmon S; Roder H; Stewart J; Amin A; Ernstoff MS; Clark JI; Atkins MB; Kaufman HL; Sosman J; Weber J; McDermott DF; Weber J; Kluger H; Halaban R; Snzol M; Roder H; Roder J; Asmellash S; Steingrimsson A; Blackmon S; Sullivan RJ; Wang C; Roman K; Clement A; Downing S; Hoyt C; Harder N; Schmidt G; Schoenmeyer R; Brieu N; Yigitsoy M; Madonna G; Botti G; Grimaldi A; Ascierto PA; Huss R; Athelogou M; Hessel H; Harder N; Buchner A; Schmidt G; Stief C; Huss R; Binnig G; Kirchner T; Sellappan S; Thyparambil S; Schwartz S; Cecchi F; Nguyen A; Vaske C; Hembrough T; Spacek J; Vocka M; Zavadova E; Skalova H; Dundr P; Petruzelka L; Francis N; Tilman RT; Hartmann A; Netikova I; Ballesteros-Merino C; Stump J; Tufman A; Berger F; Neuberger M; Hatz R; Lindner M; Sanborn RE; Handy J; Fox B; Bifulco C; Huber RM; Winter H; Reu S; Sun C; Xiao W; Tian Z; Arora K; Desai N; Kulkarni A; Rajurkar M; Rivera M; Deshpande V; Ting D; Tsai K; Nosrati A; Goldinger S; Hamid O; Algazi A; Tumeh P; Hwang J; Liu J; Chen L; Dummer R; Rosenblum M; Daud A; Tsao T-S; Ashworth-Sharpe J; Johnson D; Bhaumik S; Bieniarz C; Couto J; Farrell M; Ghaffari M; Habensus I; Hubbard A; Jones T; Kelly B; Kosmeder J; Lee C; Marner E; Meridew J; Polaske N; Racolta A; Uribe D; Zhang H; Zhang J; Zhang W; Zhu Y; Morrison L; Pestic-Dragovich L; Tang L; Tsujikawa T; Borkar RN; Azimi V; Kumar S; Thibault G; Mori M; El Rassi E; Clayburgh DR; Kulesz-Martin MF; Flint PW; Coussens LM; Villabona L; Masucci GV; Geiss G; Birditt B; Mei Q; Huang A; White AM; Eagan MA; Ignacio E; Elliott N; Dunaway D; Dennis L; Warren S; Beechem J; Dunaway D; Jung J; Merritt C; Sprague I; Webster P; Liang Y; Warren S; Beechem J; Wenthe J; Enblad G; Karlsson H; Essand M; Savoldo B; Dotti G; Höglund M; Brenner MK; Hagberg H; Loskog A; Bernett MJ; Moore GL; Hedvat M; Bonzon C; Chu S; Rashid R; Avery KN; Muchhal U; Desjarlais J; Hedvat M; Bernett MJ; Moore GL; Bonzon C; Rashid R; Chu S; Avery KN; Muchhal U; Desjarlais J; Kraman M; Kmiecik K; Allen N; Faroudi M; Zimarino C; Wydro M; Doody J; Srinivasa SP; Govindappa N; Reddy P; Dubey A; Periyasamy S; Adekandi M; Dey C; Joy M; van Loo PF; Veninga H; Shamsili S; Throsby M; Dolstra H; Bakker L; Alva A; Gschwendt J; Loriot Y; Bellmunt J; Feng D; Poehlein C; Powles T; Antonarakis ES; Drake CG; Wu H; Poehlein C; De Bono J; Bannerji R; Byrd J; Gregory G; Opat S; Shortt J; Yee AJ; Raje N; Thompson S; Balakumaran A; Kumar S; Rini BI; Choueiri TK; Mariani M; Albiges L; Haanen JB; Atkins MB; Larkin J; Schmidinger M; Magazzù D; di Pietro A; Motzer RJ; Borch TH; Andersen R; Kongsted P; Pedersen M; Nielsen M; Met Ö; Donia M; Svane IM; Boudadi K; Wang H; Vasselli J; Baughman JE; Wigginton J; Abdallah R; Ross A; Drake CG; Antonarakis ES; Canter RJ; Park J; Wang Z; Grossenbacher S; Luna JI; Withers S; Culp W; Chen M; Monjazeb A; Kent MS; Murphy WJ; Chandran S; Somerville R; Wunderlich J; Danforth D; Yang J; Sherry R; Klebanoff C; Goff S; Paria B; Sabesan A; Srivastava A; Rosenberg SA; Kammula U; Curti B; Richards J; Faries M; Andtbacka RHI; Grose M; Shafren D; Diaz LA; Le DT; Yoshino T; André T; Bendell J; Koshiji M; Zhang Y; Kang SP; Lam B; Jäger D; Bauer TM; Wang JS; Lee JK; Manji GA; Kudchadkar R; Kauh JS; Tang S; Laing N; Falchook G; Garon EB; Halmos B; Rina H; Leighl N; Lee SS; Walsh W; Dragnev K; Piperdi B; Rodriguez LP-A; Shinwari N; Wei Z; Gustafson MP; Maas ML; Deeds M; Armstrong A; Bornschlegl S; Peterson T; Steinmetz S; Gastineau DA; Parney IF; Dietz AB; Herzog T; Backes FJ; Copeland L; Del Pilar Estevez Diz M; Hare TW; Huh W; Kim B-G; Moore KM; Oaknin A; Small W; Tewari KS; Monk BJ; Kamat AM; Bellmunt J; Choueiri TK; Nam K; De Santis M; Dreicer R; Hahn NM; Perini R; Siefker-Radtke A; Sonpavde G; de Wit R; Witjes JA; Keefe S; Bajorin D; Kline J; Armand P; Kuruvilla J; Moskowitz C; Hamadani M; Ribrag V; Zinzani PL; Chlosta S; Thompson S; Balakumaran A; Bartlett N; Kyi C; Sabado R; Saenger Y; William L; Donovan MJ; Sacris E; Mandeli J; Salazar AM; Friedlander P; Bhardwaj N; Powderly J; Brody J; Nemunaitis J; Emens L; Luke JJ; Patnaik A; McCaffery I; Miller R; Laport G; Coveler AL; Smith DC; Grilley-Olson JE; Gajewski TF; Goel S; Gardai SJ; Law C-L; Means G; Manley T; Curti B; Marrone KA; Rosner G; Anagnostou V; Riemer J; Wakefield J; Zanhow C; Baylin S; Gitlitz B; Brahmer J; McDermott DF; Signoretti S; Li W; Schloss C; Michot J-M; Armand P; Ding W; Ribrag V; Christian B; Balakumaran A; Marinello P; Chlosta S; Zhang Y; Shipp M; Zinzani PL; Najjar YG; Lin ; Butterfield LH; Tarhini AA; Davar D; Zarour H; Rush E; Sander C; Kirkwood JM; Fu S; Bauer T; Molineaux C; Bennett MK; Orford KW; Papadopoulos KP; Padda SK; Shah SA; Colevas AD; Narayanan S; Fisher GA; Supan D; Wakelee HA; Aoki R; Pegram MD; Villalobos VM; Liu J; Takimoto CH; Chao M; Volkmer J-P; Majeti R; Weissman IL; Sikic BI; Page D; Yu W; Conlin A; Ruzich J; Lewis S; Acheson A; Kemmer K; Perlewitz K; Moxon NM; Mellinger S; Bifulco C; Martel M; Koguchi Y; Fox B; Urba W; McArthur H; Pedersen M; Westergaard MCW; Borch TH; Nielsen M; Kongsted P; Juhler-Nøttrup T; Donia M; Svane IM; Desai J; Markman B; Sandhu S; Gan H; Friedlander ML; Tran B; Meniawy T; Lundy J; Colyer D; Ameratunga M; Norris C; Yang J; Li K; Wang L; Luo L; Qin Z; Mu S; Tan X; Song J; Millward M; Katz MHG; Bauer TW; Varadhachary GR; Acquavella N; Merchant N; Petroni G; Slingluff CL; Rahma OE; Rini BI; Powles T; Chen M; Song Y; Puhlmann M; Atkins MB; Sathyanaryanan S; Hirsch HA; Shu J; Deshpande A; Khattri A; Reeves J; Zi T; Brisson R; Harvey C; Michaelson J; Law D; Seiwert T; Shah J; Mateos MV; Matsumoto M; Blacklock H; Rocafiguera AO; Goldschmidt H; Iida S; Yehuda DB; Ocio E; Rodríguez-Otero P; Jagannath S; Lonial S; Kher U; Marinello P; San-Miguel J; Shah J; Lonial S; de Oliveira MR; Yimer H; Mateos MV; Rifkin R; Schjesvold F; Ocio E; Rodríguez-Otero P; San-Miguel J; Ghori R; Marinello P; Jagannath S; Spreafico A; Lee V; Ngan RKC; To KF; Ahn MJ; Ng QS; Hong R-L; Lin J-C; Swaby RF; Gause C; Saraf S; Chan ATC; Lam E; Tannir NM; Meric-Bernstam F; Vaishampayan U; Orford KW; Molineaux C; Gross M; MacKinnon A; Whiting S; Voss M; Yu EY; Wu H; Schloss C; Albertini MR; Ranheim EA; Hank JA; Zuleger C; McFarland T; Collins J; Clements E; Weber S; Weigel T; Neuman H; Hartig G; Mahvi D; Henry M; Gan J; Yang R; Carmichael L; Kim K; Gillies SD; Sondel PM; Subbiah V; Murthy R; Noffsinger L; Hendricks K; Bosch M; Lee JM; Lee M-H; Garon EB; Goldman JW; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin YQ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp K; Wallace WD; Zeng G; Elashoff DA; Sharma S; Dubinett SM; Bhardwaj N; Friedlander P; Pavlick AC; Ernstoff MS; Gastman B; Hanks B; Albertini MR; Luke JJ; Keler T; Davis T; Vitale LA; Sharon E; Danaher P; Morishima C; Cheever M; Fling S; Heery CR; Kim JW; Lamping E; Marte J; McMahon S; Cordes L; Fakhrejahani F; Madan R; Tsang K; Jochems C; Salazar R; Zhang M; Helwig C; Schlom J; Gulley JL; Li R; Amrhein J; Cohen Z; Champagne M; Kamat A; Aznar MA; Labiano S; Diaz-Lagares A; Esteller M; Sandoval J; Melero I; Barbee SD; Bellovin DI; Timmer JC; Wondyfraw N; Johnson S; Park J; Chen A; Mkrtichyan M; Razai AS; Jones KS; Hata CY; Gonzalez D; Deveraux Q; Eckelman BP; Borges L; Bhardwaj R; Puri RK; Suzuki A; Leland P; Joshi BH; Bartkowiak T; Jaiswal A; Ager C; Ai M; Budhani P; Chin R; Hong D; Curran M; Hastings WD; Pinzon-Ortiz M; Murakami M; Dobson JR; Quinn D; Wagner JP; Rong X; Shaw P; Dammassa E; Guan W; Dranoff G; Cao A; Fulton RB; Leonardo S; Fraser K; Kangas TO; Ottoson N; Bose N; Huhn RD; Graff J; Lowe J; Gorden K; Uhlik M; Vitale LA; O’Neill T; Widger J; Crocker A; He L-Z; Weidlick J; Sundarapandiyan K; Ramakrishna V; Storey J; Thomas LJ; Goldstein J; Marsh HC; Keler T; Grailer J; Gilden J; Stecha P; Garvin D; Hartnett J; Fan F; Cong M; Cheng Z-JJ; Hinner MJ; Aiba R-SB; Schlosser C; Jaquin T; Allersdorfer A; Berger S; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Shane OA; Horton B; Spranger S; Gajewski TF; Moreira D; Adamus T; Zhao X; Swiderski P; Pal S; Kortylewski M; Kosmides A; Necochea K; Schneck J; Mahoney KM; Shukla SA; Patsoukis N; Chaudhri A; Pham H; Hua P; Bu X; Zhu B; Hacohen N; Wu CJ; Fritsch E; Boussiotis VA; Freeman GJ; Moran AE; Polesso F; Lukaesko L; Weinberg A; Rådestad E; Egevad L; Mattsson J; Sundberg B; Henningsohn L; Levitsky V; Uhlin M; Rafelson W; Reagan JL; Fast L; Sasikumar P; Sudarshan N; Ramachandra R; Gowda N; Samiulla D; Chandrasekhar T; Adurthi S; Mani J; Nair R; Dhudashia A; Gowda N; Ramachandra M; Sankin A; Gartrell B; Cumberbatch K; Huang H; Stern J; Schoenberg M; Zang X; Swanson R; Kornacker M; Evans L; Rickel E; Wolfson M; Valsesia-Wittmann S; Shekarian T; Simard F; Nailo R; Dutour A; Jallas A-C; Caux C; Marabelle A, 2016, '31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one', Journal for ImmunoTherapy of Cancer, 4, http://dx.doi.org/10.1186/s40425-016-0172-7

Journal articles | 2016

Mateo J; Moreno V; Gupta A; Kaye SB; Dean E; Middleton MR; Friedlander M; Gourley C; Plummer R; Rustin G; Sessa C; Leunen K; Ledermann J; Swaisland H; Fielding A; Bannister W; Nicum S; Molife LR, 2016, 'An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib', Targeted Oncology, 11, pp. 401 - 415, http://dx.doi.org/10.1007/s11523-016-0435-8

Journal articles | 2016

Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA, 2016, 'Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy', Cancer, 122, pp. 1844 - 1852, http://dx.doi.org/10.1002/cncr.29995

Journal articles | 2016

Mercieca-Bebber R; Friedlander M; Kok PS; Calvert M; Kyte D; Stockler M; King MT, 2016, 'The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols', Quality of Life Research, 25, pp. 2457 - 2465, http://dx.doi.org/10.1007/s11136-016-1339-x

Journal articles | 2016

Pelttari LM; Khan S; Vuorela M; Kiiski JI; Vilske S; Nevanlinna V; Ranta S; Schleutker J; Winqvist R; Kallioniemi A; Dörk T; Bogdanova NV; Figueroa J; Pharoah PDP; Schmidt MK; Dunning AM; García-Closas M; Bolla MK; Dennis J; Michailidou K; Wang Q; Hopper JL; Southey MC; Rosenberg EH; Fasching PA; Beckmann MW; Peto J; Dos-Santos-silva I; Sawyer EJ; Tomlinson I; Burwinkel B; Surowy H; Guénel P; Truong T; Bojesen SE; Nordestgaard BG; Benitez J; González-Neira A; Neuhausen SL; Anton-Culver H; Brenner H; Arndt V; Meindl A; Schmutzler RK; Brauch H; Brüning T; Lindblom A; Margolin S; Mannermaa A; Hartikainen JM; Chenevix-Trench G; Van Dyck L; Janssen H; Chang-Claude J; Rudolph A; Radice P; Peterlongo P; Hallberg E; Olson JE; Giles GG; Milne RL; Haiman CA; Schumacher F; Simard J; Dumont M; Kristensen V; Borresen-Dale AL; Zheng W; Beeghly-Fadiel A; Grip M; Andrulis IL; Glendon G; Devilee P; Seynaeve C; Hooning MJ; Collée M; Cox A; Cross SS; Shah M; Luben RN; Hamann U; Torres D; Jakubowska A; Lubinski J; Couch FJ; Yannoukakos D; Orr N; Swerdlow A; Darabi H; Li J; Czene K; Hall P; Easton DF; Mattson J; Blomqvist C; Aittomäki K; Nevanlinna H; Aghmesheh M; Amor D; Andrews L; Ward R; Friedlander M; Links M; Tucker K; Sayer R; Bastick P; Colley A; Underhill C, 2016, 'RAD51B in familial breast cancer', PLoS ONE, 11, pp. e0153788, http://dx.doi.org/10.1371/journal.pone.0153788

Journal articles | 2016

Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA, 2016, 'Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations', Human Reproduction, 31, pp. 1126 - 1132, http://dx.doi.org/10.1093/humrep/dew044

Journal articles | 2016

Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA, 2016, 'Anti-müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations', Obstetrical and Gynecological Survey, 71, pp. 474 - 475, http://dx.doi.org/10.1097/01.ogx.0000489566.21546.e2

Journal articles | 2016

Price MA; Butow PN; Bell ML; deFazio A; Friedlander M; Fardell JE; Protani MM; Webb PM; AOCS—Quality of Life Study Investigators on behalf of the Australian Ovarian Cancer Study Group , 2016, 'Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?', Supportive Care in Cancer, 24, pp. 2627 - 2634, http://dx.doi.org/10.1007/s00520-015-3070-5

Journal articles | 2016

Pulford DJ; Harter P; Floquet A; Barrett C; Suh DH; Friedlander M; Arranz JA; Hasegawa K; Tada H; Vuylsteke P; Mirza MR; Donadello N; Scambia G; Johnson T; Cox C; Chan JK; Imhof M; Herzog TJ; Calvert P; Wimberger P; Berton-Rigaud D; Lim MC; Elser G; Xu CF; Du Bois A, 2016, 'Communicating BRCA research results to patients enrolled in international clinical trials: Lessons learnt from the AGO-OVAR 16 study', BMC Medical Ethics, 17, pp. 63, http://dx.doi.org/10.1186/s12910-016-0144-y

Journal articles | 2016

Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P, 2016, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumours (vol 46, pg 893, 2016)', INTERNAL MEDICINE JOURNAL, 46, pp. 1459 - 1459, http://dx.doi.org/10.1111/imj.13259

Journal articles | 2016

Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P, 2016, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumours', Internal Medicine Journal, 46, pp. 893 - 898, http://dx.doi.org/10.1111/imj.13158

Journal articles | 2016

Thewes B; Prins J; Friedlander M, 2016, '70-Gene signature in early-stage breast cancer', New England Journal of Medicine, 375, pp. 2199 - 2200, http://dx.doi.org/10.1056/NEJMc1612048

Journal articles | 2016

Zeng C; Guo X; Long J; Kuchenbaecker KB; Droit A; Michailidou K; Ghoussaini M; Kar S; Freeman A; Hopper JL; Milne RL; Bolla MK; Wang Q; Dennis J; Agata S; Ahmed S; Aittomäki K; Andrulis IL; Anton-Culver H; Antonenkova NN; Arason A; Arndt V; Arun BK; Arver B; Bacot F; Barrowdale D; Baynes C; Beeghly-Fadiel A; Benitez J; Bermisheva M; Blomqvist C; Blot WJ; Bogdanova NV; Bojesen SE; Bonanni B; Borresen-Dale AL; Brand JS; Brauch H; Brennan P; Brenner H; Broeks A; Brüning T; Burwinkel B; Buys SS; Cai Q; Caldes T; Campbell I; Carpenter J; Chang-Claude J; Choi JY; Claes KBM; Clarke C; Cox A; Cross SS; Czene K; Daly MB; de la Hoya M; De Leeneer K; Devilee P; Diez O; Domchek SM; Doody M; Dorfling CM; Dörk T; dos-Santos-Silva I; Dumont M; Dwek M; Dworniczak B; Egan K; Eilber U; Einbeigi Z; Ejlertsen B; Ellis S; Frost D; Lalloo F; Fasching PA; Figueroa J; Flyger H; Friedlander M; Friedman E; Gambino G; Gao YT; Garber J; García-Closas M; Gehrig A; Damiola F; Lesueur F; Mazoyer S; Stoppa-Lyonnet D; Giles GG; Godwin AK; Goldgar DE; González-Neira A; Greene MH; Guénel P; Haeberle L; Haiman CA; Hallberg E; Hamann U; Hansen TVO, 2016, 'Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus', Breast Cancer Research, 18, http://dx.doi.org/10.1186/s13058-016-0718-0

Journal articles | 2015

Berek JS; Crum C; Friedlander M, 2015, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 131, pp. S111 - S122, http://dx.doi.org/10.1016/j.ijgo.2015.06.007

Journal articles | 2015

Domchek SM; Kaufman B; Friedlander M, 2015, 'Reply to M.G. McNamara et al and M.S. Copur et al', Journal of Clinical Oncology, 33, pp. 2583 - 2584, http://dx.doi.org/10.1200/JCO.2015.61.8298

Journal articles | 2015

Floquet A; Vergote I; Colombo N; Fiane B; Monk BJ; Reinthaller A; Calvert P; Herzog TJ; Meier W; Kim JW; Campo JMD; Friedlander M; Pisano C; Isonishin S; Crescenzo RJ; Barrett C; Wang K; Mitrica I; Bois AD, 2015, 'Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial', Gynecologic Oncology, 136, pp. 37 - 42, http://dx.doi.org/10.1016/j.ygyno.2014.11.074

Journal articles | 2015

Harrison M; Friedlander M, 2015, 'Over half of all gynaecologic cancers are rare: Barriers and challenges to improving outcomes', Cancer Forum, 39, pp. 20 - 24

Journal articles | 2015

Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A, 2015, 'BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study', Gynecologic Oncology, http://dx.doi.org/10.1016/j.ygyno.2015.12.027

Journal articles | 2015

Inglis H; Boyle FM; Friedlander ML; Watson SL, 2015, 'Dry eyes and AIs: If you don't ask you won't find out', Breast, 24, pp. 694 - 698, http://dx.doi.org/10.1016/j.breast.2015.08.008

Journal articles | 2015

Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM, 2015, 'Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation', Journal of Clinical Oncology, 33, pp. 244 - 250, http://dx.doi.org/10.1200/JCO.2014.56.2728

Journal articles | 2015

Kondrashova O; Love CJ; Lunke S; Hsu AL; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Harnett P; Sharma R; Wain G; Ward B; Papadimos D; Crandon A, 2015, 'High-throughput amplicon-based copy number detection of 11 genes in formalin-fixed paraffin-embedded ovarian tumour samples by MLPA-seq', PLoS ONE, 10, http://dx.doi.org/10.1371/journal.pone.0143006

Journal articles | 2015

Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U, 2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', Obstetrical and Gynecological Survey, 69, pp. 594 - 596, http://dx.doi.org/10.1097/ogx.0000000000000107

Journal articles | 2015

Lee CK; Lord S; Grunewald T; Gebski V; Hardy-Bessard AC; Sehouli J; Woie K; Heywood M; Schauer C; Vergote I; Scambia G; Ferrero A; Harter P; Pujade-Lauraine E; Friedlander M, 2015, 'Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial', Gynecologic Oncology, 136, pp. 18 - 24, http://dx.doi.org/10.1016/j.ygyno.2014.09.017

Journal articles | 2015

Mizrahi D; Broderick C; Friedlander M; Ryan M; Harrison M; Pumpa K; Naumann F, 2015, 'An exercise intervention during chemotherapy for women with recurrent ovarian cancer: A feasibility study', International Journal of Gynecological Cancer, 25, pp. 985 - 992, http://dx.doi.org/10.1097/IGC.0000000000000460

Journal articles | 2015

Mizrahi D; Naumann F; Broderick C; Samara J; Ryan M; Friedlander M, 2015, 'Quantifying physical activity and the associated barriers for women with ovarian cancer', International Journal of Gynecological Cancer, 25, pp. 577 - 583, http://dx.doi.org/10.1097/IGC.0000000000000349

Journal articles | 2015

Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RHJ; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M, 2015, 'Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial', The Lancet Oncology, 16, pp. 87 - 97, http://dx.doi.org/10.1016/S1470-2045(14)71135-0

Journal articles | 2015

Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MCJ; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJC; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Lynn Fink J; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; Defazio A; Grimmond SM; Bowtell DDL, 2015, 'Whole-genome characterization of chemoresistant ovarian cancer', Nature, 521, pp. 489 - 494, http://dx.doi.org/10.1038/nature14410

Journal articles | 2015

Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MCJ; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Quinn M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJC; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Fink JL; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; DeFazio A; Grimmond SM; Bowtell DDL, 2015, 'Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer', Nature, 527, pp. 398, http://dx.doi.org/10.1038/nature15716

Journal articles | 2015

Peculis LD; Ius Y; Campion M; Friedlander M; Hacker N, 2015, 'Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks' gestation', Australian and New Zealand Journal of Obstetrics and Gynaecology, 55, pp. 94 - 97, http://dx.doi.org/10.1111/ajo.12281

Journal articles | 2015

Peterlongo P; Chang-Claude J; Moysich KB; Rudolph A; Schmutzler RK; Simard J; Soucy P; Eeles RA; Easton DF; Hamann U; Wilkening S; Chen B; Rookus MA; Schmidt MK; Van Der Baan FH; Spurdle AB; Walker LC; Lose F; Maia AT; Montagna M; Matricardi L; Lubinski J; Jakubowska A; Garcia EBG; Olopade OI; Nussbaum RL; Nathanson KL; Domchek SM; Rebbeck TR; Arun BK; Karlan BY; Orsulic S; Lester J; Chung WK; Miron A; Southey MC; Goldgar DE; Buys SS; Janavicius R; Dorfling CM; Van Rensburg EJ; Ding YC; Neuhausen SL; Hansen TVO; Gerdes AM; Ejlertsen B; Jønson L; Osorio A; Martínez-Bouzas C; Benitez J; Conway EE; Blazer KR; Weitzel JN; Manoukian S; Peissel B; Zaffaroni D; Scuvera G; Barile M; Ficarazzi F; Mariette F; Fortuzzi S; Viel A; Giannini G; Papi L; Martayan A; Tibiletti MG; Radice P; Vratimos A; Fostira F; Garber JE; Donaldson A; Brewer C; Foo C; Evans DGR; Frost D; Eccles D; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Davidson R; Hodgson SV; Ellis S; Cole T; Godwin AK; Claes K; Van Maerken T; Meindl A; Gehrig A; Sutter C; Engel C, 2015, 'Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers', Cancer Epidemiology Biomarkers and Prevention, 24, pp. 308 - 316, http://dx.doi.org/10.1158/1055-9965.EPI-14-0532

Journal articles | 2015

Sandler C; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; Segelov E; Boyle FM; Chin MTM; Barry BK; Webber K; Lloyd AR, 2015, 'TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.', Journal of Clinical Oncology, 33, pp. 9571 - 9571, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9571

Journal articles | 2015

Scurry J; Hacker NF; Barlow E; Friedlander M; Jackson M, 2015, 'Is quantification of lymphovascular space invasion useful in stage 1B2 cervical carcinomas?', Journal of Obstetrics and Gynaecology, 35, pp. 377 - 381, http://dx.doi.org/10.3109/01443615.2014.958448

Journal articles | 2015

Sobral-Leite M; Wesseling J; Smit VTHBM; Nevanlinna H; van Miltenburg MH; Sanders J; Hofland I; Blows FM; Coulson P; Patrycja G; Schellens JHM; Fagerholm R; Heikkilä P; Aittomäki K; Blomqvist C; Provenzano E; Ali HR; Figueroa J; Sherman M; Lissowska J; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Phillips KA; Couch FJ; Olson JE; Vachon C; Visscher D; Brenner H; Butterbach K; Arndt V; Holleczek B; Hooning MJ; Hollestelle A; Martens JWM; van Deurzen CHM; van de Water B; Broeks A; Chang-Claude J; Chenevix-Trench G; Easton DF; Pharoah PDP; García-Closas M; de Graauw M; Schmidt MK; Aghmesheh M; Amor D; Andrews L; Antill Y; Armitage S; Arnold L; Balleine R; Bankier A; Bastick P; Beesley J; Beilby J; Bennett B; Bennett I; Berry G; Blackburn A; Bogwitz M; Brennan M; Brown M; Buckley M; Burgess M; Burke J; Butow P; Byron K; Callen D; Campbell I; Chauhan D; Chauhan M; Christian A; Clarke C; Colley A; Cotton D; Crook A; Cui J; Culling B; Cummings M; Dawson SJ; de Fazio A; Delatycki M; Dickson R; Dixon J; Dobrovic A; Dudding T; Edkins T; Edwards S; Eisenbruch M; Farshid G; Fawcett S; Fellows A; Fenton G; Field M; Firgaira F; Flanagan J; Fleming J; Fong P, 2015, 'Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis', BMC Medicine, 13, http://dx.doi.org/10.1186/s12916-015-0392-6

Journal articles | 2015

Somero G; Friedlander M, 2015, 'Temporal patterning of thermal acclimation: from behavior to membrane biophysics (vol 218, pg 167, 2015)', JOURNAL OF EXPERIMENTAL BIOLOGY, 218, pp. 500 - 500, http://dx.doi.org/10.1242/jeb.119933

Journal articles | 2015

Webber K; King MT; Friedlander ML; Webb P, 2015, 'TRAJECTORIES OF PERSISTENT SYMPTOMS AFTER COMPLETION OF PRIMARY TREATMENT FOR OVARIAN CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25, pp. 613 - 613, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145701188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2015

Webber K; Sommeijer D; Mileshkin LR; Blagden SP; McAlpine JN; Coleman RL; Herzog TJ; Witte G; Baugh E; Silberman A; Friedlander ML, 2015, 'OBESITY, PHYSICAL INACTIVITY AND SYMPTOMS AFTER OVARIAN CANCER TREATMENT: RESULTS FROM AN INTERNATIONAL INTERNET-BASED SURVEY', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25, pp. 42 - 43, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145700023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2015

Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MKB; Sydes MR; Tannock IF; Oza AM, 2015, 'Outcomes and endpoints in cancer trials: Bridging the divide', The Lancet Oncology, 16, pp. e43 - e52, http://dx.doi.org/10.1016/S1470-2045(14)70380-8

Journal articles | 2014

Amant F; Floquet A; Friedlander M; Kristensen G; Mahner S; Nam EJ; Powell MA; Ray-Coquard I; Siddiqui N; Sykes P; Westermann AM; Seddon B, 2014, 'Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma', International Journal of Gynecological Cancer, 24, pp. S67 - S72, http://dx.doi.org/10.1097/IGC.0000000000000205

Journal articles | 2014

Anuradha S; Webb PM; Blomfield P; Brand AH; Friedlander M; Leung Y; Obermair A; Oehler MK; Quinn M; Steer C; Jordan SJ, 2014, 'Survival of Australian women with invasive epithelial ovarian cancer: A populationbased study', Medical Journal of Australia, 201, pp. 283 - 288, http://dx.doi.org/10.5694/mja14.00132

Journal articles | 2014

Bock VL; Friedlander M; Waring D; Kossard S; Wood GK, 2014, 'Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature', Australasian Journal of Dermatology, 55, pp. 282 - 285, http://dx.doi.org/10.1111/ajd.12110

Journal articles | 2014

Brown J; Friedlander M; Backes FJ; Harter P; O'Connor DM; De La Motte Rouge T; Lorusso D; Maenpaa J; Kim JW; Tenney ME; Seckl MJ, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for ovarian germ cell tumors', International Journal of Gynecological Cancer, 24, pp. S48 - S54, http://dx.doi.org/10.1097/IGC.0000000000000223

Journal articles | 2014

Butow PN; Price MA; Bell ML; Webb PM; Defazio A; Friedlander M, 2014, 'Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs', Gynecologic Oncology, 132, pp. 690 - 697, http://dx.doi.org/10.1016/j.ygyno.2014.01.002

Journal articles | 2014

Davis A; Tinker AV; Friedlander M, 2014, '"platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?', Gynecologic Oncology, 133, pp. 624 - 631, http://dx.doi.org/10.1016/j.ygyno.2014.02.038

Journal articles | 2014

Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P, 2014, 'Incorporation of pazopanib in maintenance therapy of ovarian cancer', Journal of Clinical Oncology, 32, pp. 3374 - 3381, http://dx.doi.org/10.1200/JCO.2014.55.7348

Journal articles | 2014

Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract', International Journal of Gynecological Cancer, 24, pp. S78 - S82, http://dx.doi.org/10.1097/IGC.0000000000000239

Journal articles | 2014

Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT, 2014, 'Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer a reality check: Results of stage 1 of the gynecologic cancer intergroup symptom benefit study', International Journal of Gynecological Cancer, 24, pp. 857 - 864, http://dx.doi.org/10.1097/IGC.0000000000000147

Journal articles | 2014

Friedlander ML, 2014, 'Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)', Chinese Clinical Oncology, 3, http://dx.doi.org/10.3978/j.issn.2304-3865.2013.11.01

Journal articles | 2014

Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; Defazio A; Gertig D; Green A; Webb P; Hung J; Moore S; Traficante N; Fereday S; Harrap K; Sadkowsky T; Pandeya N; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Sharma R; Achen A; Wain G; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler MK; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D; Underhill C, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, 4, pp. 4669, http://dx.doi.org/10.1038/srep04669

Journal articles | 2014

Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2014, 'Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology, 25, pp. 143 - 148, http://dx.doi.org/10.1093/annonc/mdt369

Journal articles | 2014

Harter P; du Bois A; WImberger P; Schmalfeldt B; Emons G; Kreienberg R; Hilpert F; Lück HJ; Matulonis U; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Mapherson E; Dougherty B; Juergensmeier JM; Orr M; Ledermann J, 2014, 'Erhaltungstherapie mit Olaparib nach platinhaltiger Re-induktion bei platinsensitivem serösem Ovarialkarzinomrezidiv: eine Placebo-kontrollierte Phase II Studie', Geburtshilfe und Frauenheilkunde, 74, http://dx.doi.org/10.1055/s-0034-1388545

Journal articles | 2014

Hasegawa K; Nagao S; Yasuda M; Millan D; Viswanathan AN; Glasspool RM; Devouassoux-Shisheboran M; Covens A; Lorusso D; Kurzeder C; Kim JW; Gladieff L; Bryce J; Friedlander M; Fujiwara K, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix', International Journal of Gynecological Cancer, 24, pp. S90 - S95, http://dx.doi.org/10.1097/IGC.0000000000000297

Journal articles | 2014

Joly F; McAlpine J; Nout R; Åvall-Lundqvist E; Shash E; Friedlander M, 2014, 'Quality of life and patient-reported outcomes in endometrial cancer clinical trials: A call for action!', International Journal of Gynecological Cancer, 24, pp. 1693 - 1699, http://dx.doi.org/10.1097/IGC.0000000000000299

Journal articles | 2014

King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'Development of the measure of ovarian symptoms and Treatment concerns aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer', International Journal of Gynecological Cancer, 24, pp. 865 - 873, http://dx.doi.org/10.1097/IGC.0000000000000167

Journal articles | 2014

Layman J; Friedlander M, 2014, 'John Major Fowler Obituary', PHYSICS TODAY, 67, pp. 59 - 59, http://dx.doi.org/10.1063/PT.3.2456

Journal articles | 2014

Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U, 2014, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', The Lancet Oncology, 15, pp. 852 - 861, http://dx.doi.org/10.1016/S1470-2045(14)70228-1

Journal articles | 2014

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei DE; Fielding A; Spencer S; Bennett B; Parry D; Matulonis U, 2014, 'Health-Related Quality of Life (Hrqol) During Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer (Psr Soc) and a Brca Mutation (Brcam)', Annals of Oncology, 25, pp. iv308 - iv308, http://dx.doi.org/10.1093/annonc/mdu338.11

Journal articles | 2014

Ledermann JA; Luvero D; Shafer A; O'Connor D; Mangili G; Friedlander M; Pfisterer J; Mirza MR; Kim JW; Alexandre J; Oza A; Brown J, 2014, 'Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma', International Journal of Gynecological Cancer, 24, pp. S14 - S19, http://dx.doi.org/10.1097/IGC.0000000000000296

Journal articles | 2014

Long A; Toner G; Stockler MR; Thomson DB; Gebski V; Yip S; King M; Friedlander M; Quinn DI; Singhal N; Roncolato F; Grimison P, 2014, 'Anzup 1302: a Randomised Phase 3 Trial of Accelerated Versus Standard Bep Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours (P3Bep)', Annals of Oncology, 25, pp. iv303 - iv303, http://dx.doi.org/10.1093/annonc/mdu337.65

Journal articles | 2014

Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Fielding A; Spencer S; Ho TW; Ledermann JA, 2014, 'Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)', Gynecologic Oncology, 133, pp. 54 - 55, http://dx.doi.org/10.1016/j.ygyno.2014.03.152

Journal articles | 2014

McAlpine JN; Greimel E; Brotto LA; Nout RA; Shash E; Åvall-Lundqvist E; Friedlander ML; Joly F, 2014, 'Quality of life research in endometrial cancer what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic cancer InterGroup Symptom Benefit Working Group brainstorming session, leiden 2012', International Journal of Gynecological Cancer, 24, pp. 1686 - 1692, http://dx.doi.org/10.1097/IGC.0000000000000245

Journal articles | 2014

Meiser B; Price MA; Butow PN; Rahman B; Tucker K; Cheah B; Bickerstaffe A; Hopper J; Phillips KA; Bennett B; Tennant C; Milne RL; Weideman P; Stanhope L; Picken S; Friedlander ML; Goldgar D, 2014, 'Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer', Familial Cancer, 13, pp. 153 - 162, http://dx.doi.org/10.1007/s10689-013-9687-y

Journal articles | 2014

Mileshkin LR; Narayan K; Moore KN; Rischin D; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Small W; Thomas G; Fyles AW; Gebski V; Stockler MR, 2014, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).', Journal of Clinical Oncology, 32, pp. TPS5632 - TPS5632, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5632

Journal articles | 2014

Murray JE; Pickering HR; Lin CS-Y; Goldstein D; Friedlander ML; Kiernan MC; Krishnan AV, 2014, '6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy', Clinical Neurophysiology, 125, pp. e3 - e3, http://dx.doi.org/10.1016/j.clinph.2013.10.028

Journal articles | 2014

Nomura H; Hanker L; Fabbro M; Rau J; Kim Y; Arija JAA; Friedlander M; Ferrandina G; Vuylsteke P; Colombo N; Malander S; Monk BJ; Petru E; Calvert P; Herzog T; Barrett C; Jobanputra M; Wang Q; Elser G; Du Bois A, 2014, 'Pazopanib Versus Placebo in Women Without Progression After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Aeoc): Second Interim Overall Survival Analysis from the Ago-Ovar16 Trial', Annals of Oncology, 25, pp. iv307 - iv307, http://dx.doi.org/10.1093/annonc/mdu338.6

Journal articles | 2014

Park SB; Kwok JB; Loy CT; Friedlander ML; Lin CSY; Krishnan AV; Lewis CR; Kiernan MC; Goldstein D, 2014, 'Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes', BMC Cancer, 14, pp. 993, http://dx.doi.org/10.1186/1471-2407-14-993

Journal articles | 2014

Peculis LD; Ius Y; Campion M; Friedlander M; Hacker N, 2014, 'Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks gestation', Australian and New Zealand Journal of Obstetrics and Gynaecology, http://dx.doi.org/10.1111/ajo.12281

Journal articles | 2014

Reed NS; Gomez-Garcia E; Gallardo-Rincon D; Barrette B; Baumann K; Friedlander M; Kichenadasse G; Kim JW; Lorusso D; Mirza MR; Ray-Coquard I, 2014, 'Gynecologic cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary', International Journal of Gynecological Cancer, 24, pp. S35 - S41, http://dx.doi.org/10.1097/IGC.0000000000000265

Journal articles | 2014

Reed NS; Pautier P; Åvall-Lundqvist E; Choi CH; Du Bois A; Friedlander M; Fyles A; Kichenadasse G; Provencher DM; Ray-Coquard I, 2014, 'Gynecologic cancer interGroup (GCIG) consensus review for ovarian small cell cancers', International Journal of Gynecological Cancer, 24, pp. S30 - S34, http://dx.doi.org/10.1097/IGC.0000000000000293

Journal articles | 2014

Sousa M; Meiser B; Hickey M; Jarvis S; Lombard J; Chirgwin J; Segelov E; Lewis C; Friedlander M, 2014, 'PEGASUS - PREVALENCE AND SEVERITY OF GENITOURINARY SYMPTOMS AND IMPACT ON SEXUAL FUNCTION AND QOL IN POSTMENOPAUSAL WOMEN RECEIVING ENDOCRINE THERAPY FOR EARLY BREAST CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24, pp. 1041 - 1042, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966501317&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2014

Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; De Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E, 2014, 'Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer', Journal of Clinical Oncology, 32, pp. 1309 - 1316, http://dx.doi.org/10.1200/JCO.2013.51.4240

Journal articles | 2014

Webber K; Sommeijer D; Mileshkin L; Friedlander ML, 2014, 'OVQUEST: LIVING AFTER THE DIAGNOSIS AND TREATMENT OF OVARIAN CANCER. PRELIMINARY RESULTS FROM AN INTERNET-BASED SURVEY', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24, pp. 252 - 252, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2013

Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; De Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB, 2013, 'Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: A multi-institutional study', Clinical Cancer Research, 19, pp. 5485 - 5493, http://dx.doi.org/10.1158/1078-0432.CCR-13-1262

Journal articles | 2013

Baumbusch LO; Helland A; Wang Y; Liestøl K; Schaner ME; Holm R; Etemadmoghadam D; Alsop K; Brown P; Mitchell G; Fereday S; DeFazio A; Bowtell DDL; Kristensen GB; Lingjærde OC; Børresen-Dale AL, 2013, 'High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0054356

Journal articles | 2013

Blinman P; Gainford C; Donoghoe M; Martyn J; Blomfield P; Grant P; Kichenadasse G; Vaughan M; Brand A; Shannon C; Gebski V; Stockler M; Friedlander M, 2013, 'Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG study', Journal of Gynecologic Oncology, 24, pp. 359 - 366, http://dx.doi.org/10.3802/jgo.2013.24.4.359

Journal articles | 2013

Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman PC; Birch KE; Hopper JL; Phillips KA, 2013, 'Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham foundation consortium for research into familial breast cancer', Journal of Clinical Oncology, 31, pp. 3920 - 3925, http://dx.doi.org/10.1200/JCO.2013.49.3007

Journal articles | 2013

Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; Cuningham K; Hopper JL; Phillips KA, 2013, 'Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers', Medical Journal of Australia, 199, pp. 680 - 683, http://dx.doi.org/10.5694/mja13.10848

Journal articles | 2013

Couch FJ; Wang X; McGuffog L; Lee A; Olswold C; Kuchenbaecker KB; Soucy P; Fredericksen Z; Barrowdale D; Dennis J; Gaudet MM; Dicks E; Kosel M; Healey S; Sinilnikova OM; Lee A; Bacot F; Vincent D; Hogervorst FBL; Peock S; Stoppa-Lyonnet D; Jakubowska A; Radice P; Schmutzler RK; Domchek SM; Piedmonte M; Singer CF; Friedman E; Thomassen M; Hansen TVO; Neuhausen SL; Szabo CI; Blanco I; Greene MH; Karlan BY; Garber J; Phelan CM; Weitzel JN; Montagna M; Olah E; Andrulis IL; Godwin AK; Yannoukakos D; Goldgar DE; Caldes T; Nevanlinna H; Osorio A; Terry MB; Daly MB; van Rensburg EJ; Hamann U; Ramus SJ; Ewart Toland A; Caligo MA; Olopade OI; Tung N; Claes K; Beattie MS; Southey MC; Imyanitov EN; Tischkowitz M; Janavicius R; John EM; Kwong A; Diez O; Balmaña J; Barkardottir RB; Arun BK; Rennert G; Teo SH; Ganz PA; Campbell I; van der Hout AH; van Deurzen CHM; Seynaeve C; Gómez Garcia EB; van Leeuwen FE; Meijers-Heijboer HEJ; Gille JJP; Ausems MGEM; Blok MJ; Ligtenberg MJL; Rookus MA; Devilee P; Verhoef S; van Os TAM; Wijnen JT; Frost D; Ellis S; Fineberg E; Platte R; Evans DG; Izatt L; Eeles RA; Adlard J; Eccles DM; Cook J; Brewer C; Douglas F; Hodgson S, 2013, 'Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk', PLoS Genetics, 9, http://dx.doi.org/10.1371/journal.pgen.1003212

Journal articles | 2013

Cruz-Rivera E; Friedlander M, 2013, 'Effects of algal phenotype on mesograzer feeding', MARINE ECOLOGY PROGRESS SERIES, 490, pp. 69 - 78, http://dx.doi.org/10.3354/meps10429

Journal articles | 2013

Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Wimberger P; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Kim JH; Harter P, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).', Journal of Clinical Oncology, 31, pp. LBA5503 - LBA5503, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.lba5503

Journal articles | 2013

Friedlander M; Sjoquist KM; Sommeijer DW; Bailey L; Martyn J; Gillies K; Mileshkin LR; O'Connel R; Gebski V; Vaughan MM; Blomfield P; Beale PJ; Quinn M; Stockler MR; Lombard JM; Hadley AM; Amant F; Edmondson RJ, 2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', Journal of Clinical Oncology, 31, pp. TPS5614 - TPS5614, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps5614

Journal articles | 2013

Friedlander ML; King MT, 2013, 'Patient-reported outcomes in ovarian cancer clinical trials', Annals of Oncology, 24, http://dx.doi.org/10.1093/annonc/mdt474

Journal articles | 2013

Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA, 2013, 'Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: Time to think differently?', Journal of Clinical Oncology, 31, pp. 2362, http://dx.doi.org/10.1200/JCO.2012.47.7927

Journal articles | 2013

Gleeson MA; Meiser B; Barlow-Stewart K; Trainer A; Tucker K; Watts KJ; Friedlander M; Kasparian NA, 2013, 'Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing', Oncology Nursing Forum, 40, pp. 275 - 283, http://dx.doi.org/10.1188/13.ONF.40-03AP

Journal articles | 2013

Hacker NF; Barlow EL; Scurry J; Gebski V; Farrell R; Robertson G; Friedlander ML; Jackson M, 2013, 'Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer', Obstetrics and Gynecology, 121, pp. 765 - 772, http://dx.doi.org/10.1097/AOG.0b013e3182887836

Journal articles | 2013

Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Webb P, 2013, 'Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study', Gynecologic Oncology, 129, pp. 310 - 317, http://dx.doi.org/10.1016/j.ygyno.2013.02.007

Journal articles | 2013

Juraskova I; Jarvis SK; Mok K; Peate M; Meiser B; Cheah BC; Mireskandari S; Friedlander M, 2013, 'The acceptability, feasibility and efficacy (Phase I/II study) of the OVERcome (Olive oil, Vaginal Exercise and moisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer.', Journal of Sexual Medicine, EPUB ahead of print, pp. 2549 - 2558, http://dx.doi.org/10.1111/jsm.12156

Journal articles | 2013

Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Bowen K; Fielding A; Domchek SM, 2013, 'Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.', Journal of Clinical Oncology, 31, pp. 11024 - 11024, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.11024

Journal articles | 2013

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Macpherson E; Dougherty B; Jürgensmeier JM; Orr M; Matulonis U, 2013, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).', Journal of Clinical Oncology, 31, pp. 5505 - 5505, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5505

Journal articles | 2013

Lee CK; Simes RJ; Brown C; Gebski V; Pfisterer J; Swart AM; Berton-Rigaud D; Plante M; Skeie-Jensen T; Vergote I; Schauer C; Pisano C; Parma G; Baumann K; Ledermann JA; Pujade-Lauraine E; Bentley J; Kristensen G; Belau A; Nankivell M; Canzler U; Lord SJ; Kurzeder C; Friedlander M, 2013, 'A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer', Annals of Oncology, 24, pp. 937 - 943, http://dx.doi.org/10.1093/annonc/mds538

Journal articles | 2013

Luk WY; Friedlander M, 2013, 'A fibroid or cancer? A rare case of mixed choriocarcinoma and epithelioid trophoblastic tumour.', Case Rep Obstet Gynecol, 2013, pp. 492754, http://dx.doi.org/10.1155/2013/492754

Journal articles | 2013

Nagle CM; Olsen CM; Ibiebele TI; Spurdle AB; Webb PM, 2013, 'Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis', EUROPEAN JOURNAL OF NUTRITION, 52, pp. 705 - 715, http://dx.doi.org/10.1007/s00394-012-0376-7

Journal articles | 2013

Olsen CM; Nagle CM; Whiteman DC; Ness R; Pearce CL; Pike MC; Rossing MA; Terry KL; Wu AH; Group S; Risch HA; Yu H; Doherty JA; Chang-Claude J; Hein R; Nickels S; Wang-Gohrke S; Goodman MT; Carney ME; Matsuno RK; Lurie G; Moysich K; Kjaer SK; Jensen A; Hogdall E; Goode EL; Fridley BL; Vierkant RA; Larson MC; Schildkraut J; Hoyo C; Moorman P; Weber RP; Cramer DW; Vitonis AF; Bandera EV; Olson SH; Rodriguez-Rodriguez L; King M; Brinton LA; Yang H; Garcia-Closas M; Lissowska J; Anton-Culver H; Ziogas A; Gayther SA; Ramus SJ; Menon U; Gentry-Maharaj A; Webb PM, 2013, 'Obesity and risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer Association Consortium', Endocrine-Related Cancer, 20, pp. 251 - 262, http://dx.doi.org/10.1530/ERC-12-0395

Journal articles | 2013

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, http://dx.doi.org/10.1002/caac.21204

Journal articles | 2013

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, 63, pp. 419 - 437, http://dx.doi.org/10.3322/caac.21204

Journal articles | 2013

Peate M; Friedlander M, 2013, 'Using decision aids for improving treatment-choices for women with breast cancer.', Breast Cancer Management, 2, pp. 23 - 31, http://dx.doi.org/10.2217/bmt.12.61

Journal articles | 2013

Permuth-Wey J; Lawrenson K; Shen HC; Velkova A; Tyrer JP; Chen Z; Lin HY; Ann Chen Y; Tsai YY; Qu X; Ramus SJ; Karevan R; Lee J; Lee N; Larson MC; Aben KK; Anton-Culver H; Antonenkova N; Antoniou AC; Armasu SM; Bacot F; Baglietto L; Bandera EV; Barnholtz-Sloan J; Beckmann MW; Birrer MJ; Bloom G; Bogdanova N; Brinton LA; Brooks-Wilson A; Brown R; Butzow R; Cai Q; Campbell I; Chang-Claude J; Chanock S; Chenevix-Trench G; Cheng JQ; Cicek MS; Coetzee GA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Despierre E; Doherty JA; Dörk T; Du Bois A; Dürst M; Easton DF; Eccles D; Edwards R; Ekici AB; Fasching PA; Fenstermacher DA; Flanagan JM; Garcia-Closas M; Gentry-Maharaj A; Giles GG; Glasspool RM; Gonzalez-Bosquet J; Goodman MT; Gore M; Górski B; Gronwald J; Hall P; Halle MK; Harter P; Heitz F; Hillemanns P; Hoatlin M; Høgdall CK; Høgdall E; Hosono S; Jakubowska A; Jensen A; Jim H; Kalli KR; Karlan BY; Kaye SB; Kelemen LE; Kiemeney LA; Kikkawa F; Konecny GE; Krakstad C; Krüger Kjaer S; Kupryjanczyk J; Lambrechts D; Lambrechts S; Lancaster JM; Le ND; Leminen A; Levine DA; Liang D; Kiong Lim B; Lin J; Lissowska J; Lu KH; Lubiński J, 2013, 'Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2613

Journal articles | 2013

Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RAEM; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL, 2013, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Journal of Clinical Oncology, 31, pp. 3091 - 3099, http://dx.doi.org/10.1200/JCO.2012.47.8313

Journal articles | 2013

Price MA; Bell ML; Sommeijer DW; Friedlander M; Stockler MR; Defazio A; Webb PM; Butow PN, 2013, 'Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life', Gynecologic Oncology, 130, pp. 162 - 168, http://dx.doi.org/10.1016/j.ygyno.2013.03.031

Journal articles | 2013

Price MA; Butow PN; Bell ML; Webb PM; deFazio A; Friedlander M; Fardell JE, 2013, 'PSYCHOSOCIAL PREDICTORS OF SURVIVAL IN WOMEN WITH INVASIVE OVARIAN CANCER: A POPULATION-BASED PROSPECTIVE STUDY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 91 - 91, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2013

Shen H; Fridley BL; Song H; Lawrenson K; Cunningham JM; Ramus SJ; Cicek MS; Tyrer J; Stram D; Larson MC; Köbel M; Ziogas A; Zheng W; Yang HP; Wu AH; Wozniak EL; Ling Woo Y; Winterhoff B; Wik E; Whittemore AS; Wentzensen N; Palmieri Weber R; Vitonis AF; Vincent D; Vierkant RA; Vergote I; Van Den Berg D; Van Altena AM; Tworoger SS; Thompson PJ; Tessier DC; Terry KL; Teo SH; Templeman C; Stram DO; Southey MC; Sieh W; Siddiqui N; Shvetsov YB; Shu XO; Shridhar V; Wang-Gohrke S; Severi G; Schwaab I; Salvesen HB; Rzepecka IK; Runnebaum IB; Anne Rossing M; Rodriguez-Rodriguez L; Risch HA; Renner SP; Poole EM; Pike MC; Phelan CM; Pelttari LM; Pejovic T; Paul J; Orlow I; Zawiah Omar S; Olson SH; Odunsi K; Nickels S; Nevanlinna H; Ness RB; Narod SA; Nakanishi T; Moysich KB; Monteiro ANA; Moes-Sosnowska J; Modugno F; Menon U; McLaughlin JR; McGuire V; Matsuo K; Mat Adenan NA; Massuger LFAG; Lurie G; Lundvall L; Lubiński J; Lissowska J; Levine DA; Leminen A; Lee AW; Le ND; Lambrechts S; Lambrechts D; Kupryjanczyk J; Krakstad C; Konecny GE; Krüger Kjaer S; Kiemeney LA; Kelemen LE; Keeney GL; Karlan BY; Karevan R; Kalli KR; Kajiyama H; Ji BT; Jensen A; Jakubowska A, 2013, 'Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer', Nature Communications, 4, http://dx.doi.org/10.1038/ncomms2629

Journal articles | 2013

Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN, 2013, 'Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: The gynecologic cancer intergroup symptom benefit study', Oncologist, 18, pp. 1221 - 1228, http://dx.doi.org/10.1634/theoncologist.2013-0175

Journal articles | 2013

Sommeijer DW; Sjoquist KM; Friedlander M, 2013, 'Hormonal treatment in recurrent and metastatic gynaecological cancers: A review of the current literature', Current Oncology Reports, 15, pp. 541 - 548, http://dx.doi.org/10.1007/s11912-013-0343-3

Journal articles | 2013

Stockler MR; Hilpert F; Friedlander M; King M; Wenzel LB; Lee C; Joly F; De Gregorio N; Arranz Arija JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade Lauraine E, 2013, 'Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).', Journal of Clinical Oncology, 31, pp. 5542 - 5542, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5542

Journal articles | 2013

Thewes B; Bell ML; Butow P; Beith J; Boyle F; Friedlander M; McLachlan SA, 2013, 'Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: Results of a cross-sectional study', Psycho-Oncology, 22, pp. 2797 - 2806, http://dx.doi.org/10.1002/pon.3348

Journal articles | 2013

Webber K; Girgis A; Bennett BK; Bonaventura A; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).', Journal of Clinical Oncology, 31, pp. 9602 - 9602, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9602

Journal articles | 2012

Alsop K; Fereday S; Meldrum C; DeFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G, 2012, 'BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group', Journal of Clinical Oncology, 30, pp. 2654 - 2663, http://dx.doi.org/10.1200/JCO.2011.39.8545

Journal articles | 2012

Ang JE; Gourley C; High HA; Shapira-Frommer R; Powell CB; Castonguay V; De Greve J; Yap TA; Fong PCC; Olmos D; Banerjee SN; Chen L-M; Friedlander M; Kaufman B; Oza AM; De Bono JS; Gore ME; Kaye SB, 2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.', Journal of Clinical Oncology, 30, pp. 5022 - 5022, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5022

Journal articles | 2012

Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study.', Journal of Clinical Oncology, 30, pp. 9044 - 9044, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9044

Journal articles | 2012

Berek JS; Crum C; Friedlander M, 2012, 'Cancer of the ovary, fallopian tube, and peritoneum', International Journal of Gynecology and Obstetrics, 119, http://dx.doi.org/10.1016/S0020-7292(12)60025-3

Journal articles | 2012

Bonolis L; Friedlander M, 2012, 'Massimilla Baldo Ceolin Obituary', PHYSICS TODAY, 65, pp. 60 - 60, http://dx.doi.org/10.1063/PT.3.1686

Journal articles | 2012

Cowin PA; Fereday S; Loehrer E; Van Loo P; Cullinane C; Etemadmoghadam D; Ftouni S; Galletta L; Anglesio MS; Hendley J; Bowes L; Sheppard KE; Christie EL; Pearson RB; Harnett PR; Heinzelmann-Schwarz VA; Friedlander M; McNally O; Quinn MA; Campbell P; Defazio A; Bowtell DDL; George J, 2012, 'LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin', Cancer Research, 72, pp. 4060 - 4073, http://dx.doi.org/10.1158/0008-5472.CAN-12-0203

Journal articles | 2012

Friedlander M, 2012, 'A century of cosmic rays', NATURE, 483, pp. 400 - 401, http://dx.doi.org/10.1038/483400a

Journal articles | 2012

Goldstein D; Bennett BK; Webber K; Boyle F; De Souza P; Wilcken NRC; Scott E; Toppler R; Murie P; O''Malley L; Mccourt J; Friedlander M; Hickie IB; Lloyd AR, 2012, 'Cancer-related fatigue in women with breast cancer: outcomes of a 5 year prospective cohort study.', Journal of Clinical Oncology, 30, pp. 1805 - 1812, http://dx.doi.org/10.1200/JCO.2011.34.6148

Journal articles | 2012

Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA, 2012, 'Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort study', Journal of Clinical Oncology, 30, pp. 19 - 26, http://dx.doi.org/10.1200/JCO.2010.33.0068

Journal articles | 2012

Grimison PS; Chatfield MD; Mazhar D; Toner GC; Chester JD; Stockler MR; Stark DP; Thomson DB; Shamash J; Friedlander M; White J; Gebski V; Wason J; Boland AL; Rimmer YL; McDonald A; Gurney H; Rosenthal M; Singhal N; Williams MV, 2012, 'Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.', Journal of Clinical Oncology, 30, pp. 4531 - 4531, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4531

Journal articles | 2012

High H; Friedlander M, 2012, 'Pathological diagnosis of ovarian cancer', Hereditary Cancer in Clinical Practice, 10, pp. A82 - A82, http://dx.doi.org/10.1186/1897-4287-10-s2-a82

Journal articles | 2012

Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B, 2012, 'Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer', Journal of Clinical Oncology, 30, pp. 372 - 379, http://dx.doi.org/10.1200/JCO.2011.36.9215

Journal articles | 2012

Kirchhoff T; Offit K; Gaudet MM; Pharoah PDP; Easton DF; Antoniou AC; Mcguffog L; Humphreys MK; Dunning AM; Bojesen SE; Nordestgaard BG; Flyger H; Kang D; Yoo KY; Noh DY; Ahn SH; Dork T; Schürmann P; Karstens JH; Hillemanns P; Couch FJ; Olson J; Vachon C; Wang X; Cox A; Brock I; Elliott G; Reed MWR; Burwinkel B; Meindl A; Brauch H; Justenhoven C; Hamann U; Ko YD; Fischer HP; Brüning T; Pesch B; Harth V; Rabstein S; Broeks A; Schmidt MK; Van 't Veer LJ; Braaf LM; Johnson N; Fletcher O; Gibson L; Peto J; Turnbull C; Seal S; Renwick A; Rahman N; Wu PE; Yu JC; Hsiung CN; Shen CY; Southey MC; Hopper JL; Hammet F; van Dorpe T; Dieudonne AS; Hatse S; Lambrechts D; Andrulis IL; Bogdanova N; Antonenkova N; Rogov JI; Prokofieva D; Bermisheva M; Khusnutdinova E; van Asperen CJ; Tollenaar RAEM; Hooning MJ; Devilee P; Margolin S; Lindblom A; Milne RL; Arias JI; Pilar Zamora M; Benítez J; Severi G; Baglietto L; Giles GG; Chenevix-Trench G; Spurdle AB; Beesley J; Chen X; Holland H; Healey S; Wang-Gohrke S; Chang-Claude J; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Agnarsson BA; Caligo MA; Godwin AK; Nevanlinna H; Heikkinen T; Fredericksen Z, 2012, 'Breast cancer risk and 6q22.33: Combined results from breast cancer association consortium and consortium of investigators on modifiers of brca1/2', PLoS ONE, 7, http://dx.doi.org/10.1371/journal.pone.0035706

Journal articles | 2012

Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Macpherson E; Watkins C; Carmichael J; Matulonis U, 2012, 'Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer', New England Journal of Medicine, 366, pp. 1382 - 1392, http://dx.doi.org/10.1056/NEJMoa1105535

Journal articles | 2012

Mileshkin LR; Narayan K; Moore KN; Rischin D; Trimble EL; Stockler MR; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Shrivastava SK; Small W; Thomas G; Craighead PS; Gebski V, 2012, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.', Journal of Clinical Oncology, 30, pp. TPS5116 - TPS5116, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps5116

Journal articles | 2012

Molife LR; Mateo J; McGoldrick T; Krebs M; Drew Y; Banerjee SN; Nicum S; Ranson M; Rustin GJS; Sessa C; Plummer R; Leunen K; Friedlander M; Swaisland H; Burke W; McCormack P; Pemberton K; Tchakov I; Kaye SB; Gourley C, 2012, 'Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.', Journal of Clinical Oncology, 30, pp. 3048 - 3048, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3048

Journal articles | 2012

Oza AM; Cibula D; Oaknin A; Poole CJ; Mathijssen RHJ; Sonke GS; Colombo N; Špacek J; Vuylsteke P; Hirte HW; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Tchakov I; Friedlander M, 2012, 'Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.', Journal of Clinical Oncology, 30, pp. 5001 - 5001, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5001

Journal articles | 2012

Phillips KA; Milne RL; Rookus MA; Goldgar D; Friedlander M; McLachlan SA; Buys S; Antoniou AC; Birch K; Terry MB; Easton DF; Weideman P; Daly M; Andrieu N; John EM; Hooning MJ; Andrulis IL; Caldes T; Olsson H; Hopper JL, 2012, 'Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Hereditary Cancer in Clinical Practice, 10, pp. A11 - A11, http://dx.doi.org/10.1186/1897-4287-10-s2-a11

Journal articles | 2012

Ribi K; Aldridge J; Phillips K-A; Thompson A; Harvey V; Thuerlimann B; Cardoso F; Pagani O; Coates AS; Goldhirsch A; Price KN; Gelber RD; Bernhard J, 2012, 'Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer', BRITISH JOURNAL OF CANCER, 106, pp. 1618 - 1625, http://dx.doi.org/10.1038/bjc.2012.156

Journal articles | 2012

Sallo FB; Peto T; Egan C; Wolf-Schnurrbusch UEK; Clemons TE; Gillies MC; Pauleikhoff D; Rubin GS; Chew EY; Bird AC; Sahel JA; Guymer R; Soubrane G; Gaudric A; Schwartz S; Constable I; Cooney M; Singerman L; Friedlander M; Moisseiev J; Rosen R; Murphy R; Holz F; Comer G; Blodi B; Do D; Brucker A; Narayanan R; Wolf S; Rosenfeld P; Bernstein PS; Miller JW, 2012, 'The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia', Investigative Ophthalmology and Visual Science, 53, pp. 7889 - 7895, http://dx.doi.org/10.1167/iovs.12-10765

Journal articles | 2012

Sjoquist KM; Lee C; Lord S; Chatfield MD; Friedlander M; Simes J; Marschner I, 2012, 'Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).', Journal of Clinical Oncology, 30, pp. 5081 - 5081, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5081

Journal articles | 2012

Watts KJ; Meiser B; Mitchell GF; Kirk J; Saunders C; Peate M; Duffy J; Kelly PJ; Gleeson MA; Barlow-Stewart K; Rahman B; Friedlander M; Tucker K; TFGT CG; Parasyn A; Andrews L, 2012, 'How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer', BMC Cancer, 12, pp. 320, http://dx.doi.org/10.1186/1471-2407-12-320

Journal articles | 2011

Anglesio M; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin P; House CM; Chakravarty P; Gorringe K; Campbell I; George J, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, 17, pp. 2538 - 2548

Journal articles | 2011

Bae S; Friedlander M; Scott C, 2011, 'CART-WHEEL.org can facilitate research into rare gynecological tumors.', International Journal of Gynecological Cancer, 21, pp. 1517 - 1519

Journal articles | 2011

Bowtell DDL; Friedlander M; Quinn M; Mitchell G, 2011, 'A response to the forgotten fallopian tube', Nature Reviews Cancer, 11, http://dx.doi.org/10.1038/nrc2946-c2

Journal articles | 2011

Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott C, 2011, 'The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.', Asia-Pacific Journal of Clinical Oncology, 7, pp. 197 - 211

Journal articles | 2011

Collinson I; Roberts-Thomson R; Faulkner D; Rischin D; Friedlander M; Mileshkin L, 2011, 'Carboplatin dosing in ovarian cancer: problems and pitfalls.', International Journal of Gynecological Cancer, 21, pp. 1213 - 1218

Journal articles | 2011

Cruz-Rivera E; Friedlander M, 2011, 'Feeding preferences of mesograzers on aquacultured Gracilaria and sympatric algae', AQUACULTURE, 322, pp. 218 - 222, http://dx.doi.org/10.1016/j.aquaculture.2011.09.035

Journal articles | 2011

Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh M; Loman N; Scott C; Friedlander M; kaufman B; Garber J; Tutt A; Robson ME, 2011, 'Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.', Journal of CLIN ONCOL, 29, pp. 4224 - 4226

Journal articles | 2011

Friedlander M; Trimble E; Tinker A; Alberts D; Avall-lundqvist E; Brady M; Harter P; Pignata S; Pujade-lauraine E; Sehouli J; Vergote I; Beale P; Bekkers R; Calvert P; Copeland LM; Glasspool R; Gonzalez-martin A; Katsaros D; Kim JW; Miller B; Provencher D; Rubinstein L; Atri M; Zeimet A; Bacon M; Kitchener H; Stuart GW, 2011, 'Clinical trials in recurrent ovarian cancer.', International Journal of Gynecological Cancer, 21, pp. 771 - 775

Journal articles | 2011

Griffiths G, 2011, 'International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial', JOURNAL OF CLINICAL ONCOLOGY, 29, pp. 2171 - 2177, http://dx.doi.org/10.1200/JCO.2010.32.3139

Journal articles | 2011

Grimison PS; Thomson DB; Stockler MR; Chatfield MD; Friedlander M; Gebski V; Boland AL; Houghton BB; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2011, 'Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial.', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4561

Journal articles | 2011

Harvey S; Milne RL; McLachlan S; Friedlander M; Birch KE; Weideman P, 2011, 'Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.', Breast Cancer Research and Treatment, 130, pp. 1057 - 1061

Journal articles | 2011

Helland A; Anglesio MS; George J; Cowin PA; Johnstone CN; House CM; Sheppard KE; Etemadmoghadam D; Melnyk N; Rustgi AK; Phillips WA; Johnsen H; Holm R; Kristensen GB; Birrer MJ; Pearson RB; Børresen-Dale AL; Huntsman DG; deFazio A; Creighton CJ; Smyth GK; Bowtell DDL, 2011, 'Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers', PLoS ONE, 6, http://dx.doi.org/10.1371/journal.pone.0018064

Journal articles | 2011

Juraskova I; Jarvis S; Mok K; Peate M; Meiser B; Mireskandari S; Friedlander M, 2011, 'OVERcome: An intervention study to improve sexual function in women with breast cancer.', J Clin Oncol, 29, pp. 9066, http://www.ncbi.nlm.nih.gov/pubmed/28021576

Journal articles | 2011

Kiely B; Friedlander M; Milne RL; Stanhope L; Russell P; Jenkins MA; Weideman P; McLachlan S; Grant PT, 2011, 'Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.', Familial Cancer, 10, pp. 505 - 514

Journal articles | 2011

Lee CK; Friedlander M; Brown C; Gebski V; Georgoulopoulos A; Vergote I; Pignata S; Donadello N; Schmalfeldt B; Delva R; Mirza MQ; Sauthier P; Pujade-lauraine E; Lord SJ; Simes RJ, 2011, 'Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.', Journal of the National Cancer Institute, 103, pp. 1338 - 1342

Journal articles | 2011

Lee CK; Gurney H; Brown C; Sorio R; Donadello N; Tulunay G; Meier W; Bacon M; Maenpaa J; Petru E; Reed N; Gebski V; Pujade-lauraine E; Lord S; Simes RJ; Friedlander M, 2011, 'Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer', British Journal of Cancer, 105, pp. 360 - 365

Journal articles | 2011

Lee CK; Hudson M; Coates A; Ackland S; Gebski V; Lord S; Friedlander M; Boyle F; Simes RJ, 2011, 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129, pp. 467 - 476, http://dx.doi.org/10.1007/s10549-011-1471-9

Journal articles | 2011

Lee CK; Simes RJ; Brown C; Lord S; Wagner U; Plante M; Vergote I; Pisano C; Parma G; Burgess AJ; Bourgeois H; Högberg T; Bentley JD; Angleitner-boubenizek L; Ferrero A; Richter B; Hirte H; Gebski V; Pfisterer J; Pujade-lauraine E; Friedlander M, 2011, 'Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.', British Journal of Cancer, 105, pp. 1144 - 1150

Journal articles | 2011

Park SB; Goldstein D; Lin CS-Y; Krishnan AV; Friedlander M; Kiernan MC, 2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e

Journal articles | 2011

Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2011, 'Early Progressive and Sustained Dysfunction of Sensory Axons Underlies Paclitaxel-induced Neuropathy', Muscle and Nerve, 43, pp. 367 - 374, http://dx.doi.org/10.1002/mus.21874

Journal articles | 2011

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469

Journal articles | 2011

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248

Journal articles | 2011

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002

Journal articles | 2011

Peate M; Meiser B; Friedlander M; Zorbas H; Rovelli S; Sansom-daly U; Sangster J; Hadzi-Pavlovic D; Hickey MS, 2011, 'It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer. An Australian Fertility Decision Aid Collaborative Group Study.', Journal of Clinical Oncology, 29, pp. 1670 - 1677

Journal articles | 2011

Peate ML; Meiser B; Hickey MS; Thewes B; Saunders C; Butow PN; Martinello R; Martinello R; Fallon-Ferguson J; Wakefield C; Zorbas H; Rovelli S; Friedlander ML, 2011, 'Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer', The breast journal, 17, pp. 112 - 114, http://dx.doi.org/10.1111/j.1524-4741.2010.01033.x

Journal articles | 2011

Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Staehle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MKB; Oza AM, 2011, 'A Phase 3 Trial of Bevacizumab in Ovarian Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 365, pp. 2484 - 2496, http://dx.doi.org/10.1056/NEJMoa1103799

Journal articles | 2011

Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Lang I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thuerlimann B, 2011, 'Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up', LANCET ONCOLOGY, 12, pp. 1101 - 1108, http://dx.doi.org/10.1016/S1470-2045(11)70270-4

Journal articles | 2011

Regan MM; Price KN; Giobbie-Hurder A; Thuerlimann B; Gelber RD, 2011, 'Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer', BREAST CANCER RESEARCH, 13, http://dx.doi.org/10.1186/bcr2837

Journal articles | 2011

Rustin G; Vergote I; Eisenhauer E; Pujade-lauraine E; Quinn M; Thigpen T; Du bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J, 2011, 'Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 Agreed by the gynecological cancer intergroup (GCIG)', International Journal of Gynecological Cancer, 21, pp. 419 - 423

Journal articles | 2011

Sjoquist KM; Martyn J; Edmondson RJ; Friedlander ML, 2011, 'The role of hormonal therapy in gynecological cancers - Current status and future directions', International Journal of Gynecological Cancer, 21, pp. 1328 - 1333, http://dx.doi.org/10.1097/IGC.0b013e31821d6021

Journal articles | 2011

Vaughan S; Coward J; Bast R; Berchuck A; Berek JS; Brenton JD; Coukos G; Crum CC; Drapkin R; Etemadmoghadam D; Friedlander M; Gabra H; Kaye S; Lord CJ; Lengyel E; Levine DA; McNeish IA; Menon U; Mills G; Nephew KP; Oza AM; Sood A; Stronach EA; Walczak H; Bowtell D; Balkwill FR, 2011, 'Rethinking ovarian cancer: recommendations for improving outcomes.', Nature Reviews Cancer, 11, pp. 719 - 725, http://dx.doi.org/10.1038/nrc3144

Journal articles | 2011

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2011, 'A specialist breast care nurse role for women with metastatic breast cancer: Enhancing supportive care', Oncology Nursing Forum, 38, pp. 627 - 631

Journal articles | 2011

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2011, 'Development and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', Oncology Nursing Forum, 38, pp. 627 - 631

Journal articles | 2011

Webber K; Mok K; Bennett BK; Juraskova I; Goldstein D; Friedlander M; Lloyd AR; FOLCAN study group , 2011, 'Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link?', J Clin Oncol, 29, pp. 9072, http://www.ncbi.nlm.nih.gov/pubmed/28021533

Journal articles | 2011

Webber K; Mok K; Bennett BK; Lloyd AR; Friedlander M; Juraskova I; Goldstein D, 2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344

Journal articles | 2010

Audeh M; Carmichael J; Penson R; Friedlander M, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proff-of-concept trial.', The Lancet, 24, pp. 245 - 251

Journal articles | 2010

Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial', The Lancet, 376, pp. 245 - 251, http://dx.doi.org/10.1016/S0140-6736(10)60893-8

Journal articles | 2010

Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Clack G; Bianco AR, 2010, 'The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol', JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 30, pp. 596 - 604, http://dx.doi.org/10.3109/01443615.2010.492433

Journal articles | 2010

Friedlander M; Hancock K; Rischin D; Messing MJ; Stringer C; Matthys GM; Ma B; Hodge J; Lager JJ, 2010, 'A phase 11, open-label study evaluating pazopanib in patients with recurrent ovarian cancer', Gynecologic Oncology, 119, pp. 32 - 37

Journal articles | 2010

Friedlander M, 2010, 'Optimally debulked stage 111 ovarian cancer: intraperitoneal or intravenous chemotherapy?', International Journal of Gynecological Cancer, 20, pp. S20 - S23

Journal articles | 2010

Friedlander M, 2010, 'Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 20, http://dx.doi.org/10.1111/igc.0b013e3181f60d26

Journal articles | 2010

Gainford M; Tinker A; Carter J; Petru E; Nicklin J; Quinn MA; Hammond IG; Elit L; Lenhard M; Friedlander M, 2010, 'Malignant transformation within ovarian dermoid cysts:and audit of treatment received and patient outcomes', International Journal of Gynecological Cancer, 20, pp. 75 - 81

Journal articles | 2010

Gainford MC; Tinker A; Carter J; Petru E; Nicklin J; Quinn M; Hammond I; Elit L; Lenhard M; Friedlander M, 2010, 'Malignant transformation within ovarian dermoid cysts: An audit of treatment received and patient outcomes. An Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study', International Journal of Gynecological Cancer, 20, pp. 75 - 81, http://dx.doi.org/10.1111/IGC.0b013e3181c7fccf

Journal articles | 2010

Kiely B; Jenkins MA; McKinley J; Friedlander M; Weideman P; Milne RL; McLachlan S; Hopper JL; Phillips KA, 2010, 'Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for research into familial breast cancer', Breast Cancer Research and Treatment, 120, pp. 715 - 723

Journal articles | 2010

Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA, 2010, 'Erratum: Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the kathleen cuningham foundation consortium for research into familial breast cancer (kConFab) (Breast Cancer Res Treat (2010) (120) DOI: 10.1007/s10549-009-0497-8))', Breast Cancer Research and Treatment, 120, pp. 725 - 726, http://dx.doi.org/10.1007/s10549-009-0528-5

Journal articles | 2010

Luckett T; King M; Butow P; Friedlander M; Paris T, 2010, 'Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change', International Journal of Gynecological Cancer, 20, pp. 664 - 684

Journal articles | 2010

Mai PL; Friedlander M; Tucker K; Phillips KA; Hogg D; Jewett MAS; Lohynska R; Daugaard G; Richard S; Bonaïti-Pellié C; Heidenreich A; Albers P; Bodrogi I; Geczi L; Olah E; Daly PA; Guilford P; Fosså SD; Heimdal K; Liubchenko L; Tjulandin SA; Stoll H; Weber W; Easton DF; Dudakia D; Huddart R; Stratton MR; Einhorn L; Korde L; Nathanson KL; Bishop DT; Rapley EA; Greene MH, 2010, 'The international testicular cancer linkage consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred', Urologic Oncology: Seminars and Original Investigations, 28, pp. 492 - 499, http://dx.doi.org/10.1016/j.urolonc.2008.10.004

Journal articles | 2010

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025

Journal articles | 2010

Parmalee NL; Schubert C; Merriam JE; Allikmets K; Bird AC; Gillies MC; Peto T; Figueroa M; Friedlander M; Fruttiger M; Greenwood J; Moss SE; Smith LEH; Toomes C; Inglehearn CF; Allikmets R, 2010, 'Analysis of candidate genes for macular telangiectasia type 2', Molecular Vision, 16, pp. 2718 - 2726

Journal articles | 2010

Price M; Butow PN; Bullen T; Meiser B; McKinley J; Phillips KA, 2010, 'Predictors of breast cancer screening behaviors in women with a strong family history of the disease.', Breast Cancer Research and Treatment, 124, pp. 509 - 519, http://dx.doi.org/10.1007/s10549-010-0868-1

Journal articles | 2010

Trainer A; Meiser B; Watts KJ; Mitchell GF; Tucker K; Friedlander ML, 2010, 'Moving towards personalised medicine: Treatment- focused genetic testing of women newly diagnosed with ovarian cancer.', International Journal of Gynecological Cancer, 20, pp. 704 - 716, http://dx.doi.org/10.1111/IGC.0b013e3181dbd1a5

Journal articles | 2010

Trimble EL; Birrer MJ; Hoskins WJ; Marth C; Petryshyn R; Quinn M; Thomas GM; Kitchener HC, 2010, 'Current academic clinical trials in ovarian cancer: Gynecologic cancer intergroup and us national cancer institute clinical trials planning meeting, may 2009', International Journal of Gynecological Cancer, 20, pp. 1, http://dx.doi.org/10.1111/IGC.0b013e3181ee1c01

Journal articles | 2010

Tutt A; Robson M; Garber J; Domchek SM; Friedlander M; Audeh M; Weitzel J, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-content trial', The Lancet, 24, pp. 235 - 244

Journal articles | 2010

Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J; Liedtke C, 2010, 'The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer', Breast Care, 5, pp. 364 - 365, http://dx.doi.org/10.1159/000322170

Journal articles | 2010

Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial', The Lancet, 376, pp. 235 - 244, http://dx.doi.org/10.1016/S0140-6736(10)60892-6

Journal articles | 2010

Webber K; Goldstein D; Bennett BK; Boyle FM; De Souza PL; Wilcken N; Friedlander M; Lloyd AR, 2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047

Journal articles | 2009

Audeh MW; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Carmichael J; Tutt A, 2009, 'Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer', Journal of Clinical Oncology, 27, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5500

Journal articles | 2009

Bookman MA; Brady MF; McGuire WP; Harper PG; Alberts DS; Friedlander M; Colombo N; Fowler JM; Argenta PA; De Geest K; Mutch DG; Burger RA; Swart AM; Trimble EL; Accario-Winslow C; Roth LM, 2009, 'Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup', Journal of Clinical Oncology, 27, pp. 1419 - 1425, http://dx.doi.org/10.1200/JCO.2008.19.1684

Journal articles | 2009

Chang E; Milne RL; Phillips KA; Figueiredo J; Sangaramoorthy M; Keegan T; Andrulis I; Hopper JL; Goodwin P; O Malley F; Weerasooriya N; Apicella C; Southey MC; Friedlander ML; Giles GG; Whittemore A; West DJ; John E, 2009, 'Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry', Breast Cancer Research and Treatment, 117, pp. 167 - 176

Journal articles | 2009

Colleoni M; Sun Z; Martinelli G; Basser RL; Coates AS; Gelber RD; Green MD; Peccatori F; Cinieri S; Aebi S; Viale G; Price KN; Goldhirsch A, 2009, 'The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: Results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up', Annals of Oncology, 20, pp. 1344 - 1351, http://dx.doi.org/10.1093/annonc/mdp024

Journal articles | 2009

Field KM; Jenkins MA; Friedlander ML; McKinley JM; Price MA; Weideman P; Keogh LA; McLachlan SA; Lindeman GJ; Hopper JL; Butow PN; Phillips KA, 2009, 'Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer', European Journal of Cancer, 45, pp. 551 - 560, http://dx.doi.org/10.1016/j.ejca.2008.09.023

Journal articles | 2009

Friedlander M; Butow P; Stockler M; Gainford C; Martyn J; Oza A; Donovan HS; Miller B; King M, 2009, 'Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 19 Suppl 2, http://dx.doi.org/10.1111/igc.0b013e3181bf7fb8

Journal articles | 2009

Hickey MS; Peate ML; Saunders C; Friedlander ML, 2009, 'Breast cancer in young women and its impact on reproductive function', Human Reproduction Update, 15, pp. 323 - 339, http://dx.doi.org/10.1093/humupd/dmn064

Journal articles | 2009

Keidan M; Friedlander M; Arad SM, 2009, 'Effect of Brefeldin A on cell-wall polysaccharide production in the red microalga Porphyridium sp (Rhodophyta) through its effect on the Golgi apparatus', JOURNAL OF APPLIED PHYCOLOGY, 21, pp. 707 - 717, http://dx.doi.org/10.1007/s10811-009-9406-0

Journal articles | 2009

Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman PC; Milne R; McLachlan S; Hopper JL; Phillips K, 2009, 'Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', Journal of Clinical Oncology, 27, pp. 1509 - 1509, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1509

Journal articles | 2009

Mai PL; Chen BE; Tucker K; Friedlander M; Phillips KA; Hogg D; Jewett MAS; Bodrogi I; Geczi L; Olah E; Heimdal K; Fosså SD; Nathanson KL; Korde L; Easton DF; Dudakia D; Huddart R; Stratton MR; Bishop DT; Rapley EA; Greene MH, 2009, 'Younger age-at-diagnosis for familial malignant testicular germ cell tumor', Familial Cancer, 8, pp. 451 - 456, http://dx.doi.org/10.1007/s10689-009-9264-6

Journal articles | 2009

Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thuerlimann B; Paridaens R; Smith I; Mauriac L; Forbes JF; Price KN; Regan MM; Gelber RD; Coates AS, 2009, 'Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 361, pp. 766 - 776, http://dx.doi.org/10.1056/nejmoa0810818

Journal articles | 2009

Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC, 2009, 'Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 27, pp. 1243 - 1249

Journal articles | 2009

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2009, 'Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized nerve dysfunction', Oncology, 77, pp. 342 - 348

Journal articles | 2009

Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2009, 'Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy', Brain, 132, pp. 2712 - 2723

Journal articles | 2009

Pearce CL; Near AM; Van Den Berg DJ; Ramus SJ; Gentry-Maharaj A; Menon U; Gayther SA; Anderson AR; Edlund CK; Wu AH; Chen X; Beesley J; Webb PM; Holt SK; Chen C; Doherty JA; Rossing MA; Whittemore AS; McGuire V; DiCioccio RA; Goodman MT; Lurie G; Carney ME; Wilkens LR; Ness RB; Moysich KB; Edwards R; Jennison E; Kjaer SK; Hogdall E; Hogdall CK; Goode EL; Sellers TA; Vierkant RA; Cunningham JC; Schildkraut JM; Berchuck A; Moorman PG; Iversen ES; Cramer DW; Terry KL; Vitonis AF; Titus-Ernstoff L; Song H; Pharoah PDP; Spurdle AB; Anton-Culver H; Ziogas A; Brewster W; Galitovskiy V; Chenevix-Trench G; Gertig D; Vanden Bergh T; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; DeFazio A; Hung J; Chiew YE; Stenlake A; Sullivan H; Brand A; Jaworski R; Harnett P; Wain G; Green A; Moore S; Harrap K; Sadkowsky T; Purdie D; Whiteman D; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Mamers P; Healy D; Jobling T; Maniolitas T; McNealage J; Rogers P; Susil B; Veitch A; Constable J; Ping Tong S; Robinson I; Simpson I; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S, 2009, 'Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium', British Journal of Cancer, 100, pp. 412 - 420, http://dx.doi.org/10.1038/sj.bjc.6604820

Journal articles | 2009

Peate ML; Meiser B; Hickey MS; Friedlander ML, 2009, 'The fertility-related concerns, needs and preferences of younger women with breast cancer: A systematic review', Breast Cancer Research and Treatment, 116, pp. 215 - 223, http://dx.doi.org/10.1007/s10549-009-0401-6

Journal articles | 2009

Phillips KA; Milne RL; West DJ; Goodwin P; Giles GG; Chang E; Figueiredo J; Friedlander ML; Keegan T; Glendon G; Apicella C; O Malley F; Southey MC; Andrulis I; John E; Hopper JL, 2009, 'Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry', Cancer epidemiology biomarkers and prevention, 18, pp. 1792 - 1797

Journal articles | 2009

Phillips KA; Milne RL; West DW; Goodwin PJ; Giles GG; Chang ET; Figueiredo JC; Friedlander ML; Keegan THM; Glendon G; Apicella C; O'Malley F; Southey MC; Andrulis IL; John EM; Hopper JL, 2009, 'Article on Reproductive Factors and Mortality after Breast Cancer (vol 18, pg 1792, 2009)', CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18, pp. 2345 - 2345, http://dx.doi.org/10.1158/1055-9965.EPI-18-8-CORI

Journal articles | 2009

Price MA; Zachariae R; Butow PN; deFazio A; Chauhan D; Espie CA; Friedlander M; Webb PM, 2009, 'Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor', European Journal of Cancer, 45, pp. 3262 - 3270, http://dx.doi.org/10.1016/j.ejca.2009.05.030

Journal articles | 2009

Rabaglio M; Sun Z; Price KN; Castiglione-Gertsch M; Hawle H; Thürlimann B; Mouridsen H; Campone M; Forbes JF; Paridaens RJ; Colleoni M; Pienkowski T; Nogaret JM; Láng I; Smith I; Gelber RD; Goldhirsch A; Coates AS, 2009, 'Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial', Annals of Oncology, 20, pp. 1489 - 1498, http://dx.doi.org/10.1093/annonc/mdp033

Journal articles | 2009

Trimble E; Abrams J; Meyer R; Calvo F; Cazap E; Deye J; Eisenhauer E; Fitzgerald T; Lacombe D; Parmar M; Seibel N; Shankar L; Swart A; Therasse P; Vikram B; von Frenckell R; Friedlander ML; Fujiwara K; Kaplan R; Meunier F, 2009, 'Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials', Journal of Clinical Oncology, 27, pp. 5109 - U194

Journal articles | 2009

Tutt A; Robson M; Garber JE; Domchek S; Audeh MW; Weitzel JN; Friedlander M; Carmichael J, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.cra501

Journal articles | 2009

Tutt A; Robson M; Garber JE; Domchek S; Audeh MW; Weitzel JN; Friedlander M; Carmichael J, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.18_suppl.cra501

Journal articles | 2009

Tutt A; Robson M; Garber JE; Domchek S; Audeh MW; Weitzel JN; Friedlander M; Carmichael J, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', Journal of Clinical Oncology, 27, pp. CRA501 - CRA501, http://dx.doi.org/10.1200/jco.2009.27.18s.cra501

Journal articles | 2008

Dawson S; Price MA; Jenkins MA; McKinley J; Butow PN; McLachlan S; Lindeman GJ; Weideman P; Friedlander ML; Hopper JL; Phillips KA, 2008, 'Cancer risk management practices of noncarriers within BRCA1/2 mutation - Positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer', Journal of Clinical Oncology, 26, pp. 225 - 232, http://dx.doi.org/10.1200/JCO.2007.11.0262

Journal articles | 2008

Friedlander M, 2008, 'Advances in cultivation of Gelidiales', JOURNAL OF APPLIED PHYCOLOGY, 20, pp. 451 - 456, http://dx.doi.org/10.1007/s10811-007-9285-1

Journal articles | 2008

Friedlander M, 2008, 'Israeli R & D activities in seaweed cultivation', ISRAEL JOURNAL OF PLANT SCIENCES, 56, pp. 15 - 28, http://dx.doi.org/10.1560/IJPS.56.1-2.15

Journal articles | 2008

Goldstein D; Bennett B; Cameron B; Boyle F; DeSouza P; Wilcken N; Friedlander M; Scott E; Hickie I; Lloyd AAM, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer: Association with hematologic, endocrine, and immune parameters', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.9596

Journal articles | 2008

Israel A; Stambler N; Dubinsky Z; Friedlander M; Malik Z; Rothmann C; Katz S, 2008, 'Light absorption and fluorescence, and photoacclimation features in the marine macroalga Porphyra leucosticta (Rhodophyta)', ISRAEL JOURNAL OF PLANT SCIENCES, 56, pp. 61 - 68, http://dx.doi.org/10.1560/IJPS.56.1-2.61

Journal articles | 2008

Jarvis SK; Mok K; Friedlander M; Vancaillie TG, 2008, 'OVERcome Study (Olive Oil Vaginal Exercise and Replens®)', Journal of Minimally Invasive Gynecology, 15, pp. 88S - 88S, http://dx.doi.org/10.1016/j.jmig.2008.09.336

Journal articles | 2008

Lin CS-Y; Krishnan A; Goldstein D; Friedlander M; Kiernan M, 2008, '457: Sensory nerve excitability in cancer patients treated with oxaliplatin', Journal of Clinical Neuroscience, 15, pp. 362 - 362, http://dx.doi.org/10.1016/j.jocn.2007.07.067

Journal articles | 2008

Linger R; Dudakia D; Huddart R; Tucker K; Friedlander ML; Phillips KA; Hogg D; Jewett M; Lohynska R; Daugaard G; Richard S; Chompret A; Stoppa-Lyonnet D; Bonaiti-Pellie C; Heidenreich A; Albers P; Olah E; Geczi L; Bodrogi I; Daly P; Guilford P; Fossi S; Heimdal K; Tjulandin S; Liubchenko L; Stoll H; Weber W; Einhorn L; McMaster M; Korde L; Greene M; Nathanson K; Cortessis V; Easton D; Bishop D; Stratton M; Rapley EA, 2008, 'Analysis of the DNDI gene in men with sporadic and familial testicular germ cell tumors', Genes Chromosomes and Cancer, 47, pp. 247 - 252, http://dx.doi.org/10.1002/gec.20526

Journal articles | 2008

Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; Bowtell D; Chenevix-Trench G; Green A; Webb P; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Jones M; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Harnett P; Sharma R; Wain G; Purdie D; Whiteman D; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler M; Hall C, 2008, 'Skewed X chromosome inactivation and breast and ovarian cancer status: Evidence for X-linked modifiers of BRCA1', Journal of the National Cancer Institute, 100, pp. 1519 - 1529, http://dx.doi.org/10.1093/jnci/djn345

Journal articles | 2008

Meiser B; Tucker K; Friedlander ML; Barlow-Stewart K; Lobb EA; Saunders C; Mitchell GF, 2008, 'Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda', Breast Cancer Research, 10, pp. 216, http://dx.doi.org/10.1186/bcr2194

Journal articles | 2008

Merritt MA; Green AC; Nagle CM; Webb PM; Bowtell D; Chenevix-Trench G; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Laurie R; Robbie M; Healy D; Jobling T; Maniolitas T, 2008, 'Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer', International Journal of Cancer, 122, pp. 170 - 176, http://dx.doi.org/10.1002/ijc.23017

Journal articles | 2008

Mok K; Juraskova I; Friedlander M, 2008, 'The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions', Breast, 17, pp. 436 - 440, http://dx.doi.org/10.1016/j.breast.2008.04.001

Journal articles | 2008

Nagle CM; Olsen CM; Webb PM; Jordan SJ; Whiteman DC; Green AC, 2008, 'Endometrioid and clear cell ovarian cancers - A comparative analysis of risk factors', EUROPEAN JOURNAL OF CANCER, 44, pp. 2477 - 2484, http://dx.doi.org/10.1016/j.ejca.2008.07.009

Journal articles | 2008

Olsen CM; Nagle CM; Whiteman DC; Purdie DM; Green AC; Webb PM; Bowtell D; Chenevix-Trench G; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; CorrGreenish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Laurie R; Robbie M; Healy D, 2008, 'Body size and risk of epithelial ovarian and related cancers: A population-based case-control study', International Journal of Cancer, 123, pp. 450 - 456, http://dx.doi.org/10.1002/ijc.23509

Journal articles | 2008

Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander ML; Kiernan MC, 2008, 'Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies', Current Medicinal Chemistry: Cardiovascular and Hematological Agents, 15, pp. 3081 - 3094

Journal articles | 2008

Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Goldstein D; Kiernan MC, 2008, 'Oxaliplatin-induced chronic changes in sensory nerve excitability', Clinical Neurophysiology, 119, pp. e22 - e22, http://dx.doi.org/10.1016/j.clinph.2007.10.044

Journal articles | 2008

Ramus SJ; Vierkant RA; Johnatty SE; Pike MC; Van Den Berg DJ; Wu AH; Pearce CL; Menon U; Gentry-Maharaj A; Gayther SA; DiCioccio RA; McGuire V; Whittemore AS; Song H; Easton DF; Pharoah PDP; Garcia-Closas M; Chanock S; Lissowska J; Brinton L; Terry KL; Cramer DW; Tworoger SS; Hankinson SE; Berchuck A; Moorman PG; Schildkraut JM; Cunningham JM; Liebow M; Kjaer SK; Hogdall E; Hogdall C; Blaakaer J; Ness RB; Moysich KB; Edwards RP; Carney ME; Lurie G; Goodman MT; Wang-Gohrke S; Kropp S; Chang-Claude J; Webb PM; Chen X; Beesley J; Chenevix-Trench G; Goode EL; Bowtell D; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes VL; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D, 2008, 'Consortium analysis of 7 candidate SNPs for ovarian cancer', International Journal of Cancer, 123, pp. 380 - 388, http://dx.doi.org/10.1002/ijc.23448

Journal articles | 2008

Ravaioli A; Monti F; Regan MM; Maffini F; Mastropasqua MG; Spataro V; Castiglione-Gertsch M; Panzini I; Gianni L; Goldhirsch A; Coates A; Price KN; Gusterson BA; Viale G, 2008, 'p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer', ANNALS OF ONCOLOGY, 19, pp. 660 - 668, http://dx.doi.org/10.1093/annonc/mdm547

Journal articles | 2008

Viale G; Giobbie-Hurder A; Regan MM; Coates AS; Mastropasqua MG; Dell'Orto P; Maiorano E; MacGrogan G; Braye SG; Oehlschlegel C; Neven P; Orosz Z; Olszewski WP; Knox F; Thuerlimann B; Price KN; Castiglione-Gertsch M; Gelber RD; Gusterson BA; Goldhirsch A, 2008, 'Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole', JOURNAL OF CLINICAL ONCOLOGY, 26, pp. 5569 - 5575, http://dx.doi.org/10.1200/JCO.2008.17.0829

Journal articles | 2008

Yang JL; Qu X; Yu Y; Kohn E; Friedlander ML, 2008, 'Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency', International Journal of Cancer, 123, pp. 258 - 263, http://dx.doi.org/10.1002/ijc.23535

Journal articles | 2007

Beesley J; Jordan SJ; Spurdle AB; Song H; Ramus SJ; Kjaer SK; Hogdall E; DiCioccio RA; McGuire V; Whittemore AS; Gayther SA; Pharoah PDP; Webb PM; Chenevix-Trench G; Bowtell D; Green A; DeFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A, 2007, 'Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: Results from two Australian studies and an additional validation set', Cancer Epidemiology Biomarkers and Prevention, 16, pp. 2557 - 2565, http://dx.doi.org/10.1158/1055-9965.EPI-07-0542

Journal articles | 2007

Bennett BK; Goldstein D; Friedlander ML; Hickie IB; Lloyd AR, 2007, 'The experience of cancer-related fatigue and chronic fatigue syndrome: A qualitative and comparative study', Journal of Pain and Symptom Management, 34, pp. 126 - 135

Journal articles | 2007

Bennett BK; Goldstein D; Lloyd AROLA; Friedlander ML; Hickie IB, 2007, 'The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study', Journal of Pain and Symptom Management, 34, pp. 126 - 135

Journal articles | 2007

Boulus A; Spaneir E; Friedlander M, 2007, 'Effect of outdoor conditions on growth rate and chemical composition of Gelidium crinale in culture', JOURNAL OF APPLIED PHYCOLOGY, 19, pp. 471 - 478, http://dx.doi.org/10.1007/s10811-007-9158-7

Journal articles | 2007

Clarke S; Goldstein D; Mitchell P; Michael M; Beale P; Friedlander ML, 2007, 'Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy', Clinical Colorectal Cancer, 6, pp. 578 - 582

Journal articles | 2007

Colleoni M; Gelber S; Simoncini E; Pagani O; Gelber RD; Price KN; Castiglione-Gertsch M; Coates AS; Goldhirsch A; Thürlimann B; Castiglione M; Collins JP; Cortés Funes H; Green M; Hiltbrunner A; Holmberg SB; Hossfeld DK; Láng I; Lindtner J; Paganetti F; Rudenstam CM; Stahel R; Senn HJ; Veronesi A; Egli G; Rabaglio M; Studer R; Ruepp B; Maibach R; Marbot E; Strausak M; Gelber R; Cole B; Regan M; Zahrieh D; Sun Z; Bernhard J; Hürny C; Gusterson B; Viale G; Blacher L; Celano J; Isley M; Hinkle R; Lippert S; Scott K; Crivellari D; Monfardini S; Galligioni E; Magri MD; Buonadonna A; Massarut S; Rossi C; Candiani E; Carbone A; Volpe R; Roncadin M; Arcicasa M; Coran F; Morassut S; Marini G; Marpicati P; Braga M; Grigolato P; Lucini L; Martinelli G; Orlando L; Nolè F; Torrisi R; De Pas T; de Braud F; Cinieri S; Peccatori F; Luini A; Orecchia R; Renne G; Costa A; Zurrida S; Veronesi P; Sacchini V; Galimberti V; Intra M; Veronesi U; Ravaioli A; Tassinari D; Oliverio G; Barbanti F; Rinaldi P; Pini E; Drudi G; Antimi M; Minelli M; Bellini V; Porzio R; Pernazza E; Santeusanio G; Spagnoli LG; Foladore S; Foghin L, 2007, 'Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93', Annals of Oncology, 18, pp. 1177 - 1184, http://dx.doi.org/10.1093/annonc/mdm091

Journal articles | 2007

Easton DF; Pooley KA; Dunning AM; Pharoah PDP; Thompson D; Ballinger DG; Struewing JP; Morrison J; Field H; Luben R; Wareham N; Ahmed S; Healey CS; Bowman R; Meyer KB; Haiman CA; Kolonel LK; Henderson BE; Le Marchand L; Brennan P; Sangrajrang S; Gaborieau V; Odefrey F; Shen CY; Wu PE; Wang HC; Eccles D; Evans DG; Peto J; Fletcher O; Johnson N; Seal S; Stratton MR; Rahman N; Chenevix-Trench G; Bojesen SE; Nordestgaard BG; Axelsson CK; Garcia-Closas M; Brinton L; Chanock S; Lissowska J; Peplonska B; Nevanlinna H; Fagerholm R; Eerola H; Kang D; Yoo KY; Noh DY; Ahn SH; Hunter DJ; Hankinson SE; Cox DG; Hall P; Wedren S; Liu J; Low YL; Bogdanova N; Schürmann P; Dörk T; Tollenaar RAEM; Jacobi CE; Devilee P; Klijn JGM; Sigurdson AJ; Doody MM; Alexander BH; Zhang J; Cox A; Brock IW; MacPherson G; Reed MWR; Couch FJ; Goode EL; Olson JE; Meijers-Heijboer H; Van Den Ouweland A; Uitterlinden A; Rivadeneira F; Milne RL; Ribas G; Gonzalez-Neira A; Benitez J; Hopper JL; McCredie M; Southey M; Giles G; Schroen C; Justenhoven C; Brauch H; Hamann U; Ko YD; Spurdle AB; Beesley J; Chen X; Mannermaa A; Kosma VM; Kataja V; Hartikainen J; Day NE, 2007, 'Genome-wide association study identifies novel breast cancer susceptibility loci', Nature, 447, pp. 1087 - 1093, http://dx.doi.org/10.1038/nature05887

Journal articles | 2007

Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Tay EH; Kathman S; Matthys G; Lager JJ, 2007, 'Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study', Journal of Clinical Oncology, 25, pp. 5561 - 5561, http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5561

Journal articles | 2007

Friedlander ML; Buck MD; Wyld D; Findlay M; Fitzharris B; De Souza PL; Davies TM; Kalimi G; Allan S; Perez DM; Harnett PH, 2007, 'Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer', International Journal of Gynecological Cancer, 17, pp. 350 - 358

Journal articles | 2007

Hogg R; Scurry JP; Kim SN; Friedlander ML; Hacker NF, 2007, 'Microinvasion links ovarian serous borderline tumour and grade 1 invasive carcinoma', Gynecologic Oncology, 106, pp. 44 - 51

Journal articles | 2007

McKinley JM; Weideman PC; Jenkins MA; Friedlander ML; Hopper JL; McLachlan SA; Lindeman GJ; Phillips KA, 2007, 'Prostate screening uptake in Australian BRCA1 and BRCA2 carriers', Hereditary Cancer in Clinical Practice, 5, pp. 161 - 163

Journal articles | 2007

Olsen CM; Bain CJ; Jordan SJ; Nagle CM; Green AC; Whiteman DC; Webb PM; Bowtell D; Chenevix-Trench G; Green A; Defazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Rome R; Allen D; Grant P; Laurie R; Robbie M; Healy D, 2007, 'Recreational physical activity and epithelial ovarian cancer: A case-control study, systematic review, and meta-analysis', Cancer Epidemiology Biomarkers and Prevention, 16, pp. 2321 - 2330, http://dx.doi.org/10.1158/1055-9965.EPI-07-0566

Journal articles | 2006

Aghmesheh M; Suo Z; Friedlander ML; Nesland J; Kaern J; Stewart MP; Dorum A; Tucker K; Buckley MF, 2006, 'Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas', Pathology, 38, pp. 145 - 151

Journal articles | 2006

Crockford G; Linger R; Hockley S; Dudakia D; Johnson L; Huddart R; Tucker K; Friedlander ML; Phillips KA; Hogg DW; Jewett M; Lohynska R; Daugaard G; Richard S; Chompret A; Bonaiti-Pellie C; Heidenreich A; Albers P; Olah E; Geczi L; Bodrogi I; Ormiston W; Daly P; Guilford P; Fossa SD; Heimdal K; Tjulandin S; Liubchenko L; Stoll H; Weber W; Forman D; Oliver T; Einhorn L; McMaster M; Kramer J; Greene M; Weber B; Nathanson K; Cortessis V; Easton D; Bishop D; Stratton M; Rapley EA, 2006, 'Genome-wide linkage screen for testicular germ cell tumour susceptibility loci', Human Molecular Genetics, 15, pp. 443 - 451

Journal articles | 2006

Dawson S; McKinley J; Jenkins M; McLachlan S; Lindeman G; Friedlander M; Hopper J; Phillips K, 2006, 'Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab)', Journal of Clinical Oncology, 24, pp. 1020 - 1020, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.1020

Journal articles | 2006

Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR; Adams J; Baum M; Buzdar A; Cella D; Coleman R; Constenla M; Cuzick J; Distler W; Dowset M; Eastell R; Fallowfield LJ; Forbes J; George WD; Gray J; Guastalla JP; Hellmund R; Hoctin-Boes G; Houghton J; Williams N; Howell A; Klijn JGM; Locker GY; Mackey J; Mansel RE; Nabholtz JM; Naglkalnai T; Nicolucci A; Nylen U; Sainsbury R; Sapunar F; Suarez-Mendez VJ; Tobias JS; Friedlander M; Richardson G; Makar A; Neven P; Mention J; Distler DW; Eiermann W; Mouritis M; Wamsteker ; Campos O; Candeias OR; Landers G; Llombart A; Menjon S; Repolle´s M; Lindahl B; Ingvar C; Bharbra K; Bjornsson S; Charnock F; Cutner A; De Bono M; Evans-Jones J; Glass M; Holt S; Jones A; Kremer ; O'Donovan P; Omara-Boto TA; Onwude J; Phillips K; Price J; Samtaney N; Seif M; Doe A; Foster E; Woolas R; Buyse M; Wale C; Margolese R; Body JJ, 2006, 'The ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment', Human Reproduction, 21, pp. 545 - 553, http://dx.doi.org/10.1093/humrep/dei322

Journal articles | 2006

Friedlander M; Kosov Y; Keret G; Dawes C, 2006, 'Production of rhizoids by Caulerpa prolifera in culture', AQUATIC BOTANY, 85, pp. 263 - 266, http://dx.doi.org/10.1016/j.aquabot.2006.06.004

Journal articles | 2006

Goldstein D; Bennett BK; Friedlander ML; Davenport TA; Hickie IB; Lloyd AR, 2006, 'Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study', BMC Cancer, 6, pp. 240 - 240, http://dx.doi.org/10.1186/1471-2407-6-240

Journal articles | 2006

Harrison ML; Hoskins P; Du Bois A; Quinn M; Rustin GJS; Ledermann JA; Baron-Hay S; Friedlander ML, 2006, 'Small cell of the ovary, hypercalcemic type - Analysis of combined experience and recommendation for management. A GCIG study', Gynecologic Oncology, 100, pp. 233 - 238, http://dx.doi.org/10.1016/j.ygyno.2005.10.024

Journal articles | 2006

Hogg RJ; Scurry J; Kim S; Friedlander M; Hacker NF, 2006, 'Clinicopathologic Audit Of 46 Ovarian Borderline Serous Tumours And 16 Grade 1 Serous Carcinomas', International Journal of Gynecological Cancer, 16, pp. 687 - 687, http://dx.doi.org/10.1136/ijgc-00009577-200610001-00304

Journal articles | 2006

Israel A; Levy I; Friedlander M, 2006, 'Experimental tank cultivation of Porphyra in Israel', JOURNAL OF APPLIED PHYCOLOGY, 18, pp. 235 - 240, http://dx.doi.org/10.1007/s10811-006-9024-z

Journal articles | 2006

Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2006, 'Oxaliplatin and axonal Na+ channel function in vivo', Clinical Cancer Research, 12, pp. 4481 - 4484

Journal articles | 2006

Lutty GA; Chan-Ling T; Phelps DL; Adamis AP; Berns KI; Chan CK; Cole CH; D'Amore PA; Das A; Deng WT; Dobson V; Flynn JT; Friedlander M; Fulton A; Good WV; Grant MB; Hansen R; Hauswirth WW; Hardy RJ; Hinton DR; Hughes S; McLeod DS; Palmer EA; Patz A; Penn JS; Raisler BJ; Repka MX; Saint-Geniez M; Shaw LC; Shima DT; Smith BT; Smith LEH; Tahija SG; Tasman W; Trese MT, 2006, 'Proceedings of the Third International Symposium on Retinopathy of Prematurity: An update on ROP from the lab to the nursery (November 2003, Anaheim, California)', Molecular Vision, 12, pp. 532 - 580

Journal articles | 2006

Martin AC; Friedlander ML; Kiernan MC, 2006, 'Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma', Journal of Clinical Neuroscience, 13, pp. 595 - 598

Journal articles | 2006

Mitchell P; Goldstein D; Beale P; Friedlander ML; Zalcberg J; White S; Thomson JA; Clarke S; Michael M, 2006, 'Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neurotoxicity', Clinical Colorectal Cancer, 6, pp. 146 - 151

Journal articles | 2006

Phillips K; Jenkins M; Lindeman G; McLachlan S; McKinley J; Weideman P; Hopper J; Friedlander M, 2006, 'Risk management practices of Australasian BRCA1 and BRCA2 mutation carriers', European Journal of Cancer Supplements, 4, pp. 71 - 71, http://dx.doi.org/10.1016/s1359-6349(06)80114-x

Journal articles | 2006

Phillips KA; Jenkins MA; Lindeman GJ; Mclachlan SA; Mckinley JM; Weideman PC; Hopper JL; Friedlander ML, 2006, 'Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: A prospective cohort study', Clinical Genetics, 70, pp. 198 - 206, http://dx.doi.org/10.1111/j.1399-0004.2006.00665.x

Journal articles | 2006

Tiller K; Meiser B; Gaff C; Kirk J; Dudding T; Phillips KA; Friedlander ML; Tucker K, 2006, 'A randomised controlled trial of a decision aid for women at increased risk of ovarian cancer', Medical Decision Making, 26, pp. 360 - 372

Journal articles | 2005

Aghmesheh M; Edwards LS; Clarke CL; Byth K; Katzenellenbogen B; Russell PJ; Friedlander ML; Tucker K; de Fazio A, 2005, 'Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas', Gynecologic Oncology, 97, pp. 16 - 25, http://www.sciencedirect.com/science/article/B6WG6-4FDMYCP-5/2/f127ac58f5e70d17372bc0c7d403bfc7

Journal articles | 2005

Goldstein D; Mitchell P; Friedlander ML; Michael M; Beale P; Zalcberg JR; White S; Clarke SJ, 2005, 'Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients', British Journal of Cancer, 92, pp. 832 - 837, http://dx.doi.org/10.1038/sj.bjc.6602426

Journal articles | 2005

Israel A; Gavrieli J; Glazer A; Friedlander M, 2005, 'Utilization of flue gas from a power plant for tank cultivation of the red seaweed Gracilaria cornea', AQUACULTURE, 249, pp. 311 - 316, http://dx.doi.org/10.1016/j.aquaculture.2005.04.058

Journal articles | 2005

Kaern J; Aghmesheh M; Nesland JM; Danielsen HE; Sandstad B; Friedlander M; Tropé C, 2005, 'Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?', International Journal of Gynecological Cancer, 15, pp. 1014 - 1022, http://dx.doi.org/10.1111/j.1525-1438.2005.00185.x

Journal articles | 2005

Kaern J; Aghmesheh M; Nesland JM; Danielsen HE; Sandstad B; Friedlander M; Tropé C, 2005, 'Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?', International Journal of Gynecological Cancer, 15, pp. 1014 - 1022, http://dx.doi.org/10.1136/ijgc-00009577-200511000-00003

Journal articles | 2005

Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2005, 'Oxaliplatin-induced neurotoxicity and the development of neuropathy', Muscle and Nerve, 32, pp. 51 - 60

Journal articles | 2005

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips KA, 2005, 'Obesity and outcomes in premenopausal and postmenopausal breast cancer', Cancer Epidemiology Biomarkers and Prevention, 14, pp. 1686 - 1691, http://dx.doi.org/10.1158/1055-9965.EPI-05-0042

Journal articles | 2005

Mitchell P; Goldstein D; Michael M; Beale P; Friedlander M; Zalcberg J; Clarke S; White S, 2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)', Journal of Clinical Oncology, 23, pp. 3581 - 3581, http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3581

Journal articles | 2005

Nathanson K; Kanetsky P; Hawes R; Vaughn D; Letrero R; Tucker K; Friedlander ML; Phillips KA; Hogg DW; Jewett M; Lohynska R; Daugaard G; Richard S; Chompret A; Bonati-Pellie C; Heidenreich A; Olah E; Geczi L; Bodrogi I; Ormiston W; Daly P; Oosterhuis J; Gillis A; Looijenga L; Guilford P; Fossa SD; Heimdal K; Tjulandin S; Liubchenko L; Stoll H; Weber W; Huddart R; Crockford G; Forman D; Oliver D; Einhorn L; Weber B; McMaster M; Greene M; Pike M; Cortessis V; Schwartz S; Bishop D; Easton D; Stratton M; Kramer J; Chen CW; Rapley EA, 2005, 'The Y deletion gr/gr and susceptibility to testicular germ cell tumor', American Journal of Human Genetics, 77, pp. 1034 - 1043

Journal articles | 2005

Phillips KA; Butow P; Chang J; Weideman P; Price M; McLachlan S; Lindeman G; Mckay M; Friedlander ML; Hopper JL; Stewart A, 2005, 'Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort', Familial Cancer, 4, pp. 105 - 113

Journal articles | 2005

Phillips KA; Milne RL; Buys S; Friedlander ML; Ward JH; McCredie MRE; Giles GG; Hopper JL, 2005, 'Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry', Journal of Clinical Oncology, 23, pp. 4679 - 4686, http://dx.doi.org/10.1200/JCO.2005.03.002

Journal articles | 2005

Thewes B; Meiser B; Duric V; Stockler M; Taylor AJ; Stuart-Harris R; Links MR; Wilcken NW; McLachlan S; Phillips KA; Beith J; Boyle FM; Friedlander ML, 2005, 'What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?', Lancet Oncology, 6, pp. 581 - 588

Journal articles | 2005

Thewes B; Meiser B; Taylor AJ; Phillips KA; Pendlebury S; Capp A; Dalley D; Goldstein D; Baber R; Friedlander ML, 2005, 'Fertility - and Menoapuse-Related Information Needs of Younger Women With a Diagnosis of Early Breast Cancer', Journal of Clinical Oncology, 23, pp. 5155 - 5165

Journal articles | 2005

Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Friedlander ML; Andrews L; Franklin J, 2005, 'Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer', Psycho - Oncology, 14, pp. 249 - 261

Journal articles | 2004

Aghmesheh M; Friedlander M; Russell PJ; Edwards L; Yang J-L; Kconfab K; Nesland JM; Danielson H; Kaern J; Tucker KM, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas', Journal of Clinical Oncology, 22, pp. 5040 - 5040, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.5040

Journal articles | 2004

Aghmesheh M; Friedlander M; Russell PJ; Edwards L; Yang J-L; Kconfab K; Nesland JM; Danielson H; Kaern J; Tucker KM, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas', Journal of Clinical Oncology, 22, pp. 5040 - 5040, http://dx.doi.org/10.1200/jco.2004.22.90140.5040

Journal articles | 2004

Aghmesheh M; Nesland J; Kaern J; Dorum A; Edwards LS; Byth K; Friedlander ML; Jackson P; Tucker K; Russell PJ, 2004, 'No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers', Gynecologic Oncology, 95, pp. 430 - 436, http://www.sciencedirect.com/science/article/B6WG6-4DXB995-1/2/ed6c7284e0c7d1c30ad49018f2a9cb0d

Journal articles | 2004

Daly EB; Chen GW; Sun L; Friedlander ML; Goldstein D; Beer D; Chesterman CN; Hogg PJ, 2004, 'Blood level of phosphoglycerate kinase does not correlate with presenceor extent of tumor', International Journal of Biological Markers, 19, pp. 170 - 172

Journal articles | 2004

Hacker NF; Friedlander ML, 2004, 'Treatment of recurrent ovarian cancer', Chang Gung Medical Journal, 27, pp. 570 - 577, http://www.sciencedirect.com/science/article/B6WVB-4DVW7KP-2Y0/2/9a983bdc3c2e8ebecc9287dafa401635

Journal articles | 2004

Hogg R; Friedlander ML, 2004, 'Biology of Epithelial Ovarian cancer: Implications for Screening Women at High Genetic Risk', Journal of Clinical Oncology, 22, pp. 1315 - 1327

Journal articles | 2004

Kaern J; Trope C; Aghmesheh M; Friedlander M; Nesland JM; Davidsen HE; Sandstad B, 2004, '207 A Study of Prognostic Parameters Predicting Long-Term Survival in Stage III Epithelial Ovarian Cancer', International Journal of Gynecological Cancer, 14, pp. 60 - 60, http://dx.doi.org/10.1136/ijgc-00009577-200409001-00207

Journal articles | 2004

Levi B; Friedlander M, 2004, 'Identification of two putative adhesive polypeptides in Caulerpa prolifera rhizoids using an adhesion model system', JOURNAL OF APPLIED PHYCOLOGY, 16, pp. 1 - 9, http://dx.doi.org/10.1023/B:JAPH.0000019034.12015.87

Journal articles | 2004

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips K-A, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer', Journal of Clinical Oncology, 22, pp. 9540 - 9540, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.9540

Journal articles | 2004

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips K-A, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer', Journal of Clinical Oncology, 22, pp. 9540 - 9540, http://dx.doi.org/10.1200/jco.2004.22.90140.9540

Journal articles | 2004

Meiser B; Tucker M; Andrews L; Tucker K; Friedlander ML; Muir A, 2004, 'The feasibility of women at high risk for breast cancer participating in chemoprevention trials: An attitudinal study', Journal of Psychosocial Oncology, 22, pp. 31 - 45

Journal articles | 2004

Phillips KA; Milne RL; Friedlander ML; Jenkins MA; Mccredie M; Giles GG; Hopper JL, 2004, 'Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis', Journal of Clinical Oncology, 22, pp. 699 - 705

Journal articles | 2004

Rapley EA; Hockley S; Warren W; Johnson L; Huddart R; Crockford G; Forman D; Leahy M; Oliver D; Tucker K; Friedlander ML; Phillips KA; Hogg D; Jewett M; Lohynska R; Daugaard G; Richard S; Heidenreich A; Geczi L; Bodrogi I; Olah E; Ormiston W; Daly P; Looijenga L; Guilford P; Aass N; Fossa SD; Heimdal K; Tjulandin S; Liubchenko L; Stoll H; Weber W; Einhorn L; Weber B; McMaster M; Greene M; Bishop D; Easton D; Stratton M, 2004, 'Somatic mutations of KIT in familial testicular germ cell tumours', British Journal of Cancer, 90, pp. 2397 - 2401

Journal articles | 2004

Rischin D; Phillips KA; Friedlander ML; Harnett P; Quinn MA; Richardson G; Martin A, 2004, 'A Phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer', Gynecologic Oncology, 93, pp. 417 - 421

Journal articles | 2004

Webster GJ; Kurtovic J; Singh-Grewal I; Friedlander ML; Riordan SM, 2004, 'Prevention of hepatotoxicity but loss of antimelanoma effect withcombined fotemustine and anti-oxidant treatment', Internal Medicine Journal, 34, pp. 298 - U2

Journal articles | 2003

Apicella C; Andrews L; Hodgson SV; Fisher SA; Lewis CM; Solomon E; Tucker K; Friedlander ML; Bankier A; Southey MC; Venter DJ; Hopper JL, 2003, 'Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defines personal and family history in an Ashkenazi Jewish woman LAMBDA', Breast Cancer Research, 5, pp. 206 - 216

Journal articles | 2003

Friedlander M; Hogg R; Phillips KA, 2003, 'Management of women at increased genetic risk of ovarian cancer', Cancer Forum, 27, pp. 151 - 156

Journal articles | 2003

Friedlander ML; Jones R; Ryan M, 2003, 'Carboplatin hypersentivity reactions: re-treatment with cisplatin desensitisation', Gynecologic Oncology, 89, pp. 112 - 115

Journal articles | 2003

Friedlander ML; Thewes B, 2003, 'Counting the costs of treatment: the reporductive and gynaecological consequences of adjuvant therapy in young women with breast cancer', Internal Medicine Journal, 33, pp. 372 - 379

Journal articles | 2003

Hogg R; Friedlander M, 2003, 'Role of systemic chemotherapy in metastatic cervical cancer', Expert Review of Anticancer Therapy, 3, pp. 234 - 240, http://dx.doi.org/10.1586/14737140.3.2.234

Journal articles | 2003

Scott CI; Iorgulescu DG; Thorne HJ; Henderson MA; Phillips KA; Sambrook J; Chenevix-Trench G; Friedlander M; Baxter N; Evans G; Waring P; Clouston D, 2003, 'Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy', Clinical Genetics, 64, pp. 111 - 121, http://dx.doi.org/10.1034/j.1399-0004.2003.00097.x

Journal articles | 2003

TILLER K; MEISER B; REESON E; TUCKER M; ANDREWS L; GAFF C; KIRK J; PHILLIPS KA; FRIEDLANDER M, 2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecological Cancer, 13, pp. 15 - 22, http://dx.doi.org/10.1136/ijgc-00009577-200301000-00003

Journal articles | 2003

Thewes B; Meiser B; Rickard J; Friedlander ML, 2003, 'The fertility and menopause-related information needs of younger women with a diagnosis of breast cancer', Psycho - Oncology, 12, pp. 500 - 511

Journal articles | 2003

Tiller K; Meiser B; Reeson E; Tucker M; Andrews L; Gaff C; Kirk J; Phillips KA; Friedlander ML, 2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecological Cancer, 13, pp. 15 - 22

Journal articles | 2002

Friedlander ML, 2002, 'Guidelines for the treatment of recurrent and metastatic cervical cancer', Oncologist, 7, pp. 342 - 347

Journal articles | 2002

Hogg R; Friedlander M, 2002, 'Management of embryonal carcinoma of the ovary', CME Journal of Gynecologic Oncology, 7, pp. 234 - 237

Journal articles | 2002

Leary JA; Friedlander ML, 2002, 'The molecular genetics of epithelial ovarian cancer', Current Medical Literature Gynaecology and Obstetrics, 8, pp. 1 - 7

Journal articles | 2002

Meiser B; Butow P; Friedlander ML; Barratt AJ; Schnieden V, 2002, 'Psychological impact of genetic testing in women from high risk breast cancer families', European Journal of Cancer, 38, pp. 2025 - 2031

Journal articles | 2002

Tiller K; Meiser B; Butow P; Clifton M; Thewes B, 2002, 'Psychological Impact of Prophylactic Oophorectomy in Women at Increased Risk of Developing Ovarian Cancer: A Prospective Study', Gynecologic Oncology, 86, pp. 212 - 219

Journal articles | 2001

Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D; Abdi E; Kotasek D; Beadle G; Friedlander M; Anton A; Aranda E; Murillo E; Nogueira M; Balli M; De Lena M; Lopez M; Luporini G; Micheletti E; Morrica B; Tordiglione M; Breitbach GP; Dornhoff W; Klinkenstein C; Villena C; Wilken H; Cervek J; Chacòn R; Estévez R; Mickiewicz E; Muro H; Damianov D; Donat D; Vuletic L; Ezzat A; Gershanovich MNN; Ghilezan N; Hegg R; Jassem J; Pawlicki M; Ramlau C; Siedlecki P; Kocak I; Korec S; Muse IM; Nagykàlnai T; Perenyi L; Pinter T; Vallejos CS; Vogel C, 2001, 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19, pp. 943 - 953, http://dx.doi.org/10.1200/JCO.2001.19.4.943

Journal articles | 2001

Bahar A; Taylor P; Andrews L; Proos AL; Burnett L; Tucker K; Friedlander M; Buckley M, 2001, 'The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data', Cancer, 92, pp. 440 - 445

Journal articles | 2001

Bahar AY; Taylor PC; Andrews L; Proos A; Tucker K; Burnett L; Friedlander ML; Buckley MF, 2001, 'Genetic Analysis of Breast, Ovarian and Colorectal Cancer in the Sydney Ashkenazi Jewish Population', Cancer, pp. 440 - 445

Journal articles | 2001

Evans VE; Vockler C; Friedlander ML; Walsh B; Willcox MD, 2001, 'Lacroglobin in Human Tears, a Potential Marker for Cancer', Clinical and Experimental Ophthalmology, pp. 161 - 163

Journal articles | 2001

Evans VE; Vockler C; Friedlander ML; Walsh B; Willcox MD, 2001, 'Lacryglobin in human tears, a potential marker for cancer', Clinical and Experimental Ophthalmology, pp. 161 - 163

Journal articles | 2001

Friedlander M; Kashman Y; Weinberger F; Dawes CJ, 2001, 'Gracilaria and its epiphytes:: 4.: The response of two Gracilaria species to Ulva lactuca in a bacteria-limited environment', JOURNAL OF APPLIED PHYCOLOGY, 13, pp. 501 - 507, http://dx.doi.org/10.1023/A:1012593400901

Journal articles | 2001

Marx GM; Friedlander ML; Hacker NF, 2001, 'Cytotoxic drug treatment of vulval and vaginal cancer', CME Journal of Gynecologic Oncology, 6, pp. 67 - 72

Journal articles | 2001

Marx GM; Friedlander ML, 2001, 'Drug toxicity prevention and management', CME Journal of Gynecologic Oncology, 6, pp. 29 - 33

Journal articles | 2001

Pribill I; Speiser P; Leary JA; Leodolter S; Hacker NF; Friedlander ML; Birnbaum D; Zeillinger R; Krainer M, 2001, 'High Frequency of Allelic Imbalance at Regions of Chromosome 8p in Ovarian Carcinoma', Cancer, 129, pp. 23 - 29

Journal articles | 2001

Weinberger F; Richard C; Kloareg B; Kashman Y; Hoppe HG; Friedlander M, 2001, 'Structure-activity relationships of oligoagar elicitors toward Gracilaria conferta (Rhodophyta)', JOURNAL OF PHYCOLOGY, 37, pp. 418 - 426, http://dx.doi.org/10.1046/j.1529-8817.2001.037003418.x

Journal articles | 2001

Yang JL; Friedlander ML, 2001, 'Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect', Lancet, 357, pp. 1767 - 1768, http://dx.doi.org/10.1016/S0140-6736(00)04892-3

Journal articles | 2001

Yang JL; Friedlander ML, 2001, 'Therapeutic Benefit of Nifedipine in Metastatic Colon Cancer with DNA Mismatch Repair Gene Defect: Clinical Observation and Supportive Laboratory Evidence', Lancet, pp. 1767 - 1768

Journal articles | 2000

Bonevski B; Sanson-Fisher R; Girgis A; Burton L; Cook P; Boyes AW; Ackland S; Baker RW; Berry M; Biggs J, 2000, 'Evaluation of an instrument to assess the needs of patients with cancer', Cancer, 88, pp. 217 - 225

Journal articles | 2000

Dawes CJ; Teasdale BW; Friedlander M, 2000, 'Cell wall structure of the agarophytes Gracilaria tikvahiae and G-cornea (Rhodophyta) and penetration by the epiphyte Ulva lactuca (Chlorophyta)', JOURNAL OF APPLIED PHYCOLOGY, 12, pp. 567 - 575, http://dx.doi.org/10.1023/A:1026501613984

Journal articles | 2000

Faulkner SW; Friedlander ML, 2000, 'Microsatellite instability in germ cell tumors of the testis and ovary', Gynecologic Oncology, 79, pp. 38 - 43, http://dx.doi.org/10.1006/gyno.2000.5906

Journal articles | 2000

Faulkner SW; Friedlander ML, 2000, 'Molecular genetic analysis of malignant ovarian germ cell tumors', Gynecologic Oncology, 77, pp. 283 - 288, http://dx.doi.org/10.1006/gyno.2000.5762

Journal articles | 2000

Faulkner SW; Leigh DA; Oosterhuis JW; Roelofs H; Looijenga LHJ; Friedlander ML, 2000, 'Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults: Evidence suggestive of the linear progression model', British Journal of Cancer, 83, pp. 729 - 736, http://dx.doi.org/10.1054/bjoc.2000.1334

Journal articles | 2000

Marsden DE; Friedlander ML; Hacker NF, 2000, 'Current management of Epithelial Ovarian Carcinoma: A Review', Seminars in Surgical Oncology, 19, pp. 11 - 19

Journal articles | 2000

Meiser B; Butow P; Barratt A; Friedlander M; Kirk J; Gaff C; Haan E; Aittomäki K; Tucker K, 2000, 'Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer', Breast Cancer Research and Treatment, 59, pp. 101 - 111, http://dx.doi.org/10.1023/A:1006330631832

Journal articles | 2000

Meiser B; Butow P; Friedlander M; Schnieden V; Gattas M; Kirk J; Suthers G; Haan E; Tucker K, 2000, 'Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer', Journal of Clinical Oncology, 18, pp. 2250 - 2257, http://dx.doi.org/10.1200/JCO.2000.18.11.2250

Journal articles | 2000

Rapley EA; Crockford GP; Teare D; Biggs P; Seal S; Barfoot R; Edwards S; Hamoudi R; Heimdal K; Fosså SD; Tucker K; Donald J; Collins F; Friedlander M; Hogg D; Goss P; Heidenreich A; Ormiston W; Daly PA; Forman D; Oliver RTD; Leahy M; Huddart R; Cooper CS; Bodmer JG; Easton DF; Stratton MR; Bishop DT, 2000, 'Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours', Nature Genetics, 24, pp. 197 - 200, http://dx.doi.org/10.1038/72877

Journal articles | 2000

Sanson-Fisher R; Girgis A; Boyes A; Bonevski B; Burton L; Cook P; Ackland S; Baker R; Berry M; Biggs J; Bishop J; Bokey L; Burnard A; Clingan P; Cregan P; Dunn S; Friedlander M; Goulston K; Hacker N; Kearsley J; Langlands A; Levi J; Moylan E; Stewart J; Tattersall M, 2000, 'The unmet supportive care needs of patients with cancer', Cancer, 88, pp. 225 - 236, http://dx.doi.org/10.1002/(sici)1097-0142(20000101)88:1<226::aid-cncr30>3.0.co;2-p

Journal articles | 2000

Vergote I; Rustin GJS; Eisenhauer EA; Kristensen GB; Pujade-Lauraine E; Parmar MKB; Friedlander M; Jakobsen A; Vermorken JB, 2000, 'Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] [3]', Journal of the National Cancer Institute, 92, pp. 1534 - 1535

Journal articles | 2000

Weinberger F; Friedlander M, 2000, 'Endogenous and exogenous elicitors of a hypersensitive response in Gracilaria conferta (Rhodophyta)', JOURNAL OF APPLIED PHYCOLOGY, 12, pp. 139 - 145, http://dx.doi.org/10.1023/A:1008119125911

Journal articles | 1999

Friedlander ML, 1999, 'Multivariate prognostic models in ovarian cancer', CME Journal of Gynecologic Oncology, 4, pp. 256 - 258

Journal articles | 1999

Friedlander ML, 1999, 'Surgical stage, ascites, peritoneal cytology, tumour spillage, dense adherence', CME Journal of Gynecologic Oncology, 4, pp. 38 - 40

Journal articles | 1999

Israel A; Katz S; Dubinsky Z; Merrill JE; Friedlander M, 1999, 'Photosynthetic inorganic carbon utilization and growth of Porphyra linearis (Rhodophyta)', JOURNAL OF APPLIED PHYCOLOGY, 11, pp. 447 - 453, http://dx.doi.org/10.1023/A:1008122306268

Journal articles | 1999

Israel A; Martinez-Goss M; Friedlander M, 1999, 'Effect of salinity and pH on growth and agar yield of Gracilaria tenuistipitata var. liui in laboratory and outdoor cultivation', JOURNAL OF APPLIED PHYCOLOGY, 11, pp. 543 - 549, http://dx.doi.org/10.1023/A:1008141906299

Journal articles | 1999

Links MJ; Watson SR; Lethlean K; Aherne W; Kirsten F; Clarke SP; Law MG; Friedlander ML; Galettis P; Mckeage M, 1999, 'Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin', Cancer Investigation, 17, pp. 479 - 485

Journal articles | 1999

Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K, 1999, 'Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer', Gynecologic Oncology, 75, pp. 122 - 129, http://dx.doi.org/10.1006/gyno.1999.5544

Journal articles | 1998

Friedlander M, 1998, 'A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer', Annals of Oncology, 9, pp. 1343 - 1345, http://dx.doi.org/10.1023/A:1008469212268

Journal articles | 1998

Friedlander ML, 1998, 'Prognostic factors and tumour markers in ovarian teratomas', CME Journal of Gynecologic Oncology, 3, pp. 177 - 180

Journal articles | 1998

Friedlander ML, 1998, 'Prognostic factors in ovarian cancer', Seminars in Oncology, 25, pp. 305 - 314

Journal articles | 1998

Hacker NF; Bancher-Todesca D; Williams KL; Neunteufel W; Friedlander ML, 1998, 'Influence of post operative treatment on survival in patients with uterine papillary serous carcinoma', Gynecologic Oncology, pp. 344 - 347

Journal articles | 1998

Israel AA; Friedlander M, 1998, 'Inorganic carbon utilization and growth abilities in the marine red macroalga Gelidiopsis sp.', ISRAEL JOURNAL OF PLANT SCIENCES, 46, pp. 117 - 124, http://dx.doi.org/10.1080/07929978.1998.10676718

Journal articles | 1998

Kefford R; Tucker K; Friedlander M; Kirk J, 1998, 'Cancer in the family. Part 2.', Australian family physician, 27, pp. 40 - 44

Journal articles | 1998

Links MJ; Ribeiro JC; Jackson P; Friedlander ML; Russell PJ, 1998, 'Regulation and deregulation of G2 checkpoint proteins with cisplatin', Anticancer Research, 18, pp. 4057 - 4066

Journal articles | 1998

Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J, 1998, 'Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer', Journal of Clinical Oncology, 16, pp. 1948 - 1953, http://dx.doi.org/10.1200/JCO.1998.16.5.1948

Journal articles | 1997

Beller E; Tattersall M; Lumley T; Levi J; Dalley D; Olver I; Page J; Abdi E; Wynne C; Friedlander M; Boadle D; Wheeler H; Margrie S; Simes RJ, 1997, 'Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial', Annals of Oncology, 8, pp. 277 - 283, http://dx.doi.org/10.1023/A:1008291825695

Journal articles | 1997

Friedlander M; De Gramont A; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Rippche V; Kayitalire L, 1997, 'Activity of Gemcitablne in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens', European Journal of Cancer, 33, pp. S120 - S121, http://dx.doi.org/10.1016/s0959-8049(97)85054-x

Journal articles | 1997

Friedlander M, 1997, 'A menopausal woman with a history of breast cancer: Should she receive HRT?', Modern Medicine of Australia, 40, pp. 164 - 165

Journal articles | 1997

Friedlander ML; Kerr JL; Hurst T; Shih A; Purdie DM; Bergman L; Chenevix-Trench G; Sanderson B; Zournazi A; Coombs T; Leary JA; Crawford E; Shelling AN; Cooke I; Ganesan TS; Searle J; Choi J; Barrett JW; Khoo SK; Ward B, 1997, 'Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations', Genes Chromosomes and Cancer, pp. 75 - 83

Journal articles | 1997

Friedlander ML; Tucker K, 1997, 'Hereditary ovarian cancer: genetic basic and management issues', Cancer Forum, 21, pp. 10 - 13

Journal articles | 1997

Katz S; Dubinsky Z; Rothmann C; Malik Z; Friedlander M, 1997, 'Single-cell pigmentation of Porphyra linearis analyzed by Fourier transform multi-pixel spectroscopy and image analysis', JOURNAL OF PHYCOLOGY, 33, pp. 425 - 432, http://dx.doi.org/10.1111/j.0022-3646.1997.00425.x

Journal articles | 1997

Kefford R; Tucker K; Friedlander M; Kirk J, 1997, 'Cancer in the family. Guidelines for general practice.', Australian family physician, 26, pp. 545 - 549

Journal articles | 1997

Michael M; Bishop JF; Levi JA; Bell DR; Zalcberg JR; Friedlander ML; Olver LN; Smith JG; Toner GC, 1997, 'Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy', Medical Journal of Australia, 166, pp. 520 - 523, http://dx.doi.org/10.5694/j.1326-5377.1997.tb123243.x

Journal articles | 1997

Weinberger F; Hoppe HG; Friedlander M, 1997, 'Bacterial induction and inhibition of a fast necrotic response in Gracilaria conferta (Rhodophyta)', JOURNAL OF APPLIED PHYCOLOGY, 9, pp. 277 - 285, http://dx.doi.org/10.1023/A:1007990712925

Journal articles | 1996

Friedlander M; Gonen Y; Kashman Y; Beer S, 1996, 'Gracilaria conferta and its epiphytes .3. Allelopathic inhibition of the red seaweed by Ulva cf lactuca', JOURNAL OF APPLIED PHYCOLOGY, 8, pp. 21 - 25, http://dx.doi.org/10.1007/BF02186217

Journal articles | 1996

Friedlander M; Levy D; Hornung H, 1996, 'The effect of cooling seawater effluents of a power plant on growth rate of cultured Gracilaria conferta (Rhodophyta)', HYDROBIOLOGIA, 332, pp. 167 - 174, http://dx.doi.org/10.1007/BF00031922

Journal articles | 1996

Friedlander M; Weintraub N; Freedman A; Sheer J; Snovsky Z; Shapiro J; Kissil GW, 1996, 'Fish as potential biocontrollers of Gracilaria (Rhodophyta) culture', AQUACULTURE, 145, pp. 113 - 118, http://dx.doi.org/10.1016/S0044-8486(96)01350-6

Journal articles | 1996

Kavallaris M; Leary JA; Barrett JA; Friedlander ML, 1996, 'MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors', Cancer Letters, 102, pp. 7 - 16, http://dx.doi.org/10.1016/0304-3835(96)04143-2

Journal articles | 1996

Kerr J; Leary JA; Hurst T; Shih YC; Antalis TM; Friedlander M; Crawford E; Khoo SK; Ward B; Chenevix-Trench G, 1996, 'Allelic loss on chromosome 7q in ovarian adenocarcinomas: Two critical regions and a rearrangement of the PLANH1 locus', Oncogene, 13, pp. 1815 - 1818

Journal articles | 1996

Millward MJ; Bishop JF; Friedlander M; Levi JA; Goldstein D; Olver IN; Smith JG; Toner GC; Rischin D; Bell DR, 1996, 'Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer', Journal of Clinical Oncology, 14, pp. 142 - 148, http://dx.doi.org/10.1200/JCO.1996.14.1.142

Journal articles | 1996

Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Erratum: Treatment principles in advanced colorectal cancer (Australian and New Zealand Journal of Surgery (1996) 66 (202-205))', Australian and New Zealand Journal of Surgery, 66, pp. 503

Journal articles | 1996

Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Treatment principles in advanced colorectal cancer (vol 66, pg 202, 1996)', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 66, pp. 503 - 503, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996UX20100021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 1996

Zalcberg JR; Friedlander ML; Collopy BT; Barton M; Gray B, 1996, 'Treatment principles in advanced colorectal cancer', Australian and New Zealand Journal of Surgery, 66, pp. 202 - 205, http://dx.doi.org/10.1111/j.1445-2197.1996.tb01164.x

Journal articles | 1995

De Souza PL; Friedlander ML, 1995, 'Humoral hypercalcemia associated with adenocarcinoma of the rectum: A case report and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 18, pp. 126 - 129, http://dx.doi.org/10.1097/00000421-199504000-00006

Journal articles | 1995

GONEN Y; KIMMEL E; FRIEDLANDER M, 1995, 'DIFFUSION BOUNDARY-LAYER TRANSPORT IN GRACILARIA-CONFERTA (RHODOPHYTA)', JOURNAL OF PHYCOLOGY, 31, pp. 768 - 773, http://dx.doi.org/10.1111/j.0022-3646.1995.00768.x

Journal articles | 1995

Gitch G; Friedlander ML; Wain GV; Hacker NF, 1995, 'Uterine papillary serous carcinaoma: a clinical study', Cancer, pp. 2239 - 2243

Journal articles | 1995

ISRAEL AA; FRIEDLANDER M; NEORI A, 1995, 'BIOMASS YIELD, PHOTOSYNTHESIS AND MORPHOLOGICAL EXPRESSION OF ULVA-LACTUCA', BOTANICA MARINA, 38, pp. 297 - 302, http://dx.doi.org/10.1515/botm.1995.38.1-6.297

Journal articles | 1995

Leary JA; Kerr J; Chenevix‐Trench G; Doris CP; Hurst T; Houghton CRS; Friedlanders ML, 1995, 'Increased expression of the nme1 gene is associated with metastasis in epithelial ovarian cancer', International Journal of Cancer, 64, pp. 189 - 195, http://dx.doi.org/10.1002/ijc.2910640308

Journal articles | 1995

Links M; Friedlander M, 1995, 'High-dose chemotherapy in gynaecological cancers', Current Opinion in Obstetrics and Gynecology, 7, pp. 49 - 52, http://dx.doi.org/10.1097/00001703-199502000-00010

Journal articles | 1995

Links M; Friedlander M, 1995, 'High-dose chemotherapy in gynaecological cancers: Does more mean better?', Current Opinion in Obstetrics and Gynecology, 7, pp. 49 - 52, http://dx.doi.org/10.1097/00001703-199507010-00010

Journal articles | 1995

Phillips KA; Fitzharris B; Friedlander M; McCrystal M; Olver I; Joughin J; Bishop J; Evans B; Smith J, 1995, 'Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer', Australian and New Zealand Journal of Medicine, 25, pp. 337 - 343, http://dx.doi.org/10.1111/j.1445-5994.1995.tb01899.x

Journal articles | 1995

Shannon JA; Donnellan MJ; Friedlander ML; Harnett PR, 1995, 'Persisting elevation of alphafetoprotein after chemotherapy for germ cell tumour-not always due to viable malignancy?', European Journal of Cancer, 31, pp. 1722, http://dx.doi.org/10.1016/0959-8049(95)00303-Z

Journal articles | 1995

Van Der Velden J; Gitch G; Wain GV; Friedlander ML; Hacker NF, 1995, 'Tamoxifen in patients with advanced epithelial ovarian cancer', International Journal of Gynecological Cancer, pp. 301 - 305

Journal articles | 1995

Zalcberg JR; Bishop JF; Millward MJ; Zimet A; Laird J; Barter C; Seward D; McKeage MJ; Friedlander ML; Toner G; Berille J; Blanc C, 1995, '1084 Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', European Journal of Cancer, 31, pp. S226 - S226, http://dx.doi.org/10.1016/0959-8049(95)96330-g

Journal articles | 1994

Chenevix-Trench G; Kerr J; Friedlander M; Hurst T; Sanderson B; Coglan M; Ward B; Leary J; Khoo SK, 1994, 'Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors', American Journal of Human Genetics, 55, pp. 143 - 149

Journal articles | 1994

De Souza P; Friedlander M; Wilde C; Kirsten F; Ryan M, 1994, 'Hypersensitivity reactions to etoposide: A report of three cases and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 17, pp. 387 - 389, http://dx.doi.org/10.1097/00000421-199410000-00005

Journal articles | 1994

FRIEDLANDER M; LEWIS C; GOLDSTEIN D, 1994, 'UNTITLED', MEDICAL JOURNAL OF AUSTRALIA, 161, pp. 638 - 638, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PT68600027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 1994

GONEN Y; KIMMEL E; FRIEDLANDER M, 1994, 'ATTENUATION OF WATER VELOCITY AND INCIDENT LIGHT AS A FUNCTION OF SHAPE-PARAMETERS IN GRACILARIA', JOURNAL OF APPLIED PHYCOLOGY, 6, pp. 381 - 390, http://dx.doi.org/10.1007/BF02182154

Journal articles | 1994

LEVY I; FRIEDLANDER M, 1994, 'SEASONAL GROWTH-ACTIVITY OF LOCAL AND FOREIGN GRACILARIOID STRAINS IN ISRAEL', JOURNAL OF APPLIED PHYCOLOGY, 6, pp. 447 - 454, http://dx.doi.org/10.1007/BF02182397

Journal articles | 1994

Mackintosh JF; Friedlander M; Lewis C; Goldstein D; Herrmann RP; Kearsley JH, 1994, 'Wanted: Guidelines for 'palliative' anti-cancer drug use [3]', Medical Journal of Australia, 161, pp. 638 - 639, http://dx.doi.org/10.5694/j.1326-5377.1994.tb127659.x

Journal articles | 1994

Mayordomo JI; Paz-Ares L; Diaz-Puente MT; Lianes P; Garcia-Prats MD; Cortes-Funes H; Segelov E; Friedlander M, 1994, 'Prognostic factors for women with ovarian germ cell tumors [2]', Journal of Clinical Oncology, 12, pp. 1737 - 1738, http://dx.doi.org/10.1200/JCO.1994.12.8.1737

Journal articles | 1994

Quinn M; Murray J; Friedlander M; Steigrad S; Khoo S; Marsden D; Hammond I; Jobling T, 1994, 'EMACO in High Risk Gestational Trophoblast Disease ‐ The Australian Experience', Australian and New Zealand Journal of Obstetrics and Gynaecology, 34, pp. 90 - 92, http://dx.doi.org/10.1111/j.1479-828X.1994.tb01047.x

Journal articles | 1994

SEGELOV E; FRIEDLANDER M, 1994, 'PROGNOSTIC FACTORS FOR WOMEN WITH OVARIAN GERM-CELL TUMORS - REPLY', JOURNAL OF CLINICAL ONCOLOGY, 12, pp. 1738 - 1738, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PA25700031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 1994

Segelov E; Campbell J; Ng M; Tattersall M; Rome R; Free K; Hacker N; Friedlander ML, 1994, 'Cisplatin-based chemotherapy for ovarian germ cell malignancies: The Australian experience', Journal of Clinical Oncology, 12, pp. 378 - 384, http://dx.doi.org/10.1200/JCO.1994.12.2.378

Journal articles | 1994

Segelov E; Stuart-Harris R; Bell D; Tattersall M; Hutton-Potts J; Friedlander M, 1994, 'A phase II study of carboplatin and cisplatin in advanced ovarian cancer', European Journal of Gynaecological Oncology, 15, pp. 277 - 282

Journal articles | 1993

FRIEDLANDER M; DAWES C; LEVY I, 1993, 'EXPOSURE OF GRACILARIA TO VARIOUS ENVIRONMENTAL-CONDITIONS .1. THE EFFECT ON GROWTH', BOTANICA MARINA, 36, pp. 283 - 288, http://dx.doi.org/10.1515/botm.1993.36.4.283

Journal articles | 1993

Leary JA; Doris CP; Boltz EM; Houghton CRS; Kefford RF; Friedlander ML, 1993, 'Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer 11p, 17p and 17q in ovarian cancer', International Journal of Gynecological Cancer, 3, pp. 293 - 298, http://dx.doi.org/10.1046/j.1525-1438.1993.03050293.x

Journal articles | 1993

Lewis CR; Segelov E; Goldstein D; Friedlander ML, 1993, 'Chemotherapy made easier.', Australian and New Zealand journal of medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x

Journal articles | 1992

Chenevix-Trench G; Leary J; Kerr J; Michel J; Kefford R; Hurst T; Parsons PO; Friedlander M; Khoo SK, 1992, 'Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus', Oncogene, 7, pp. 1059 - 1065

Journal articles | 1992

De Souza PL; Friedlander ML, 1992, 'Prognostic factors in ovarian cancer', Hematology/Oncology Clinics of North America, 6, pp. 761 - 781, http://dx.doi.org/10.1016/s0889-8588(18)30309-5

Journal articles | 1992

FRIEDLANDER M, 1992, 'GRACILARIA-CONFERTA AND ITS EPIPHYTES - THE EFFECT OF CULTURE CONDITIONS ON GROWTH', BOTANICA MARINA, 35, pp. 423 - 428, http://dx.doi.org/10.1515/botm.1992.35.5.423

Journal articles | 1992

Friedlander M; De Souza P; Segelov E, 1992, 'Risk factors, epidemiology, screening, and prognostic factors in female genital cancer', Current Opinion in Oncology, 4, pp. 913 - 922, http://dx.doi.org/10.1097/00001622-199210000-00016

Journal articles | 1992

Leary JA; Edwards BG; Houghton CRS; Kefford RF; Friedlander ML, 1992, 'Amplification of HER-2/neu oncogene in human ovarian cancer', International Journal of Gynecological Cancer, 2, pp. 291 - 294, http://dx.doi.org/10.1046/j.1525-1438.1992.02060291.x

Journal articles | 1992

Levi JA; Wheeler HR; Friedlander M; Tattersall MHN; Kefford R; Dalley D, 1992, 'Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix', Gynecologic Oncology, 45, pp. 329 - 333, http://dx.doi.org/10.1016/0090-8258(92)90314-9

Journal articles | 1991

Cope C; Delbridge L; Philips E; Friedlander M, 1991, 'PROGNOSTIC SIGNIFICANCE OF NUCLEAR DNA CONTENT IN PHAEOCHROMOCYTOMA', Australian and New Zealand Journal of Surgery, 61, pp. 695 - 698, http://dx.doi.org/10.1111/j.1445-2197.1991.tb00323.x

Journal articles | 1991

Cope C; Rowe D; Delbridge L; Philips J; Friedlander M, 1991, 'Comparison of image analysis and flow cytometric determination of cellular DNA content', Journal of Clinical Pathology, 44, pp. 147 - 151, http://dx.doi.org/10.1136/jcp.44.2.147

Journal articles | 1991

FRIEDLANDER M; BENAMOTZ A, 1991, 'THE EFFECT OF OUTDOOR CULTURE CONDITIONS ON GROWTH AND EPIPHYTES OF GRACILARIA-CONFERTA', AQUATIC BOTANY, 39, pp. 315 - 333, http://dx.doi.org/10.1016/0304-3770(91)90006-Q

Journal articles | 1991

FRIEDLANDER M; KROM MD; BENAMOTZ A, 1991, 'THE EFFECT OF LIGHT AND AMMONIUM ON GROWTH, EPIPHYTES AND CHEMICAL-CONSTITUENTS OF GRACILARIA-CONFERTA IN OUTDOOR CULTURES', BOTANICA MARINA, 34, pp. 161 - 166, http://dx.doi.org/10.1515/botm.1991.34.3.161

Journal articles | 1991

FRIEDLANDER M, 1991, 'GROWTH-RATE, EPIPHYTE BIOMASS AND AGAR YIELD OF GRACILARIA-CONFERTA IN AN ANNUAL OUTDOOR EXPERIMENT .1. IRRADIANCE AND NITROGEN', BIORESOURCE TECHNOLOGY, 38, pp. 203 - 208, http://dx.doi.org/10.1016/0960-8524(91)90155-D

Journal articles | 1991

Friedlander M, 1991, 'CURRENT GENITOURINARY CANCER SURGERY', Australian and New Zealand Journal of Medicine, 21, pp. 492 - 492, http://dx.doi.org/10.1111/j.1445-5994.1991.tb01367.x

Journal articles | 1991

Friedlander ML; Dembo AJ, 1991, 'Prognostic factors in ovarian cancer', Seminars in Oncology, 18, pp. 205 - 212

Journal articles | 1990

Bishop JF; Kefford R; Raghavan D; Zalcberg J; Stuart-Harris R; Ball D; Olver IN; Friedlander M; Bull C; Yuen K; Matthews JP; Zimet A, 1990, 'Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer', Cancer Chemotherapy and Pharmacology, 25, pp. 367 - 370, http://dx.doi.org/10.1007/BF00686239

Journal articles | 1990

Boltz EM; Harnett P; Kefford RF; Leary J; Houghton R; Friedlander ML, 1990, 'Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting', British Journal of Cancer, 62, pp. 23 - 27, http://dx.doi.org/10.1038/bjc.1990.222

Journal articles | 1990

FRIEDLANDER M; GALAI N; FARBSTEIN H, 1990, 'A MODEL OF SEAWEED GROWTH IN AN OUTDOOR CULTURE IN ISRAEL', HYDROBIOLOGIA, 204, pp. 367 - 373, http://dx.doi.org/10.1007/BF00040258

Journal articles | 1990

LEVY I; BEER S; FRIEDLANDER M, 1990, 'GROWTH, PHOTOSYNTHESIS AND AGAR IN WILD-TYPE STRAINS OF GRACILARIA-VERRUCOSA AND GRACILARIA-CONFERTA (GRACILARIALES, RHODOPHYTA), AS A STRAIN SELECTION EXPERIMENT', HYDROBIOLOGIA, 204, pp. 381 - 387, http://dx.doi.org/10.1007/BF00040260

Journal articles | 1989

Antonjuk DJ; Boadle DK; Cheung HTA; Friedlander ML; Gregory PM; Tattersall MHN, 1989, 'α-Monoamides of methotrexate as potential prodrugs', Arzneimittel-Forschung/Drug Research, 39, pp. 12 - 15

Journal articles | 1989

Bishop JF; Raghavan D; Olver IN; Reece P; Morris R; Friedlander ML, 1989, 'A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion', Cancer Chemotherapy and Pharmacology, 24, pp. 246 - 250, http://dx.doi.org/10.1007/BF00257627

Journal articles | 1989

Boltz EM; Kefford RF; Leary JA; Houghton CR; Friedlander ML, 1989, 'Amplification of c‐ras‐ki oncogene in human ovarian tumours', International Journal of Cancer, 43, pp. 428 - 430, http://dx.doi.org/10.1002/ijc.2910430314

Journal articles | 1989

Boyer M; Friedlander M; Bannatyne P; Atkinson K, 1989, 'Hypercalcemia in association with mucinous adenocarcinoma of the ovary: A case report', Gynecologic Oncology, 35, pp. 387 - 390, http://dx.doi.org/10.1016/0090-8258(89)90085-1

Journal articles | 1989

Dalrymple JC; Bannatyne P; Russell P; Solomon HJ; Tattersall MHN; Atkinson K; Carter J; Duval P; Elliott P; Friedlander M; Murray J; Coppleson M, 1989, 'Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases', Cancer, 64, pp. 110 - 115, http://dx.doi.org/10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5

Journal articles | 1989

Friedlander ML; Bell DR; Leary J; Davey RA, 1989, 'Comparison of Western blot analysis and immunocytochemical detection of P-glycoprotein in multidrug resistant cells', Journal of Clinical Pathology, 42, pp. 719 - 722, http://dx.doi.org/10.1136/jcp.42.7.719

Journal articles | 1989

Friedlander ML; Bell DR, 1989, 'Multidrug resistance: clinical findings and implications.', Cancer treatment and research, 42, pp. 63 - 77, http://dx.doi.org/10.1007/978-1-4613-1747-0_4

Journal articles | 1989

Friedlander ML; Quinn MA; Fortune D; Foo MS; Toppila M; Hudson CN; Russell P, 1989, 'The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors', Gynecologic Oncology, 32, pp. 184 - 190, http://dx.doi.org/10.1016/S0090-8258(89)80031-9

Journal articles | 1988

Friedlander M; Leary J; Russelli P, 1988, 'An evaluation of CA125, CA1 and peanut lectin immunoreactivity in epithelial ovarian neoplasms: Correlation with histopathological features, prognostic variables and patient outcome', Pathology, 20, pp. 38 - 44, http://dx.doi.org/10.3109/00313028809085194

Journal articles | 1988

Friedlander ML; Hedley DW; Swanson C; Russell P, 1988, 'Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer', Journal of Clinical Oncology, 6, pp. 282 - 290, http://dx.doi.org/10.1200/JCO.1988.6.2.282

Journal articles | 1988

Solomon HJ; Atkinson KH; Coppleson JVM; Elliott PM; Houghton CRS; Murray J; Tattersall MHN; Friedlander ML; Green D, 1988, 'Ovarian carcinoma: Abdominopelvic irradiation following reexploration', Gynecologic Oncology, 31, pp. 396 - 401, http://dx.doi.org/10.1016/S0090-8258(88)80023-4

Journal articles | 1987

FRIEDLANDER M; SHALEV R; GANOR T; STRIMLING S; BENAMOTZ A; KLAR H; WAX Y, 1987, 'SEASONAL FLUCTUATIONS OF GROWTH-RATE AND CHEMICAL-COMPOSITION OF GRACILARIA CF CONFERTA IN OUTDOOR CULTURE IN ISRAEL', HYDROBIOLOGIA, 151, pp. 501 - 507, http://dx.doi.org/10.1007/BF00046174

Journal articles | 1987

KIRSTEN F; ATKINSON KH; COPPLESON JVM; ELLIOTT PM; GREEN D; HOUGHTON R; MURRAY JC; RUSSELL P; SOLOMON HJ; FRIEDLANDER M; SWANSON CE; TATTERSALL MHN, 1987, 'Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer', BJOG: An International Journal of Obstetrics & Gynaecology, 94, pp. 583 - 588, http://dx.doi.org/10.1111/j.1471-0528.1987.tb03154.x

Journal articles | 1987

Trebeck CE; Friedlander ML; Russell P; Baird PJ, 1987, 'Brenner tumours of the ovary: A study of the histology, immunohistochemistry and cellular dna content in benign, borderline and malignant ovarian tumours', Pathology, 19, pp. 241 - 246, http://dx.doi.org/10.3109/00313028709066557

Journal articles | 1986

Zalcberg JR; Friedlander ML; Minden MD, 1986, 'Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia', British Journal of Cancer, 53, pp. 459 - 464, http://dx.doi.org/10.1038/bjc.1986.73

Journal articles | 1985

Eckstein RP; Russell P; Friedlander ML; Tattersall MHN; Bradfield A, 1985, 'Metastasizing placental site trophoblastic tumor: A case study', Human Pathology, 16, pp. 632 - 636, http://dx.doi.org/10.1016/S0046-8177(85)80114-3

Journal articles | 1985

Friedlander M; Foo MS; Quinn M, 1985, 'Relationship of steroid receptors and tumor ploidy in epithelial ovarian cancer', Proceedings of the American Association for Cancer Research, VOL. 26

Journal articles | 1985

Friedlander M; Zalcberg J; Patterson B; Minden M; Bergsagel DE, 1985, 'APPARENT T-CELL NEOPLASMS WITH IMMUNOGLOBULIN GENE REARRANGEMENTS', The Lancet, 326, pp. 670, http://dx.doi.org/10.1016/S0140-6736(85)90036-4

Journal articles | 1985

Friedlander ML; Russell P; Taylor IW; Tattersall MHN, 1985, 'Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer', British Journal of Cancer, 51, pp. 319 - 333, http://dx.doi.org/10.1038/bjc.1985.44

Journal articles | 1985

Hedley DW; Friedlander ML; Taylor IW, 1985, 'Application of DNA flow cytometry to paraffin‐embedded archival material for the study of aneuploidy and its clinical significance', Cytometry, 6, pp. 327 - 333, http://dx.doi.org/10.1002/cyto.990060409

Journal articles | 1985

Taylor IW; Slowiaczek P; Friedlander ML; Tattersall MHN, 1985, 'Selective Toxicity of a New Lipophilic Antifolate, BW301U, for Methotrexate-resistant Cells with Reduced Drug Uptake', Cancer Research, 45, pp. 978 - 982

Journal articles | 1984

FRIEDLANDER M; DAWES CJ, 1984, 'STUDIES ON SPORE RELEASE AND SPORELING GROWTH FROM CARPOSPORES OF GRACILARIA-FOLIIFERA (FORSSKAL) BORGESEN VAR ANGUSTISSIMA (HARVEY) TAYLOR .1. GROWTH-RESPONSES', AQUATIC BOTANY, 19, pp. 221 - 232, http://dx.doi.org/10.1016/0304-3770(84)90040-8

Journal articles | 1984

FRIEDLANDER M; DAWES CJ, 1984, 'STUDIES ON SPORE RELEASE AND SPORELING GROWTH FROM CARPOSPORES OF GRACILARIA-FOLIIFERA (FORSSKAL) BORGESEN VAR ANGUSTISSIMA (HARVEY) TAYLOR .2. PHOTOSYNTHETIC AND RESPIRATORY RESPONSES', AQUATIC BOTANY, 19, pp. 233 - 241, http://dx.doi.org/10.1016/0304-3770(84)90041-X

Journal articles | 1984

FRIEDLANDER M; ZELIKOVITCH N, 1984, 'GROWTH-RATES, PHYCOCOLLOID YIELD AND QUALITY OF THE RED SEAWEEDS, GRACILARIA SP, PTEROCLADIA-CAPILLACEA, HYPNEA-MUSCIFORMIS, AND HYPNEA-CORNUTA, IN FIELD STUDIES IN ISRAEL', AQUACULTURE, 40, pp. 57 - 66, http://dx.doi.org/10.1016/0044-8486(84)90216-3

Journal articles | 1984

Friedlander ML; Atkinson K; Coppleson JVM; Elliot P; Green D; Houghton R; Solomon HJ; Russell P; Tattersall MHN, 1984, 'The integration of chemotherapy into the management of locally advanced cervical cancer: A pilot study', Gynecologic Oncology, 19, pp. 1 - 7, http://dx.doi.org/10.1016/0090-8258(84)90150-1

Journal articles | 1984

Friedlander ML; Hedley DW; Taylor IW, 1984, 'Clinical and biological significance of aneuploidy in human tumours', Journal of Clinical Pathology, 37, pp. 961 - 974, http://dx.doi.org/10.1136/jcp.37.9.961

Journal articles | 1984

Friedlander ML; Russell P; Taylor IW; Hedley DW; Tattersall MHN, 1984, 'Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy', Pathology, 16, pp. 301 - 306, http://dx.doi.org/10.3109/00313028409068541

Journal articles | 1984

Friedlander ML; Taylor IW; Russell P; Tattersall MH, 1984, 'Cellular DNA content—a stable feature in epithelial ovarian cancer', British Journal of Cancer, 49, pp. 173 - 179, http://dx.doi.org/10.1038/bjc.1984.29

Journal articles | 1984

Friedlander ML, 1984, 'Prognostic Variables in Epithelial Ovarian Cancer: A Review', Australian and New Zealand Journal of Obstetrics and Gynaecology, 24, pp. 256 - 261, http://dx.doi.org/10.1111/j.1479-828X.1984.tb01506.x

Journal articles | 1984

Hedley DW; Friedlander ML; Taylor IW; Rugg CA; Musgrove EA, 1984, 'DNA flow cytometry of paraffin‐embedded tissue', Cytometry, 5, pp. 660 - 660, http://dx.doi.org/10.1002/cyto.990050618

Journal articles | 1984

Hedley DW; Taylor IW; Coates AS; Tattersall MHN; Russell P; Friedlander ML, 1984, 'Influence of Cellular DNA Content on Survival in Advanced Ovarian Cancer', Cancer Research, 44, pp. 397 - 400

Journal articles | 1983

, 1983, 'Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry', Journal of Histochemistry and Cytochemistry, 31, pp. 1333 - 1335, http://dx.doi.org/10.1177/31.11.6619538

Journal articles | 1983

FRIEDLANDER ML; KEARSLEY JH; SIMS K; COATES A; HEDLEY D; RAGHAVAN D; FOX RM; TATTERSALL MHN, 1983, 'LORAZEPAM AS AN ADJUNCT TO ANTIEMETIC THERAPY WITH HALOPERIDOL IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY', Australian and New Zealand Journal of Medicine, 13, pp. 53 - 56, http://dx.doi.org/10.1111/j.1445-5994.1983.tb04550.x

Journal articles | 1983

Friedlander M; Kaye SB; Sullivan A; Atkinson K; Elliott P; Coppleson M; Houghton R; Solomon J; Green D; Russell P; Hudson CN; Langlands AO; Tattersall MHN, 1983, 'Cervical carcinoma: A drug-responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy', Gynecologic Oncology, 16, pp. 275 - 281, http://dx.doi.org/10.1016/0090-8258(83)90102-6

Journal articles | 1983

Friedlander ML; Sims K; Kearsley JH, 1983, 'IMPAIRMENT OF RECALL IMPROVES TOLERANCE OF CYTOTOXIC CHEMOTHERAPY', The Lancet, 322, pp. 686, http://dx.doi.org/10.1016/S0140-6736(83)92568-0

Journal articles | 1983

Friedlander ML; Taylor IW; Russell P; Musgrove EA; Hedley DH; Tattersall MHN, 1983, 'Ploidy as a prognostic factor in ovarian cancer', International Journal of Gynecological Pathology, 2, pp. 55 - 63, http://dx.doi.org/10.1097/00004347-198301000-00005

Journal articles | 1983

Taylor IW; Musgrove EA; Friedlander ML; Foo MS; Hedley DW, 1983, 'The influence of age on the DNA ploidy levels of breast tumours', European Journal of Cancer and Clinical Oncology, 19, pp. 623 - 628, http://dx.doi.org/10.1016/0277-5379(83)90178-5

Journal articles | 1982

Friedlander ML; Halley JBW; Sinosich MJ; Coates A, 1982, 'Pulmonary Pseudotumours Following Chemotherapy for Endodermal Sinus Tumour of the Ovary', Australian and New Zealand Journal of Obstetrics and Gynaecology, 22, pp. 110 - 112, http://dx.doi.org/10.1111/j.1479-828X.1982.tb01417.x

Journal articles | 1982

Friedlander ML; Tattersall MHN, 1982, 'Counting the costs of cancer therapy', European Journal of Cancer and Clinical Oncology, 18, pp. 1237 - 1241, http://dx.doi.org/10.1016/0277-5379(82)90124-9

Journal articles | 1982

Raghavan D; Coates A; Friedlander M, 1982, 'Mitoxantrone (XAN): Progress in a phase ii trial in Sydney, Australia', Proceedings of the American Society of Clinical Oncology, Vol. 1

Journal articles | 1982

Tattersall MH; Friedlander ML, 1982, 'Cost considerations in cancer chemotherapy.', Australian health review : a publication of the Australian Hospital Association, 5, pp. 21 - 24

Journal articles | 1981

Friedlander M; Kearsley JH; Tattersall MHN, 1981, 'ORAL LORAZEPAM TO IMPROVE TOLERANCE OF CYTOTOXIC THERAPY', The Lancet, 317, pp. 1316 - 1317, http://dx.doi.org/10.1016/S0140-6736(81)92489-2

Journal articles | 1981

Friedlander M; Tattersall MHN, 1981, 'Postoperative radiotherapy in breast cancer', British Medical Journal (Clinical research ed.), 282, pp. 2133 - 2134, http://dx.doi.org/10.1136/bmj.282.6282.2133-d

Journal articles | 1980

FRIEDLANDER ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC-CANCER', LANCET, 2, pp. 1373 - 1373, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KU80600049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 1980

Friedlander ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC CANCER', The Lancet, 316, pp. 1373, http://dx.doi.org/10.1016/S0140-6736(80)92440-X
Conference Abstracts | 2025

Nahm SH; Kiely BE; O'Connell RL; Lee YC; Davis A; Avall-Lundqvist E; Berek JS; Berton D; Donnellan P; Hilpert F; Joly F; Lanceley A; Ledermann JA; Okamoto A; Oza A; Pignata S; Sehouli J; King MT; Friedlander M; Stockler MR; Roncolato FT, 2025, 'Prognostic significance and accuracy of oncologists’ estimates of survival time in recurrent ovarian cancer', in International Journal of Gynecological Cancer, Vol. 35, http://dx.doi.org/10.1016/j.ijgc.2024.100030

Conference Abstracts | 2024

Konstantinopoulos P; Kim J-W; Freyer G; Lee J-Y; Gaba L; Grisham R; Colombo N; Wu X; Sehouli J; Cruz F; Cibula D; Monk B; Nyvang G-B; Friedlander M; Lorusso D; Van Nieuwenhuysen E; Glasspool R; Marth C; Hinson P; Zuradellit M; Wangt C; Su F; Miller M; Matulonis U; Gonzalez-Martin A, 2024, 'Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 190, pp. S12 - S12

Preprints | 2024

Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Barnes EH; Goldstein D; Park SB, 2024, Peripheral Neuropathy in Cancer Patients- Multifactorial Contributors to Dose Limiting and Chronic Toxicity, http://dx.doi.org/10.1101/2024.07.24.24310956

Conference Papers | 2024

Naidoo M; Mcnally O; Scott C; Friedlander M; Cohen P; Perera S; Brand A; Richardson G; Bunting M; Mohan R; Oehler M; Hyde S; Jobling T; Farrell R; Evans S; Rome R; Zalcberg J, 2024, 'EV306/#612 Patterns of ovarian cancer care and overall survival in Australia: a prospective study from the National Gynae-Oncology Registry (NGOR)', in E-Poster Viewing Abstracts, BMJ Publishing Group Ltd, pp. A240.1 - A240, presented at IGCS 2024 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2024-igcs.425

Conference Abstracts | 2024

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis', in Supportive Care in Cancer, Vol. 32, http://dx.doi.org/10.1007/s00520-024-08460-z

Conference Abstracts | 2023

Kee D; Lin FP-Y; Thavaneswaran S; Napier CE; Harrison ML; Beale PJ; Lynch J; Davis AJ; Ananda S; Lombard JM; Friedlander M; Kansara M; Sebastian L; Lee CK; Ballinger ML; Simes J; Thomas DM, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Data from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, http://dx.doi.org/10.1158/1940-6207.c.6547304

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Data from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.c.6547304.v1

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 1 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533917

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 1 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533917.v1

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 2 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533914

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 2 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533914.v1

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 3 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533911

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 3 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533911.v1

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 4 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533908

Other | 2023

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan S-A; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips K-A, 2023, Supplementary Data 4 from Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians, , http://dx.doi.org/10.1158/1940-6207.22533908.v1

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.c.6532782

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.c.6532782.v1

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.22488654

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.22488654.v1

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.22488651

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.22488651.v1

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.22488645

Other | 2023

Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt K-A; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim B-G; Kim J-W; Kim J-H; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park S-Y; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ, 2023, Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes, http://dx.doi.org/10.1158/1078-0432.22488645.v1

Conference Papers | 2023

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Conference Abstracts | 2022

Deva S; Millward M; Friedlander M; Gan HK; Hovarth LG; Lee J-S; Hill A; Sandhu S; Liang L; Shi J; Zhang Y; Shi Y; Ma X; Wu X; Shen Z; Desai J, 2022, 'Abstract LB511: The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. LB511 - LB511, http://dx.doi.org/10.1158/1538-7445.am2022-lb511

Conference Abstracts | 2022

DiSilvestro P; Banerjee S; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander ML; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Oza AM; Martin AJG; Aghajanian C; Bradley WH; Mathews C; McNamara J; Lowe E; Moore KN, 2022, 'Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S779 - S779, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.645

Conference Papers | 2022

Konstantinopoulos P; Gonzalez-Martin A; Cruz F; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk B; Kim J-W; Ajipa O; Su F; Han Y; Matulonis U, 2022, 'TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer', in E-Posters (Trials In Progress), BMJ Publishing Group Ltd, pp. A238.1 - A238, presented at IGCS 2022 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2022-igcs.539

Conference Abstracts | 2022

Meagher NS; Hamilton PT; Anglesio MS; Harris HR; Konecny GE; Schildkraut JM; Talhouk A; Friedlander ML; Pearce CL; Pike MC; Kobel M; Doherty JA; Goode EL; Nelson BH; DeFazio A; Ramus SJ, 2022, 'Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia', in JOURNAL OF IMMUNOLOGY, AMER ASSOC IMMUNOLOGISTS, Vol. 208, http://dx.doi.org/10.4049/jimmunol.208.Supp.179.04

Conference Abstracts | 2022

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', in Medicine & Science in Sports & Exercise, LIPPINCOTT WILLIAMS & WILKINS, San Diego, California, Vol. 54, pp. 322 - 322, presented at ACSM 2022 Annual Meeting & World Congresses, San Diego, California, 31 May 2022 - 04 June 2022, http://dx.doi.org/10.1249/01.mss.0000879060.88938.0b

Conference Abstracts | 2022

Pitiyarachchi O; Lee YC; Ramus SJ; deFazio A; Friedlander M, 2022, 'Rates of somatic variants in homologous recombination DNA repair deficiency genes in older patients with high-grade serous ovarian carcinoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 30 - 30

Conference Abstracts | 2022

Tan DSP; Choi CH; Ngoi N; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Goss G; Goh JC; Luo V; Tai BC; Lim D; Kaliaperumal N; AU VB; Connolly J; Kim J-W; Friedlander M; Kim K, 2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5565 - 5565, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5565

Conference Abstracts | 2022

Tan DSP; Choi CH; Ngoi N; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Goss G; Goh JC; Luo V; Tai BC; Lim D; Kaliaperumal N; Au VB; Connolly J; Kim J-W; Friedlander M; Kim K, 2022, 'A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Conference Abstracts | 2022

Trillsch F; Mahner S; Ataseven B; Asher R; Aryal N; Dubot C; Clamp A; Penson RT; Oza A; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; Denys H; Lowe ES; Lee CK; Pujade-Lauraine E, 2022, 'Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study', in Gynecologic Oncology, Vol. 165, pp. 40 - 48, http://dx.doi.org/10.1016/j.ygyno.2022.01.024

Conference Abstracts | 2022

Woodford R; Zhou D; Kok P-S; Lord S; Friedlander M; Marschner I; Simes J; Lee CK, 2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Conference Abstracts | 2022

Woodford R; Zhou D; Kok P-S; Lord S; Friedlander M; Marschner I; Simes J; Lee CK, 2022, 'Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 6518 - 6518, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6518

Conference Abstracts | 2021

Bradley W; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke G; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Cain T; Lowe E; DiSilvestro P, 2021, 'Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 162, pp. S25 - S26, http://dx.doi.org/10.1016/S0090-8258(21)00694-6

Conference Abstracts | 2021

Feiglin T; Armstrong G; Sinha R; Robertson G; Friedlander M; Wan K, 2021, 'Two Cases of Intraplacental Choriocarcinoma Causing Severe Fetal Anaemia at Term', in AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, WILEY, Vol. 61, pp. 7 - 7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000651190000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2021

Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R, 2021, 'Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)', in Gynecologic Oncology, Vol. 161, pp. 160 - 165, http://dx.doi.org/10.1016/j.ygyno.2021.02.016

Conference Abstracts | 2021

Gersekowski K; Jordan S; Delahunty R; Alsop K; Goode EL; Bowtell D; DeFazio A; Friedlander M; Obermair A; Grant P; Webb P, 2021, 'Impact of BRCA mutation status and lifestyle factors on survival among women with ovarian cancer', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, Vol. 50, pp. 79 - 79, http://dx.doi.org/10.1093/ije/dyab168.217

Conference Abstracts | 2021

Mapagu C; Srirangan S; Pattnaik S; Nevins N; Provan P; Bouantoun N; Kirk J; Chiew Y-E; Dobrovic A; Musafer A; Zhang F; Balleine R; Beale P; Bowtell D; Brand A; Friedlander M; Harnett P; Marsh D; Goli S; deFazio A, 2021, 'Assessment of HR deficiency in ovarian cancer to increase PARP inhibitor targets beyond BRCA1/2', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 54 - 55, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2021

Meagher N; Koebel M; Anderson L; Tan A; Bolithon A; Anglesio M; Cohen P; Crowe P; Doherty J; Fasching P; Harris H; Hogdall E; Huntsman D; James P; Karlan B; Kelemen L; Kommoss S; Konecny G; Gorringe K; Modugno F; Park S; Pharoah P; Staebler A; Sundfeldt K; Thorne H; Wu A; DeFazio A; Friedlander M; Ramus S, 2021, 'Pattern of invasion in stage I mucinous ovarian cancer is prognostic within 2-years of diagnosis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2021

Ngoi NYL; Tan TZ; Kuay KT; Tan ACY; Lee JY; Pang MY; Tham KW; Chan J; Wong WL; Chay WY; Anne D; Friedlander M; Varma S; Meniawy T; Au-Yeung G; Scott C; Mileshkin L; Bowtell D; Huang RY-J; Tan DSP, 2021, 'Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S736 - S736, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1179

Conference Abstracts | 2021

Pavanello M; Chiew Y-E; Mapagu C; Srirangan S; Nevins N; Bouantoun N; Pattnaik S; Gao B; Kennedy CJ; Boros J; Provan P; Friedlander M; Samimi G; Brand A; Marsh DJ; Beale P; Anderson L; Bowtell DDL; Balleine RL; Harnett PR; DeFazio A, 2021, 'Cyclin E1 (CCNE1) gene amplification assessment in prospectively recruited ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 67 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2021

Simon S; Francis K; Dalrymple J; Gebski V; Lord S; Friedlander M; Lee CK, 2021, 'Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S745 - S745, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1195

Conference Abstracts | 2021

Smith D; Robledo K; Yip S; Cummins M; Kok P-S; Lee YC; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Lombard JM; Spurdle AB; Andrews J; Stockler MR; Mileshkin LR; Antill YC, 2021, 'Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5584

Conference Papers | 2021

Wildiers H; Ayoub J-P; Friedlander M; Kaufman B; Arun BK; Han HS; Puhalla SL; Maag D; Feng D; Ratajczak CK; Bach BA; Diéras V, 2021, 'Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ps11-03

Conference Abstracts | 2021

Woodford R; Zhou D; Kok P-S; Lord S; Marschner I; Friedlander M; Lee CK, 2021, 'The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1516

Conference Papers | 2021

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Kobel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263503257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2021

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, http://dx.doi.org/10.1158/1538-7445.am2021-1045

Conference Abstracts | 2020

Aghajanian C; Bookman MA; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Sullivan DM; Fallstrom M; Dinh M; Ratajczak C; Coleman RL, 2020, 'PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302501&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Ayoub J-P; Friedlander ML; Dieras VC; Wildiers H; Arun B; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Kundu MG; Wu M; Ratajczak C; Maag D; Kaufman B, 2020, 'Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S65 - S65, presented at ESMO Breast Cancer Virtual Meeting, ELECTR NETWORK, 23 May 2020 - 24 May 2020, http://dx.doi.org/10.1016/j.annonc.2020.03.241

Conference Papers | 2020

Banerjee S; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; Gonzalez Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; DiSilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S613 - S613, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.950

Conference Papers | 2020

Colombo N; Bradley W; Moore K; Gonzalez-Martin A; Scambia G; Oaknin A; Friedlander M; Lowe E; Rowe P; Disilvestro P, 2020, 'MAINTENANCE OLAPARIB IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: SUBGROUP ANALYSIS BY RISK IN THE PHASE III SOLO1 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A76 - A77, http://dx.doi.org/10.1136/ijgc-2020-ESGO.130

Conference Abstracts | 2020

Dieras V; Arun B; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla S; Hudgens S; Floden L; Khandelwal N; Benjamin K; Kamalakar R; Maag D, 2020, 'Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S348 - S349, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.376

Conference Papers | 2020

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; Disilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1334 - S1334, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.228

Conference Abstracts | 2020

Han HS; Arun B; Kaufman B; Wildiers H; Friedlander M; Ayoub J-PM; Puhalla SL; Bach BA; Dudley M; Kundu MG; Maag D; Ratajczak C; Dieras V, 2020, 'Veliparib (V) monotherapy (monoTx) following combination therapy with V plus carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2020

Jones T; Spence R; Sandler C; Obermair A; Friedlander M; Mileshkin L; Davis A; Janda M; Eakin E; Barnes E; Beesley V; Gordon L; Brand A; Hayes S, 2020, 'Are The ACSM Exercise Guidelines Safe And Achievable For Women Receiving Chemotherapy For Ovarian Cancer?', in MEDICINE & SCIENCE IN SPORTS & EXERCISE, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 52, pp. 483 - 484, presented at 67th Annual Meeting of the American-College-of-Sports-Medicine (ACSM), ELECTR NETWORK

Conference Abstracts | 2020

Kaufman B; Han H; Arun B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla S; Maag D; Feng D; Fages S; Dieras VC, 2020, 'Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S374 - S374, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.427

Conference Abstracts | 2020

Li T; Timmins H; McCrary J; Trinh T; Friedlander M; Horvath L; Kiernan M; Goldstein D; Park S, 2020, 'Patient reported outcome scores used in chemotherapy-induced peripheral neuropathy: Defining minimal important differences', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, ELECTR NETWORK, Vol. 25, pp. 481 - 481, presented at Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK

Conference Papers | 2020

Macdonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper J; Friedlander M; Emery J; Phillips KA, 2020, 'The cognitive, affective, social and environmental drivers of inappropriate ovarian cancer screening: A survey of women and their clinicians using the theoretical domains framework', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S958 - S958, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.2057

Conference Papers | 2020

Meiser B; Gleeson M; Kentwell M; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill Y; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker K, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 62 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2020

O'Malley DM; Bookman MA; Moore KN; Fleming GF; Brady MF; Swisher EM; Aghajanian C; Steffensen KD; Friedlander M; Okamoto A; Spirtos NM; Shahin MS; Reid TJ; Sullivan DM; Sehgal V; Ansell PJ; Dinh MH; Coleman RL, 2020, 'Anti-tumor activity of veliparib during combination phase with chemotherapy in velia study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, Vol. 159, pp. 52 - 53, http://dx.doi.org/10.1016/j.ygyno.2020.06.110

Conference Abstracts | 2020

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon T-W; Sonke GS; Lisyanskaya AS; Kim J-H; Abdo Filho E; Vergote I; Rowe P; Pujade-Lauraine E, 2020, 'Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302431&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2020

Puhalla SL; Dieras V; Arun B; Kaufman B; Wildiers H; Han HS; Ayoub J-PM; Stearns V; Yuan Y; Helsten TL; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak C; Ramathal C; Friedlander M, 2020, 'Veliparib (V) monotherapy after progression on placebo (PL) plus carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368300315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Sivakumaran T; Krasovitsky M; Freimund A; Chen Lee K; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, '402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, pp. A166.2 - A167, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.347

Conference Abstracts | 2020

Sivakumaran T; Krasovitsky M; Freimund A; Lee KC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, 'TREATMENT PATTERNS POST PARP INHIBITOR IN EPITHELIAL OVARIAN CANCER PATIENTS: RESULTS FROM AN AUSTRALIAN, RETROSPECTIVE, MULTI-INSTITUTE COHORT STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 30, pp. A166 - A167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000616549600346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2020

Sivakumaran T; Krasovitsky M; Lee YC; Norris C; Friedlander M, 2020, '403 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, pp. A167.1 - A167, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.348

Conference Papers | 2020

Swisher EM; Coleman RL; Bookman MA; Brady MF; Fleming GF; Friedlander M; Cunningham MJ; Tewari KS; Edraki B; Moxley K; Mantia-Smaldone GM; Ratajczak C; Dinh MH; Sullivan DM; McClain S; Okubo S; Steffensen KD; Aghajanian C, 2020, 'Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 20 - 21, http://dx.doi.org/10.1016/j.ygyno.2020.06.040

Conference Papers | 2020

Yoon W-H; Kok PS; Marschner I; Lord S; Friedlander M; Lee CK, 2020, 'Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S715 - S715, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1162

Conference Abstracts | 2019

Antill Y; Kok PS; Stockler MR; Robledo K; Yip S; Parry M; Smith D; Spurdle A; Barnes E; Friedlander ML; Baron-Hay S; Shannon C; Coward J; Beale J; Goss G; Meniawy T; Andrews J; Kelly M; Mileshkin L, 2019, 'Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700534&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Antill YC; Kok PS; Robledo K; Barnes E; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Yip S; Smith D; Spurdle AB; Parry M; Andrews J; Kelly M; Stockler MR; Mileshkin LR, 2019, 'Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5501

Conference Papers | 2019

Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bach BA; Dudley M; Ratajczak CK; Maag D; Dieras V, 2019, 'First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-PD4-01

Conference Abstracts | 2019

Beesley VL; Ross TL; Na NR; Sivakumaran T; Au-Yeung G; Nagle CM; deFazio A; Grant P; Obermair A; Friedlander M; Webb P, 2019, 'Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 82 - 83, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Coleman RL; Fleming GF; Brady MF; Swisher E; Steffensen KD; Friedlander M; Okamoto A; Moore K; Ben-Baruch N; Werner TL; Oaknin A; Nam J-H; Leath CA; Nicum S; Cella D; Sullivan DM; Ansell PJ; Dinh M; Aghajanian C; Bookman MA, 2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 895 - 896, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Colombo N; Moore KN; Scambia G; Oaknin A; Friedlander M; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley WH; Kim J-W; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5539

Conference Papers | 2019

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in Clinical Trials, American Association for Cancer Research, pp. CT084 - CT084, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct084

Conference Abstracts | 2019

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-CT084

Conference Abstracts | 2019

Dieras VC; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palacova M; Park YH; Shparyk Y; Yanez E; Dudley M; Ratajczak CK; Maag D; Arun BK, 2019, 'Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 857 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019

Conference Abstracts | 2019

Friedlander M; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley WH; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5551

Conference Abstracts | 2019

Friedlander ML; Hettle R; Parkhomenko E, 2019, 'Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700218&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; DiSilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Friedlander ML; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; Disilvestro P, 2019, 'Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SINGAPORE, Singapore, Vol. 30, presented at European-Society-for-Medical-Oncology (ESMO) Asia Congress, SINGAPORE, Singapore, 22 November 2019 - 24 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000503487700217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2019

Friedlander ML, 2019, 'Do all patients with recurrent ovarian cancer need systemic therapy?', in Cancer, pp. 4602 - 4608, http://dx.doi.org/10.1002/cncr.32476

Conference Abstracts | 2019

Kok PS; Yoon W-H; Marschner I; Lord SJ; Friedlander M; Lee CK, 2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 520 - 520, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2019

Mathews CA; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley WH; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5541

Conference Abstracts | 2019

Mizrahi D; Trinh T; Au K; Timmins HC; Li T; McCrary JM; Friedlander M; Grimison P; Park SB; Goldstein D, 2019, 'Does physical activity participation associate with the degree of chemotherapy-induced peripheral neuropathy after neurotoxic treatment?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 179 - 179, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2019

Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'MAINTENANCE OLAPARIB AFTER PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: EFFICACY BY THE TIMING OF SURGERY AND RESIDUAL TUMOUR STATUS FOLLOWING UPFRONT OR INTERVAL CYTOREDUCTIVE SURGERY IN THE PHASE III SOLO1 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A14 - A15, http://dx.doi.org/10.1136/ijgc-2019-ESGO.17

Conference Abstracts | 2019

Oaknin A; Moore K; Colombo N; Scambia G; Kim B-G; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 405 - 405, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019

Conference Papers | 2019

Piskorz A; Robertson D; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; McNeish IA; Swisher E; Wason J; Brenton JD, 2019, 'Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1557-3265.ovcasymp18-gmm-048

Conference Abstracts | 2019

Poveda A; Sackeyfio A; Friedlander M, 2019, 'MAINTENANCE OLAPARIB FOR BRCA-MUTATED OVARIAN CANCER (OC) PATIENTS IN 1ST LINE AND PLATINUM-SENSITIVE RELAPSED (PSR) SETTINGS: MAXIMIZING TREATMENT OPPORTUNITIES', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, Vol. 29, pp. A133 - A133, http://dx.doi.org/10.1136/ijgc-2019-IGCS.321

Conference Abstracts | 2019

Roncolato F; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sehouli J; Ledermann JA; Berton-Rigaud D; Kiely BE; Friedlander M; Stockler MR, 2019, 'How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5549

Conference Abstracts | 2019

Scott C; Lee CK; Lee YC; Friedlander M; Hollis S; Diamante K; Davies C; Stockler M; Plebanski M, 2019, 'SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 160 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400250&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2019

Sun Y; Friedlander M, 2019, 'One-shot atomic detection', in 2019 IEEE 8TH INTERNATIONAL WORKSHOP ON COMPUTATIONAL ADVANCES IN MULTI-SENSOR ADAPTIVE PROCESSING (CAMSAP 2019), IEEE, FRANCE, Guadeloupe, pp. 1 - 5, presented at 8th IEEE International Workshop on Computational Advances in Multi-Sensor Adaptive Processing (CAMSAP), FRANCE, Guadeloupe, 15 December 2019 - 18 December 2019, http://dx.doi.org/10.1109/camsap45676.2019.9022441

Conference Papers | 2018

Antill Y; Barlow-Stewart K; Friedlander M; Meiser B; Do J; Nevin S; Gleeson M; Kentwell M; Tucker K; Taylor N; Kirk J, 2018, 'Changing a nation: The development and evaluation of a training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 202 - 203, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471153100137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Banerjee SN; Tang M; O'Connell R; Clamp AR; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Edmondson RJ; Friedlander M, 2018, 'PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5524

Conference Abstracts | 2018

Beesley VL; Webber K; Nagle C; Grant P; DeFazio A; Obermair A; Friedlander M; Webb PM, 2018, 'When will i feel normal again? Exploring the trajectories and predictors of patient-reported outcomes after completion of primary therapy for ovarian cancer', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018

Conference Papers | 2018

Friedlander M; Chan JK; Java J; Armstrong DK; Markman M; Herzog TJ; Monk BJ; Backes FJ; Secord AA; Bonebrake AJ; Rose PG; Tewari KS; Mannel RS; Lentz SS; Geller MA; Copeland LJ, 2018, 'Characterization and predictors of long term (>= 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5556

Conference Papers | 2018

Friedlander M; King M; Nagle C; Obermair A; Grant PT; deFazio A; Webb PM, 2018, 'Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10062

Conference Abstracts | 2018

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett P; Millward M; Lundy J; Freimund AE; Norris C; Wu J; Paton V; Wang L; Gao B, 2018, 'A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 58 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett P; Millward M; Lundy J; Freimund AE; Norris C; Wu J; Paton V; Wang L; Gao B, 2018, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 25 January 2018 - 27 January 2018, http://dx.doi.org/10.1200/JCO.2018.36.5_suppl.48

Conference Abstracts | 2018

Friedlander M; Scott CL; Lindeman GJ; Gibbs E; Badger HD; Paterson RJ; Macnab L; Zdenkowski N; Kwan EM; Boyle FM; Lee CK, 2018, 'A Phase 1 Trial of Olaparib and Oral Metronomic. Cyclophosphamide in Patients with Metastatic BRCA-Associated Breast/Ovarian Cancers or Non-BRCA Associated Triple-Negative Breast Cancer/High Grade Serous Ovarian Cancers', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Goh JC; Baron-Hay S; Bonaventura T; Buck M; Dean A; Friedlander M; Gao B; Mileshkin L; Oehler MK; Steer C; Vi N; Goble S; Grechko N; Monk BJ; Kristeleit RS, 2018, 'ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 196 - 196, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200343&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2018

Hasenburg A; Harter P; Park-Simon T-W; Gropp-Meier M; Heitz F; Soergel P; Ataseven B; Friedlaender M; Hilpert F; Pujade-Lauraine E, 2018, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, Vol. 41, pp. 88 - 89, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424914300235&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Mileshkin L; Sivakumaran T; Grant P; Na L; Friedlander M; Webb P; Au-Yeung G, 2018, 'COMPARING THE IMPACT OF DOSE REDUCTIONS/ DELAYS ON OVARIAN CANCER OUTCOMES USING THREE WEEKLY OR DOSE DENSE CARBOPLATIN/ PACLITAXEL REGIMENS IN THE NATIONAL PROSPECTIVE OPAL COHORT', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 770 - 770, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471152401334&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, pp. 727 - 727, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277305017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii727, http://dx.doi.org/10.1093/annonc/mdy424.041

Conference Papers | 2018

Nayar N; Lawrence NJ; Stockler MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; McDermott R; Walker R; Winstanley M; Hanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC; Grimison PS, 2018, 'P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poorrisk metastatic germ cell tumors (GCTs).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.TPS574

Conference Abstracts | 2018

Oza AM; Cibula D; Oaknin A; Poole C; Mathijssen RHJ; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Pfisterer J; Plante M; Hanker LC; Fielding A; Haddad V; Chmielecki J; Friedlander M, 2018, 'Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii340, http://dx.doi.org/10.1093/annonc/mdy285.158

Conference Abstracts | 2018

Peate M; Jayasinghe Y; Gamage NR; Allingham C; Meiser B; Friedlander M; Hickey M, 2018, 'From development to implementation: The Australian experience of oncofertility decision aids', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 44 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2018

Peate M; Patterson T; Girgis A; Friedlander M; Durcinoska I; Hickey M; Sousa MS, 2018, 'Genitourinary and sexual health after breast cancer: The role of breast care nurses in providing support and care', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 184 - 185, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2018

Piskorz A; Robertson D; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; McNeish IA; Swisher E; Wason J; Brenton JD, 2018, 'CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, WA, Seattle, Vol. 25, pp. 112 - 112, presented at 12th Rivkin-Centre Biennial Ovarian Cancer Research Symposium, WA, Seattle, 13 September 2018 - 15 September 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000497337700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2018

Sackeyfio A; Nussey F; Friedlander M; Pujade-Lauraine E, 2018, 'Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 43 - 44, http://dx.doi.org/10.1016/j.ygyno.2018.04.094

Conference Abstracts | 2018

Sackeyfio A; Santi I; Friedlander M, 2018, 'EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 21, pp. S73 - S73, http://dx.doi.org/10.1016/j.jval.2018.09.429

Conference Papers | 2018

Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, pp. 28 - 28, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018

Conference Papers | 2018

Sandhu SK; Hill AG; Gan HK; Friedlander M; Voskoboynik M; Barlow P; Townsend AR; Song J; Zhang Y; Shen Z; Qi Q; Desai J, 2018, 'Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.445

Conference Papers | 2018

Sivakumaran T; Mileshkin LR; Grant PT; Friedlander M; Webb PM; Au-Yeung G, 2018, 'Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5568

Conference Papers | 2018

Sjoquist KM; Mileshkin LR; Ananda S; Shannon CM; Bowtell D; Yip S; Espinoza D; Goh JC; Harrison ML; Plebanski M; Gebski V; Stockler MR; Livingstone K; Tang M; Friedlander M, 2018, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10097

Conference Papers | 2018

Vergote I; Hanker LC; Floquet A; Rau J; Kim J-W; Izquierdo EO; Friedlander M; Pignata S; Fujiwara K; Colombo N; Mirza MR; Monk BJ; Moertl M; Calvert P; Herzog TJ; Jackisch C; Meunier J; Lee J-Y; Belau AK; Du Bois A, 2018, 'AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer-Overall survival (OS) results', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5518

Conference Papers | 2018

Webb PM; Beesley V; Nagle C; Grant PT; deFazio A; Obermair A; Friedlander M, 2018, 'When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.172

Conference Papers | 2018

Webb PM; Beesley V; deFazio A; Obermair A; Grant PT; Nagle C; Friedlander M, 2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.155

Conference Papers | 2018

Webb PM; Beesley V; deFazio A; Obermair A; Grant PT; Nagle CM; Friedlander M, 2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10081

Conference Papers | 2018

Webb PM; deFazio A; Obermair A; Grant PT; Friedlander M; Beesley V; Nagle C, 2018, 'The Ovarian cancer Prognosis And Lifestyle (OPAL) study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.88

Conference Papers | 2018

Wilson MK; Chawla T; Wang L; Friedlander M; Oza AM; Lheureux S, 2018, 'Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5555

Conference Papers | 2017

Desai J; Gan H; Barrow C; Jameson MB; Solomon B; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Gibbs D; Parente P; Yang J; Wang L; Chen Y; Luo L, 2017, 'A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-CT002

Conference Abstracts | 2017

Friedlander M; Gebski V; Gibbs E; Bloomfield R; Hilpert F; Wenzel LB; Joly F; Eek D; Rodrigues M; Clamp A; Penson R; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Pujade-Lauraine E, 2017, 'HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1941 - 1941, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Friedlander M; Gebski V; Gibbs E; Bloomfield R; Hilpert F; Wenzel LB; Joly F; Eek D; Rodrigues M; Clamp AR; Penson RT; Provencher DM; Korach J; Huzarski T; Vidal L; Salutari V; Scott CL; Nicoletto MO; Tamura K; Pujade-Lauraine E, 2017, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5507

Conference Abstracts | 2017

Friedlander M; Gourley C; Matulonis U; Shirinkin V; Selle F; Scott C; Safra T; Fielding A; Rowe P; Ledermann JA, 2017, 'CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1942 - 1943, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205226&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett PR; Millward M; Lundy J; Freimund AE; Norris C; Mu S; Wu J; Paton VE; Wang L; Gao B, 2017, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.3013

Conference Papers | 2017

Friedlander M; Pujade-Lauraine E; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Colombo N, 2017, 'Treatment with Maintenance Olaparib Significantly Improves Progression-Free Survival in Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Results of SOLO2 Study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 51 - 51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427542700014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Grimison PS; Lawrence NJ; Stockier MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; Walker R; Winstanley M; Nanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC, 2017, 'P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.TPS4592

Conference Papers | 2017

Heinzelmann-Schwarz VA; Russell K; Omar S; Schoetzau A; Hoeck K; Vetter M; Fink DA; Friedlander M; Hacker NF, 2017, 'Should MMMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5563

Conference Abstracts | 2017

Hettle R; Sackeyfio A; Gill J; Siddiqui K; Nussey F; Friedlander M, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 300 MG TABLETS BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088

Conference Papers | 2017

Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M, 2017, 'Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer', in European Journal of Cancer, pp. 133 - 138, http://dx.doi.org/10.1016/j.ejca.2017.03.019

Conference Papers | 2017

Ledermann JA; Embleton AC; Perren T; Jayson GC; Rustin GJS; Kaye SB; Hirte HW; Oza AM; Vaughan MM; Friedlander M; Martin AG; Clark E; Popoola B; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB, 2017, 'Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5506

Conference Abstracts | 2017

Meagher NS; deFazio A; Russell K; Voss A; Ramus SJ; Friedlander ML, 2017, 'Mucinous Ovarian Cancers of Uncertain Primary (MO-CUP) - Does the Site of Origin Really Matter?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 73 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Peate M; Jayasinghe Y; Allingham C; Hucker A; Kemertzis M; Meiser B; Friedlander M; Hickey M, 2017, 'Supporting fertility decision-making: the role of decision aids in oncofertility.', in PSYCHO-ONCOLOGY, WILEY, pp. 166 - 166, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407688900459&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Penson R; Kaminsky-Forrett M-C; Ledermann J; Brown C; Plante M; Korach J; Huzarski T; Lista AGDL; Pisano C; Friedlander M; Colombo N; Gropp-Meier M; Nakai H; Sonke GS; Kim J-W; Vergote I; Allen A; Pujade-Lauraine E, 2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324002120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Piskorz A; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Rosenfeld N; Raponi M; McNeish IA; Swisher E; Brenton JD, 2017, 'Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. AP27 - AP27, http://dx.doi.org/10.1158/1557-3265.ovcasymp16-ap27

Conference Papers | 2017

Pujade-Lauraine E; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N, 2017, 'Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 219 - 220, http://dx.doi.org/10.1016/j.ygyno.2017.03.505

Conference Papers | 2017

Ritchie G; Gasper H; Man J; Lord S; Friedlander M; Lee C; Marschner I, 2017, 'is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2017

Rohr I; Hilpert V; Heitz F; Fehm T; Canzler U; Friedlander M, 2017, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS ≥3) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)', in Geburtshilfe und Frauenheilkunde, Georg Thieme Verlag KG, presented at Jahrestagung der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) gemeinsam mit der Bayerischen Gesellschaft für Geburtshilfe und Frauenheilkunde e.V (BGGF), 14 June 2017 - 17 June 2017, http://dx.doi.org/10.1055/s-0037-1602307

Conference Papers | 2017

Roncolato F; Joly F; O'Connell R; Lanceley A; Heitz F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan PP; Oza AM; AvalI-Lundqvist E; Berek JS; Hilpert F; Feeney A; Roemer-Becuwe C; Stockier MR; King MT; Friedlander M, 2017, 'Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had >= 3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5575

Conference Abstracts | 2017

Sackeyfio A; Gill J; Hettle R; Siddiqui K; Friedlander M; Ledermann JA, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087

Conference Papers | 2017

Wong N; Nayar N; Lawrence N; Stockler M; Martin A; Yip S; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn D; Walker R; Winstanley M; Weickhardt A; Hanning F; Stevanovic A; Davis I; Toner G; Grimison P, 2017, 'P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 168 - 168

Conference Papers | 2016

Desai J; Markman B; Sandhu SK; Gan HK; Friedlander M; Tran B; Meniawy T; Boolell V; Colyer D; Norris C; Ameratunga M; Yang J; Li K; Wang L; Luo L; Qin Z; Millward M, 2016, 'A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.3066

Conference Papers | 2016

Dieras V; Han HS; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Puhalla S; Isakoff SJ, 2016, 'Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 39th San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-P4-22-02

Conference Papers | 2016

Grimison PS; Stockler MR; Martin AJ; Buizen L; Lawrence NJ; Thomson DB; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16056

Conference Papers | 2016

Grunewald T; Tang M; Chen J; Lord S; Friedlander M; Lee CK, 2016, 'Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5559

Conference Papers | 2016

Han HS; Dieras V; Robson ME; Palacova M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Man BK; Ratajczak C; Coates A; Bonnet P; Qin Q; Qian J; Giranda VL; Shepherd SP; Isakoff SJ; Puhalla S, 2016, 'Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 39th San Antonio Breast Cancer Symposium, TX, San Antonio, 06 December 2016 - 10 December 2016, http://dx.doi.org/10.1158/1538-7445.SABCS16-S2-05

Conference Papers | 2016

Hickey M; Sousa MS; Peate M; Jarvis S; Friedlander M, 2016, 'SHORT-TERM FINDINGS OF THE PEGASUS STUDY: GENITOURINARY SYMPTOMS, SEXUALITY AND QUALITY OF LIFE IN BREAST CANCER SURVIVORS ON ENDOCRINE THERAPY - WHAT ARE WE MISSING?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 71 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2016

Hipert F; Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King M, 2016, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3) - GCIG Symptom Benefit Study (AGO PRO1).', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, pp. 138 - 139, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000371353700449&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2016

Lawrence N; Grimison P; Stockler M; Martin A; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Toner G, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL (3033)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380005100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2016

Lawrence N; Martin A; Toner G; Stockler M; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Grimison P, 2016, 'LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380004900011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2016

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei DE; Fielding A; Spencer S; Rowe P; Lowe ES; Matulonis UA, 2016, 'Overall survival (OS) in patients (pts) with platinum sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5501

Conference Papers | 2016

Lee YC; Milne RL; Smith C; Picken S; Camm S; McLachlan S-A; Friedlander M; Hopper JL; Phillips K-A, 2016, 'Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.1529

Conference Papers | 2016

Mercieca-Bebber R; Calvert MJ; Kok P-S; Friedlander M; Kyte DG; Stockler M; King M, 2016, 'Does the patient-reported outcome (PRO) content of protocols impact PRO completion rates and the standard of reporting? A review of international ovarian cancer randomized controlled trials (RCTs)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 119 - 119, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600288&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2016

Mileshkin LR; Edmondson RJ; O'Connell R; Sjoquist KM; Cannan D; Jyothirmayi R; Beale PJ; Bonaventura T; Goh JC; Hall M; Clamp AR; Green JA; Lord R; Scurry J; Friedlander M, 2016, 'Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial-ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5520

Conference Papers | 2016

Piskorz A; Lin KK; Morris JA; Mann E; Oza AM; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Raponi M; McNeish IA; Swisher EM; Brenton JD, 2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5549

Conference Papers | 2016

Piskorz AM; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; Raponi M; McNeish IA; Swisher E; Brenton JD, 2016, 'Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, GERMANY, Munich, pp. S123 - S123, presented at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, GERMANY, Munich, 29 November 2016 - 02 December 2016, http://dx.doi.org/10.1016/S0959-8049(16)32966-5

Conference Papers | 2016

Roncolato F; Gibbs E; Lee C; Davies LC; Gebski V; Friedlander M; Hilpert F; Wenzel LB; Stockler MR; King MT; Pujade-Lauraine E, 2016, 'Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5575

Conference Papers | 2016

Roncolato F; O'Connell R; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Stockler MR; King MT; Friedlander M, 2016, 'Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.5508

Conference Papers | 2016

Wenzel L; King M; Lee C; Kirby A; Friedlander M; Hilpert F; Stockler M; Gelski V, 2016, 'Relationship between distress and survival in women with platinum-resistant ovarian cancer (PROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398451600301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Banerjee S; Ledermann J; Matulonis U; Molife LR; Friedlander M; Fielding A; Robertson JD; Spencer S; McMurtry E; Kaye S, 2015, 'Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, pp. S550 - S550, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31525-8

Conference Papers | 2015

Beale P; O'Connell R; Sjoquist K; Martyn J; Cannon D; Bonaventura T; Grant P; Goh J; Antill Y; Friedlander M; Scurry J, 2015, 'PARAGON-AN ANZGOG PHASE 2 STUDY OF ANASTRAZOLE IN ASYMPTOMATIC WOMEN WITH ESTROGEN (ER)/PROGESTERONE (PR) POSITIVE OVARIAN CANCER WITH A CA125 PROGRESSION AFTER FIRST LINE TREATMENT', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 118 - 118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Debernardo R; Mahdi H; Russell K; Xiu J; Millis SZ; Reddy SK; Friedlander M, 2015, 'Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5595

Conference Papers | 2015

Domchek SM; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmana J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B, 2015, 'Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5529

Conference Papers | 2015

Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2015, 'Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5540

Conference Papers | 2015

Friedlander M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; King MT, 2015, 'IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING >= 3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 111 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800146&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Friedlander M; Stockler MR; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; King MT, 2015, 'Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5536

Conference Papers | 2015

Huggins-Puhalla SL; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shah M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Breast Cancer Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 25 September 2015 - 27 September 2015, http://dx.doi.org/10.1200/jco.2015.33.28_suppl.155

Conference Papers | 2015

King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Butow P; Friedlander M; Gillies K; Martyn J, 2015, 'VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 457 - 458, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377145701081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

King M; Stockler M; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Buizen L; Sjoquist K; Gillies K; Butow P; Friedlander M, 2015, 'Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. 22 - 23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361991100056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Lawrence N; Toner G; Martin A; Stockler M; Yeung A; Wong N; Thomson D; Gebski V; Yip S; King M; Friedlander M; Quinn D; Tan TH; Chan H; Hanning F; Weickhardt A; Jeffery M; Stevanovic A; Hovey E; Wyld D; Davis I; Grimison P, 2015, 'A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS: THE P3BEP TRIAL (ANZUP 1302)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 146 - 147, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800237&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Lee C; Gibbs E; Roncolato FT; Davies LC; Le Maignan C; Meier W; Lanza MAA; Rosenberg P; Marchetti C; Vergote I; Witteveen P; Bamias A; Serra S; Provencal J; De Rauglaudre G; Gebski V; Friedlander M; Pujade-Lauraine E, 2015, 'Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5547

Conference Papers | 2015

Matulonis U; Friedlander M; Du Bois A; Gourley C; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; McMurtry E; Spencer S; Mann H; Parry D; Ledermann JA, 2015, 'Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5550

Conference Papers | 2015

Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Fielding A; Spencer S; Parry D; Ledermann JA, 2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 8 - 8, http://dx.doi.org/10.1016/j.ygyno.2015.01.015

Conference Papers | 2015

Phillips K-A; Collins IM; Milne RL; Fisher R; Stern C; Kannemeyer G; Smith C; Friedlander M; McLachlan S-A; Hickey M; Hopper JL, 2015, 'Do women with BRCA1 or BRCA2 mutations have reduced ovarian reserve?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.1537

Conference Papers | 2015

Puhalla S; Han HS; Dieras V; Friedlander M; Somlo G; Arun B; Wildiers H; Kaufman B; Ayoub J-PM; Shan M; Burmedi D; Qin Q; Qian J; Giranda VL; Shepherd SP, 2015, 'Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1102

Conference Papers | 2015

Rafii S; Gourley C; Ang JE; Kumar R; Geuna E; Rye T; Ashcroft L; Powell B; Shapira-Frommer R; Friedlander M; Chen L-M; Matulonis U; Kaufman B; De Greve J; Oza AM; Banerjee SN; Gore ME; Molife LR; Kaye SB; Yap TA, 2015, 'What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5546

Conference Papers | 2015

Roncolato F; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Sjoquist K; Gillies K; Butow P; Stockler M; King M; Friedlander M; Kok P-S, 2015, 'BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING >= 3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 125 - 125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2015

Roncolato FT; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sjoquist KM; Gillies K; Butow P; Stockler MR; King MT; Friedlander M, 2015, 'Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5564

Conference Papers | 2015

Segelov E, 2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015

Conference Papers | 2014

Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2014, 'COMPARISON OF OVARIAN AND RENAL CLEAR CELL CARCINOMA BY COMPREHENSIVE TUMOR PROFILING', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 148 - 148, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500123&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Friedlander M; Russell K; Millis SZ; Gatalica Z; Voss A, 2014, 'Molecular profiling of clear cell ovarian carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5516

Conference Papers | 2014

Friedlander M; Sjoquist KM; Beale P; Sommeijer DW; Mileshkin L; Martyn J; McNally O; O'Connell R; Grant P; Hadley A; Gillies K; Goh J; Bonaventura A, 2014, 'PARAGON (ANZGOG0903): PHASE 2 STUDY OF ANASTROZOLE IN WOMEN WITH ESTROGEN(ER)/PROGESTERONE (PR) POSITIVE PLATINUM RESISTANT/REFRACTORY RECURRENT OVARIAN CANCER (PRROC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 38 - 38, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Friedlander M; Stockier MR; Butow PN; Oza AM; O'Connell R; Martyn J; Glilles K; Sjoquist KM; King M, 2014, 'Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5615

Conference Papers | 2014

Hadley AM; Ryland G; Christie M; Antill Y; Bae S; Hunter S; Lipton L; Boussioutas A; Bowtell D; Jobling T; Friedlander M; Fox S; DeFazio A; Wakefield M; Campbell I; Gorringe K; Pyman J; Scott CL; Ananda S, 2014, 'HIGH-GRADE MUCINOUS OVARIAN CANCER: CLINICAL AND MOLECULAR ANNOTATION OF A RARE CANCER, ORIGINS AND THERAPEUTIC POTENTIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 426 - 427, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500300&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; King K; Stinnett S; Barrett C; Jobanputra M; Chun-Fang X; du Bois A, 2014, 'BRCA1/2 MUTATIONS ASSOCIATED WITH PROGRESSION FREE SURVIVAL IN OVARIAN CANCER PATIENTS WHO RECEIVED PAZOPANIB OR PLACEBO IN THE AGO-OVAR16 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Presentations | 2014

Hayes S; Friedlander M; Obermair A; Mileshkin L; Janda M; Gordon L; Barnes E; Beesley V; Eakin E; Sommeijer D; Martyn J; Stockler M; Gebski VAL; Naumann F; Schmitz K; Webb P, 2014, 'EXERCISE DURING CHEMOTHERAPY FOR OVARIAN CANCER (ECHO): STUDY DESIGN FEATURES AND OUTCOMES OF A CANCER AUSTRALIA AND CANCER COUNCIL AUSTRALIA FUNDED RANDOMISED, CONTROLLED TRIAL', Vol. 24, pp. 200 - 201, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500161&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Inglis H; Boyle F; Friedlander M; Watson S, 2014, 'DRY EYES & AIS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 33 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Inglis H; Boyle F; Friedlander M; Watson S, 2014, 'DRY EYES & AIS', in CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, WILEY-BLACKWELL, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344530600094&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Inglis H; Friedlander M; Watson SL, 2014, 'Dry Eyes and AIs', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433199700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 20 - 20, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Lheureux S; Ledermann J; Kaye S; Gourley C; Friedlander M; Bowtell D; De Greve J; DeFazio A; Frommer R; De Bono JS; Audeh MW; Kohn E; Alsop K; Scott C; Matulonis U; Kaufman B; Burger B; Robertson J; Ho T; Oza A, 2014, 'A PILOT INTEGRATED ANALYSIS OF LONG-TERM BENEFIT OF OLAPARIB IN OVARIAN CANCER: RESULTS OF FEASIBILITY TESTING.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 141 - 142, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Lheureux S; Ledermann JA; Kaye SB; Gourley C; Friedlander M; Bowtell D; De Greve J; deFazio A; Shapira-Frommer R; De Bono JS; Audeh MW; Kohn EC; Alsop K; Scott CL; Matulonis U; Kaufman B; Burger B; Robertson JD; Ho T; Oza AM, 2014, 'Characterization of ovarian cancer long-term responders on olaparib.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5534

Conference Papers | 2014

Long A; Sommeijer D; Roncolato F; King M; Brundage M; Stockler M; Friedlander M, 2014, 'QUALITY OF REPORTING OF PATIENT RATED OUTCOMES IN OVARIAN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEW', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Long A; Toner GC; Stockler M; Thompson DB; Gebski V; Yip S; King M; Friedlander M; Quinn D; Singhal N; Roncolato F; Grimison PS, 2014, 'THE ANZUP PHASE 3 ACCELERATED BEP TRIAL: A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Mileshkin L; Sjoquist KM; Sommeijer DW; Cannan D; Martyn J; Gillies K; O'Connell R; Gebski V; Sykes P; Blomfield P; Beale P; Quinn M; Lombard J; Hadley A; Grant P; Antill Y; Stockler M; Amant F; Edmondson RJ; Friedlander M, 2014, 'PARAGON- PHASE II STUDY OF AROMATASE INHIBITORS IN WOMEN WITH POTENTIALLY HORMONE RESPONSIVE RECURRENT/METASTATIC GYNAECOLOGICAL NEOPLASMS: ANZGOG 0903', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 167 - 167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Mileshkin LR; Narayan K; Moore KN; Rischin D; King M; Kolodziej I; Marlyn J; Friedlander M; Quinn M; Small W; Thomas G; Fyles AW; Gebski V; Stockier MR, 2014, 'A phase III trial of adjuvant chemotherapy following chemoradialion as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/G0G0274/RTOG1174).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358613202170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Ryland G; Hadley A; Wakefield M; Hunter S; Antill Y; Ananda S; Bae S; Lipton L; Boussioutas A; Friedlander M; Liauw W; Fox S; DeFazio A; Bowtell D; Christie M; Pyman J; Scott C; Campbell I; Gorringe K, 2014, 'GAMUT - GENOMIC ANALYSIS OF MUCINOUS TUMOURS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 129 - 130, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Sjoquist KM; Friedlander M; Mileshkin LR; Quinn M; Goh JC; Shannon CM; Bovdell D; Plebanskl M; Yip S; Canton K; Gillies K; Martyn J; Gebski V, 2014, 'The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab no patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5627

Conference Papers | 2014

Sjoquist KM; Sommelier DW; Lombard JM; Mileshkin LR; Beale PJ; Grant PT; Blomfield P; Quinn M; Hadley AM; Sykes P; Antill YC; O'Connell R; Martyn J; Gillies K; Cannan D; Gebski V; Stockier MR; Edmondson RJ; Amant F; Friedlander M, 2014, 'The PARAGON phase 2 trial of anastrozole us women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5621

Conference Papers | 2014

Sousa M; Meiser B; Hickey M; Jarvis S; Lombard J; Chirgwin J; Segelov E; Friedlander M, 2014, 'PEGASUS - Prevalence and severity of genitourinary symptoms and impact on sexual function and quality of life in postmenopausal women receiving adjuvant endocrine therapy for early stage breast cancer - A prospective study', in MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, LIPPINCOTT WILLIAMS & WILKINS, DC, Washington, pp. 1364 - 1364, presented at 25th Annual Meeting of the North-American-Menopause-Society, DC, Washington, 15 October 2014 - 18 October 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345846600165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2014

Wuttke M; Milne R; Weideman P; Picken S; Smith C; Friedlander M; McLachlan S-A; Hopper JL; Phillips K-A, 2014, 'Breast cancer screening by women from BRCA1 & BRCA2 mutation positive families', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2014 - 13 December 2014, http://dx.doi.org/10.1158/1538-7445.SABCS14-P3-02-03

Conference Papers | 2014

Wuttke M; Milne R; Weideman P; Picken S; Smith C; Friedlander M; McLachlan S; Hopper JL; Phillips K, 2014, 'OVARIAN CANCER SCREENING BY AUSTRALIAN WOMEN FROM FAMILIES WITH BRCA1 OR BRCA2 MUTATIONS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 223 - 224, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Butow P; Price M; Bell M; Fardell J; Aldridge L; McGowan N; Fazio A; Friedlander M; Webb P, 2013, 'Quality of Life, Distress and Coping in Women With Ovarian Cancer: A Population Based, Longitudinal Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 44 - 44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Butow P; Price M; Bell M; Webb P; deFazio A; Friedlander M, 2013, 'CARING FOR WOMEN WITH OVARIAN CANCER IN THE LAST YEAR OF THEIR LIFE: IMPACT ON THE CAREGIVER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 103 - 103, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Campbell I; Hunter S; Mathew W; Antill Y; Bae S; Ananda S; Topp M; Lipton L; Liauw W; Jobling T; Boussioutas A; Christie M; Allan P; Friedlander M; Fox S; Defazio A; Bowtell D; Pyman J; Scott C; Gorringe K, 2013, 'Mucinous ovarian tumors: Are they all the same?', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1078-0432.OVCA13-A3

Conference Papers | 2013

Collins I; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman P; Birch KE; Hopper JL; Phillips K-A, 2013, 'DO BRCA1 AND BRCA2 MUTATION CARRIERS HAVE EARLIER NATURAL MENOPAUSE THAN THEIR NON-CARRIER RELATIVES?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 54 - 54, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Collins I; Milne RL; Weideman P; McLachlan SA; Friedlander M; Hopper JL; Phillips K-A, 2013, 'RISK-REDUCING BEHAVIOUR OF FEMALE BRCA1 AND BRCA2 MUTATION CARRIERS; LONG-TERM FOLLOW-UP OF PARTICIPANTS IN kConFab', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Wimberger P; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Kim JH; Harter P, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605347&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Du Bois A; Floquet A; Kim JW; Rau J; Maria Del Campo J; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Wimberger P; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Kim JH; Harter P, 2013, 'Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, http://dx.doi.org/10.1200/jco.2013.31.18_suppl.lba5503

Conference Papers | 2013

Friedlander M; Knoll S; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Du Bois A, 2013, 'Quality of life in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC) receiving either pazopanib monotherapy or placebo after first-line chemotherapy: AGO-OVAR16 results', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S713 - S713, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Friedlander M; Sjoquist KM; Sommeijer DW; Bailey L; Marlyn J; Gillies K; Mileshkin LR; O'Connel R; Gebski V; Vaughan MM; Blomtield P; Beale PJ; Quinn M; Stockier MR; Lombard JM; Hadley AM; Amant F; Edmondson RJ, 2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605470&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Gorringe K; Hunter S; Wakefield MJ; Antill Y; Ryland G; Bae S; Topp M; Lipton L; Liauw W; Jobling T; Boussioutas A; Christie M; Friedlander M; Fox S; DeFazio A; Bowtell D; Pyman J; Scott CL; Campbell I, 2013, 'MUCINOUS OVARIAN TUMOURS: IS ONE OF THESE THINGS NOT LIKE THE OTHERS?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmana J; Mitchell G; Fried G; Bowen K; Fielding A; Domchek SM, 2013, 'Olaparib monotherapy in patients with advanced cancer and a germ-line BRAC1/2 mutation: An open-label phase II study', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013

Conference Papers | 2013

King MT; Freudensprung U; Stockler M; Friedlander M; Lee C; Sneller V; Hilpert F; Pujade-Lauraine E; Wenzel L, 2013, 'Analyzing patient-reported outcome (PRO) endpoints in advanced cancer clinical trials: responder analysis versus mixed model for repeated measures (MMRM) illustrated with results from the AURELIA ovarian cancer trial', in QUALITY OF LIFE RESEARCH, SPRINGER, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209359000043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin GJS; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Macpherson E; Dougherty B; Juergensmeier JM; Orr M; Matulonis U, 2013, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419602019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Mateo J; Friedlander M; Sessa C; Leunen K; Nicum S; Gourley C; Fielding A; Bowen K; Kaye S; Molife LR, 2013, 'Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S161 - S161, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013

Conference Papers | 2013

Mizrahi D; Naumann F; Broderick C; Ryan M; Friedlander M, 2013, 'PHYSICAL ACTIVITY AND SLEEP DISTURBANCES FOR WOMEN WITH RECURRENT OVARIAN CANCER UNDERGOING CHEMOTHERAPY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379502010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Mizrahi D; Naumann F; Broderick C; Yip D; Davis A; Samara J; Ryan M; Friedlander M, 2013, 'PHYSICAL ACTIVITY (PA) PARTICIPATION FOR WOMEN WITH OVARIAN CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 114 - 114, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Oza AM; Cibula D; Oaknin Benzaquen A; Poole CJ; Mathijssen RHJ; Sonke GS; Mackay H; Lowe ES; Read J; Friedlander M, 2013, 'Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S712 - S713, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604308&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Price M; Butow P; Bell M; Friedlander M; deFazio A; Webb P, 2013, 'Psychosocial Predictors of Survival in Invasive Ovarian Cancer: A Population-Based Prospective Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 46 - 47, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Sandler C; Webber K; Friedlander M; Lewis C; Chin M; Venkateswaran R; Segelov E; Bastick P; Lynch J; Thomas D; Liauw W; Boyle F; Goldstein D; Lloyd A, 2013, 'BARRIERS TO RECRUITMENT FOR A POST-CANCER FATIGUE INTERVENTION STUDY - THE TOPS TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 116 - 116, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Sousa M; Meiser B; Hickey M; Jarvis S; Peatte M; Lewis C; Friedlander M, 2013, 'QUALITATIVE ANALYSIS OF KNOWLEDGE, ATTITUDES AND EXPERIENCES REGARDING URINARY SYMPTOMS AMONG POSTMENOPAUSAL WOMEN TAKING AROMATASE INHIBITORS FOR EARLY STAGE BREAST CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 143 - 143, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

Stockler MR; Hilpert F; Friedlander M; King M; Wenzel LB; Lee C; Joly F; De Gregorio N; Arija JAA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; lauraine EP, 2013, 'Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013

Conference Abstracts | 2013

Webber K; Girgis A; Kaye B; Bonaventura BA; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2013

del Campo JM; Kurzeder C; Berton-Rigaud D; Kim BG; Friedlander M; Zamagni C; Sakuragi N; Canzler U; Crescenzo RJ; du Bois A, 2013, 'PROGRESSION-FREE SURVIVAL BY GCIG CRITERIA: ANALYSIS OF THE SECONDARY ENDPOINT OF THE AGO-OVAR16 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379500111&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Ang JE; Gourley C; High HA; Shapira-Frommer R; Powell CB; Castonguay V; De Greve J; Yap TA; Fong PCC; Olmos D; Banerjee SN; Chen L-M; Friedlander M; Kaufman B; Oza AM; De Bono JS; Gore ME; Kaye SB, 2012, 'Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803479&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802389&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Collins IM; Milne RL; McLachlan SA; Friedlander M; Birch KE; Weideman PC; Hopper JL; Phillips K-A, 2012, 'Do BRCA1 and BRCA2 mutation carriers have an earlier natural menopause than their non-carrier relatives: A study from the Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab).', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS12-P4-13-10

Conference Papers | 2012

Friedlander M, 2012, 'Cosmic Rays And The Birth of Particle Physics', in Ormes JF (ed.), CENTENARY SYMPOSIUM 2012: DISCOVERY OF COSMIC RAYS, AMER INST PHYSICS, CO, Univ Denver, Denver, pp. 23 - 24, presented at Centenary Symposium on Discovery of Cosmic Rays, CO, Univ Denver, Denver, 26 June 2012 - 28 June 2012, http://dx.doi.org/10.1063/1.4792534

Conference Papers | 2012

Grimison PS; Chatfield MD; Mazhar D; Toner GC; Chester JD; Stockler MR; Stark DP; Thomson DB; Shamash J; Friedlander M; White J; Gebski V; Wason J; Boland AL; Rimmer YL; McDonald A; Gurney H; Rosenthal M; Singhal N; Williams MV, 2012, 'Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and UK phase I/II trials', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802677&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Isakoff SJ; Pulhalla S; Shepherd SP; Falotico N; Kaufman B; Friedlander M; Robson M; Domchek S; Garber J; McKeegan E; Chyla B; Qian J; Giranda VL, 2012, 'A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/0008-5472.SABCS12-OT2-3-07

Conference Papers | 2012

Mercieca-Bebber RL; Butow PN; Friedlander M; King MT, 2012, 'OVARIAN CANCER PATIENTS' EXPECTATIONS OF PALLIATIVE CHEMOTHERAPY: THE FINE LINE BETWEEN HOPE AND MISUNDERSTANDING', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 244 - 244, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Mileshkin LR; Narayan K; Moore KN; Rischin D; Trimble EL; Stockler MR; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Shrivastava SK; Small W; Thomas G; Craighead PS; Gebski V, 2012, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803669&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Molife LR; Mateo J; McGoldrick T; Krebs M; Drew Y; Banerjee SN; Nicum S; Ranson M; Rustin GJS; Sessa C; Plummer R; Leunen K; Friedlander M; Swaisland H; Burke W; McCormack P; Pemberton K; Tchakov I; Kaye SB; Gourley C, 2012, 'Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802292&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Oza AM; Cibula D; Oaknin A; Poole CJ; Mathijssen RHJ; Sonke GS; Colombo N; Spacek J; Vuylsteke P; Hirte HW; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Tchakov I; Friedlander M, 2012, 'Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803631&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Sjoquist KM; Lee C; Lord S; Chatfield MD; Friedlander M; Simes J; Marschner I, 2012, 'Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009803651&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Sommeijer DW; Price MA; Bell M; Friedlander M; Stockler M; Defazio A; Webb PM; Butow PN, 2012, 'QUALITY OF LIFE AND COPING IN OVARIAN CANCER: THE LAST YEAR OF LIFE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 355 - 355, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400415&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2012

Webber K; Girgis A; Bennett BK; Bonaventura T; Boyle F; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2012, 'CURRENT CARE AND NEEDS OF ADULT CANCER SURVIVORS - A CROSS-SECTIONAL SURVEY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 8, pp. 356 - 357, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2011

Alsop K; Fereday S; Meldrum C; deFazio A; Webb P; Birrer MJ; Friedlander M; Fox SB; Bowtell D; Mitchell G, 2011, 'Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5026

Conference Papers | 2011

Bennett BK; Goldstein D; Friedlander M; Park SB; Kiernan MG, 2011, 'Oxaliplatin-induced Neurotoxicity - Comparing Four Methods of Assessment', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S234 - S234, presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, SWEDEN, Stockholm, 23 September 2011 - 27 September 2011, http://dx.doi.org/10.1016/S0959-8049(11)71114-5

Conference Papers | 2011

Friedlander M; Stockler MR; King M; Oza AM; Voysey M; Martyn J; Gillies K; Sjoquist KM; Butow P, 2011, 'Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.tps241

Conference Papers | 2011

Harvey S; Milne RL; Birch KE; Weideman P; McLachlan S; Friedlander M; Goldgar D; Hopper JL; Phillips K, 2011, 'Prospective study of breast cancer risk in mutation-negative women from BRCA1 or BRCA2 mutation-positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1516

Conference Papers | 2011

Houghton BB; Grimison PS; Toner GC; Chatfield M; Thomson DB; Friedlander M; Gebski V; Rosenthal M; Gurney H; Stockler M, 2011, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.7_suppl.227

Conference Papers | 2011

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Macpherson E; Watkins C; Carmichael J; Matulonis U, 2011, 'Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.5003

Conference Papers | 2011

Park SB; Lin CSY; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2011, 'A Novel Approach to the Emerging and Frequent Problem of Sustained Long-term Oxaliplatin-induced Neurotoxicity', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SWEDEN, Stockholm, pp. S436 - S436, presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, SWEDEN, Stockholm, 23 September 2011 - 27 September 2011, http://dx.doi.org/10.1016/S0959-8049(11)71792-0

Conference Papers | 2011

Phillips K; Milne RL; Rookus MA; Goldgar D; Friedlander M; McLachlan S; Buys SS; Antoniou AC; Birch KE; Terry MB; Easton D; Weideman P; Daly MB; Andrieu N; John EM; Hooning M; Andrulis IL; Caldes T; Olsson H; Hopper JL, 2011, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.1500

Conference Papers | 2011

Stuart GCE; Kitchener H; Bacon M; DuBois A; Friedlander M; Ledermann J; Marth C; Thigpen T; Trimble E, 2011, '2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference', in International Journal of Gynecological Cancer, pp. 750 - 755, http://dx.doi.org/10.1097/IGC.0b013e31821b2568

Conference Papers | 2010

Bennett BK; Goldstein D; De Souza PL; Wilken N; Friedlander M; Hickie IB; Scott E; Rogers N; Lloyd AR, 2010, 'What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study', in Journal of Clinical Oncology, American Society of Clinical Oncology, United States, pp. 93s

Conference Papers | 2010

Lee CK; Guardiola E; Hogberg T; Friedlander M; Bentley J; Denison U; Vergote IB; Pisano C; Parma G; Wimberger P, 2010, 'Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.5105

Conference Papers | 2010

Lemech CR; Cosman R; Lee C; Friedlander M; Lewis C; Lynch J; Thomas D; Clingan P; Glasgow A, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf

Conference Papers | 2010

Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2010, 'Pathophysiology of paclitaxel-induced neurotoxicity', in Small D (ed.), Australian Neurosciences Society Annual Scientific Meeting 2010, ANS, Sydney, pp. 160 - 160, presented at Australian Neurosciences Society Annual Scientific Meeting 2010, Sydney, 31 January 2010 - 03 February 2010

Conference Papers | 2010

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2010, 'Implementation and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia, Australia, presented at Clinical Oncological Society of Australia 37th Annual Scientific Meeting, Melbourne, 09 November 2010 - 12 November 2010

Conference Papers | 2010

Webber K; Goldstein D; Bennett BK; Boyle F; De Souza PL; Wilken N; Friedlander M; Lloyd AR, 2010, 'Late fatigue after adjuvant therapy for early breast cancer is largely unrelated to cancer or its treatment: 5 year follow-up of a prospective cohort study', in Asia-Pacific Journal of Clinical Oncology, Blackwell Publishing Asia Pty Ltd, Australia, pp. 53 - 60, presented at ., -

Conference Papers | 2009

Audeh MW; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Carmichael J; Tutt A, 2009, 'Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009

Conference Papers | 2009

Goodwin P; Phillips K; West D; Ennis M; Hopper J; John EM; O'Malley F; Milne R; Andrulis I; Friedlander M; Longacre T, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2072 - 2072, http://dx.doi.org/10.1158/0008-5472.sabcs-2072

Conference Papers | 2009

Goodwin P; Phillips KA; West DJ; Ennis M; Hopper JL; John E; O Malley F; Milne RS; Andrulis I; Friedlander ML; Longacre T, 2009, 'Prognosis in BRCA1, BRCA2 associated breast cancer (BC): a prospective Breast Cancer Family Registry (BCFR) international population-based cohort study', in Cancer research, American Association Cancer Research, Philadelphia, PA, pp. 178S - 178S, presented at 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000262583200363&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Conference Papers | 2009

Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman PC; Milne R; McLachlan S; Hopper JL; Phillips K, 2009, 'Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606602105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters | 2009

Lemech CR; Friedlander M, 2009, 'Clear cell cancer of the ovary: from resistance to response', Canberra Australia, presented at MOGA Annual Scientific Meeting, Canberra Australia, 12 August 2009 - 14 August 2009, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2009.01218.x/pdf

Conference Papers | 2009

Tutt A; Robson M; Garber JE; Domchek S; Audeh MW; Weitzel JN; Friedlander M; Carmichael J, 2009, 'Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009

Conference Papers | 2008

Bennett BK; Goldstein D; Friedlander ML; Boyle F; De Souza PL; Wilken N; Hickie IB; Scott E; Lloyd AR, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S36 - S37, presented at Psycho-Oncology 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000257874200071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Conference Papers | 2008

Field KM; Phillips K; Jenkins MA; McKinley J; Weideman P; Price M; Friedlander M; McLachlan S; Lindeman G; Butow P, 2008, 'Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.1528

Conference Papers | 2008

Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Hodge JP; Ma B; Matthys G; Lager JJ, 2008, 'PAZOPANIB (GW786034) IS ACTIVE IN WOMEN WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE AND PERITONEAL CANCERS: RESULTS OF A PHASE II STUDY', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWEDEN, Stockholm, pp. 211 - 211, presented at 33rd European-Society-for-Medical-Oncology Congress, SWEDEN, Stockholm, 12 September 2008 - 16 September 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259973300662&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2008

Friedlander M, 2008, 'Medical Oncology Group of Australia (MOGA)/Novartis cancer achievement award', in Cancer Forum, pp. 27 - 31

Conference Papers | 2008

Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2008, 'Early detection of oxaliplatin-induced neurotoxicity: Getting it before it hurts', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.15015

Conference Papers | 2007

Friedlander M; Hancock KC; Benigno B; Rischin D; Messing M; Stringer CA; Tay EH; Kathman S; Matthys G; Lager JJ, 2007, 'Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000455043701341&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2007

Peate ML; Meiser B; Hickey MS; Thewes B; Butow PN; Saunders C; Rovelli S; Zorbas H; Friedlander ML, 2007, 'Breast cancer and fertility: Making hard choices easier - The development and evaluation of fertility-related decision aid for young women with early breast cancer', in Psycho - Oncology, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S15 - S16, presented at Psycho-Oncology 2007

Conference Papers | 2006

Dawson S; McKinley J; Jenkins M; McLachlan S; Lindeman G; Friedlander M; Hopper J; Phillips K, 2006, 'Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, GA, Atlanta, pp. 53S - 53S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009400210&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2006

Mok K; Mireskandari S; Juraskova I; Jarvis S; Friedlander M, 2006, 'OVER (Olive oil Vaginal Exercises and Replens) come', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, Vol. 15, pp. S332 - S332, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000242413901224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2005

Friedlander ML; Bishop J; Levi J; Zalcberg JR; Olver IN; Smith JV; Toner GC, 2005, 'A phase II trial of Paclitaxel in previously treated patients with metastatic breast cancer.', in Medical Journal of Australia, Australasian Med Publishing Company Ltd, Sydney, NSW, Australia, pp. 520 - 523, presented at Medical Journal of Australia

Conference Papers | 2005

Mitchell P; Goldstein D; Michael M; Beale P; Friedlander M; Zalcberg J; Clarke S; White S, 2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, pp. 266S - 266S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326601475&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2005

Thigpen T; Stuart G; du Bois A; Friedlander M; Fujiwara K; Guastalla JP; Kaye S; Kitchener H; Kristensen G; Mannel R; Meier W; Miller B; Poveda A; Provencher D; Stehman F; Vergote I, 2005, 'Clinical trials in ovarian carcinoma: Requirements for standard approaches and regimens', in Annals of Oncology, http://dx.doi.org/10.1093/annonc/mdi962

Conference Papers | 2004

Aghmesheh M; Friedlander M; Russell PJ; Edwards L; Yang JL; Kconfab K; Nesland JM; Danielson H; Kaern J; Tucker KM, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 459S - 459S, presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, LA, New Orleans, 05 June 2004 - 08 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512401819&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2004

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips KA, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 845S - 845S, presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, LA, New Orleans, 05 June 2004 - 08 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512403351&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2004

Thewes B; Meiser B; Duric V; Stockler M; Friedlander M, 2004, 'What survival benefits do pre-menopausal early breast cancer patients consider necessary to make endocrine therapy worthwhile?', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S40 - S41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223957800084&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2003

Thewes B; Meiser B; Rickard J; Friedlander M, 2003, 'The fertility and menopause related information needs of younger women with a diagnosis of breast cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, pp. S125 - S125, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400153&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2003

Tiller K; Meiser B; Tucker K; Andrews L; Gaff C; Kirk J; Phillips KA; Duding T; Friedlander M, 2003, 'A randomised trial of a decision aid for women at risk for ovarian cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, Vol. 12, pp. S107 - S107, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Proceedings (Editor of) | 2003

Thewes B; Meiser B; Rickard J; Friedlander ML, (eds.), 2003, '6th World Congress Psycho-Oncology', Banff Alberta Canada, presented at 6th World Congress Psycho-Oncology, Banff Alberta Canada, 23 April 2003 - 27 April 2003

Conference Proceedings (Editor of) | 2003

Tiller K; Meiser B; Tucker K; Andrews L; Gaff C; Kirk J; Phillips KA; Duding T; Friedlander ML, (eds.), 2003, '6th World Congress Psycho-Oncology', Banff Alberta Canada, presented at 6th World Congress Psycho-Oncology, Banff Alberta Canada, 23 April 2003 - 27 April 2003

Conference Papers | 2002

Aghmesheh M; Edwards L; Clarke CL; Russell PJ; Friedlander ML; Tucker K; Defazio A, 2002, 'Steroid hormone receptor expression in heriditary and sporadic ovarian cancers', in Proceedings of the American Association for Cancer Research, American Association Cancer Research, Philadelphia, PA, USA, pp. 6 - 6, presented at 93rd Annual Meeting of the AACR, San Francisco, California USA, 06 April 2002 - 10 April 2002

Conference Papers | 1999

Apicella C; Andrews L; Tucker K; Bankier A; Friedlander M; Venter D; Hopper J, 1999, 'Australian Jewish women's experiences with a breast cancer gene testing program as part of the co-operative family registry for breast cancer studies (CFR-BCS).', in AMERICAN JOURNAL OF HUMAN GENETICS, UNIV CHICAGO PRESS, pp. A191 - A191, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000082879801051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 1999

Friedlander M, 1999, 'Inorganic nutrition in pond cultivated Gracilaria conferta (Rhodophyta):: nitrogen, phosphate and sulfate', in JOURNAL OF APPLIED PHYCOLOGY, SPRINGER, CHILE, PUERTO VARAS, pp. 279 - 286, presented at Symposium on Cultivation and Uses of Red Algae, CHILE, PUERTO VARAS, http://dx.doi.org/10.1023/A:1011139329415

Conference Papers | 1999

Katz S; Kizner Z; Dubinsky Z; Friedlander M, 1999, 'Responses of Porphyra linearis (Rhodophyta) to environmental factors under controlled culture conditions', in JOURNAL OF APPLIED PHYCOLOGY, KLUWER ACADEMIC PUBL, ITALY, MONTECATINI TERME, pp. 535 - 542, presented at 8th Tri Annual International Conference on Applied Algology (8th ICAA), ITALY, MONTECATINI TERME, 26 September 1999 - 01 October 1999, http://dx.doi.org/10.1023/A:1008138227520

Conference Papers | 1999

Links M; Friedlander M; Russell P, 1999, 'Enhancement of cisplatin cytotoxicity by caffeine does not correlate with abrogation of G2 arrest.', in BRITISH JOURNAL OF CANCER, CHURCHILL LIVINGSTONE, pp. 42 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081955000151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 1998

Bishop DT; Rapley E; Tucker K; Collins F; Donald J; Friedlander M; Peng HQ; Goss P; Hogg D; Easton DF; Teare D; Crockford G; Forman D; Leahy M; Bodmer JG; Moses J; Tonks S; Oliver RTD; Biggs P; Seal S; Barfoot R; Gill S; Patel S; Hamoudi R; Hunter R; Thomlinson I; Cooper C; Stratton M; Huddart R; Fosså SD; Heimdal K, 1998, 'Candidate regions for testicular cancer susceptibility genes: The International Testicular Cancer Linkage Consortium', in APMIS, pp. 64 - 72, http://dx.doi.org/10.1111/j.1699-0463.1998.tb01320.x

Conference Papers | 1997

Friedlander M; DeGramont A; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Ripoche V; Kayitalire L, 1997, 'Activity of Gemcitabine in stage 3 or 4 ovarian cancer: Patients previously treated with cisplatin (CP)-containing regimens', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 538 - 538, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997XX83000533&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 1997

Rapley E; Tucker K; Collins F; Donald J; Friedlander M; Peng HQ; Goss P; Hogg D; Easton DF; Teare D; Bishop DT; Crockford G; Forman D; Leahy M; Bodmer JG; Moses J; Tonks S; Oliver RTD; Biggs P; Seal S; Barfoot R; Gill S; Patel S; Hamoudi R; Hunter R; Thomlinson I; Cooper C; Stratton M; Huddart R; Fossa SD; Heimdal K, 1997, 'Candidate regions for testicular cancer susceptibility genes', in APMIS, WILEY, DENMARK, COPENHAGEN UNIV HOSP, COPENHAGEN, pp. 64 - 70, presented at 4th Copenhagen Workshop on Carcinoma In Situ and Cancer of the Testis - Molecular and Endocrine Aspects, DENMARK, COPENHAGEN UNIV HOSP, COPENHAGEN, 18 May 1997 - 21 May 1997

Conference Papers | 1995

Zalcberg JR; Bishop JF; Millward MJ; Zimet A; Laird J; Barter C; Seward D; McKeage MJ; Friedlander ML; Toner G; Berille J; Blanc C, 1995, 'Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)', in EUROPEAN JOURNAL OF CANCER, PERGAMON-ELSEVIER SCIENCE LTD, pp. 1084 - 1084, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995TH91901079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 1994

FRIEDLANDER M; LEVY I, 1994, 'CULTIVATION OF GRACILARIA IN OUTDOOR TANKS AND PONDS', in JOURNAL OF APPLIED PHYCOLOGY, KLUWER ACADEMIC PUBL, ITALY, TRIESTE, pp. 315 - 324, presented at Workshop on Gracilaria and its Cultivation, ITALY, TRIESTE, http://dx.doi.org/10.1007/BF00004005

Conference Papers | 1983

FRIEDLANDER ML; MUSGROVE L; RUSSELL P; TOPPLIA M; HEDLEY D; TAYLOR IW; TATTERSALL MHN, 1983, 'FLOW CYTOMETRIC ANALYSIS OF DNA CONTENT IN OVARIAN-CANCER', in CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, BLACKWELL SCIENCE, pp. 489 - 489, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RB75800115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Follow

Professor Michael Friedlander